0001628280-24-020011.txt : 20240502 0001628280-24-020011.hdr.sgml : 20240502 20240502161110 ACCESSION NUMBER: 0001628280-24-020011 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 75 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240502 DATE AS OF CHANGE: 20240502 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABBOTT LABORATORIES CENTRAL INDEX KEY: 0000001800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 360698440 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-02189 FILM NUMBER: 24908340 BUSINESS ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 BUSINESS PHONE: 2246676100 MAIL ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 10-Q 1 abt-20240331.htm 10-Q abt-20240331
000000180012-312024Q1falseP12M00000018002024-01-012024-03-310000001800exch:XNYS2024-01-012024-03-310000001800exch:XCHI2024-01-012024-03-3100000018002024-03-31xbrli:sharesiso4217:USD00000018002023-01-012023-03-31iso4217:USDxbrli:shares00000018002023-12-310000001800us-gaap:CommonStockMember2023-12-310000001800us-gaap:CommonStockMember2022-12-310000001800us-gaap:CommonStockMember2024-01-012024-03-310000001800us-gaap:CommonStockMember2023-01-012023-03-310000001800us-gaap:CommonStockMember2024-03-310000001800us-gaap:CommonStockMember2023-03-310000001800us-gaap:TreasuryStockCommonMember2023-12-310000001800us-gaap:TreasuryStockCommonMember2022-12-310000001800us-gaap:TreasuryStockCommonMember2024-01-012024-03-310000001800us-gaap:TreasuryStockCommonMember2023-01-012023-03-310000001800us-gaap:TreasuryStockCommonMember2024-03-310000001800us-gaap:TreasuryStockCommonMember2023-03-310000001800us-gaap:RetainedEarningsMember2023-12-310000001800us-gaap:RetainedEarningsMember2022-12-310000001800us-gaap:RetainedEarningsMember2024-01-012024-03-310000001800us-gaap:RetainedEarningsMember2023-01-012023-03-310000001800us-gaap:RetainedEarningsMember2024-03-310000001800us-gaap:RetainedEarningsMember2023-03-310000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000001800us-gaap:NoncontrollingInterestMember2023-12-310000001800us-gaap:NoncontrollingInterestMember2022-12-310000001800us-gaap:NoncontrollingInterestMember2024-01-012024-03-310000001800us-gaap:NoncontrollingInterestMember2023-01-012023-03-310000001800us-gaap:NoncontrollingInterestMember2024-03-310000001800us-gaap:NoncontrollingInterestMember2023-03-3100000018002022-12-3100000018002023-03-31abt:segment0000001800us-gaap:OperatingSegmentsMemberabt:KeyEmergingMarketsMemberabt:EstablishedPharmaceuticalProductsMembercountry:US2024-01-012024-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:KeyEmergingMarketsMemberabt:EstablishedPharmaceuticalProductsMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:KeyEmergingMarketsMemberabt:EstablishedPharmaceuticalProductsMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:KeyEmergingMarketsMemberabt:EstablishedPharmaceuticalProductsMembercountry:US2023-01-012023-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:KeyEmergingMarketsMemberabt:EstablishedPharmaceuticalProductsMember2023-01-012023-03-310000001800us-gaap:OperatingSegmentsMemberabt:KeyEmergingMarketsMemberabt:EstablishedPharmaceuticalProductsMember2023-01-012023-03-310000001800us-gaap:OperatingSegmentsMemberabt:OtherEmergingMarketsMemberabt:EstablishedPharmaceuticalProductsMembercountry:US2024-01-012024-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:OtherEmergingMarketsMemberabt:EstablishedPharmaceuticalProductsMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:OtherEmergingMarketsMemberabt:EstablishedPharmaceuticalProductsMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:OtherEmergingMarketsMemberabt:EstablishedPharmaceuticalProductsMembercountry:US2023-01-012023-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:OtherEmergingMarketsMemberabt:EstablishedPharmaceuticalProductsMember2023-01-012023-03-310000001800us-gaap:OperatingSegmentsMemberabt:OtherEmergingMarketsMemberabt:EstablishedPharmaceuticalProductsMember2023-01-012023-03-310000001800us-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMembercountry:US2024-01-012024-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMembercountry:US2023-01-012023-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMember2023-01-012023-03-310000001800us-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMember2023-01-012023-03-310000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMembercountry:USabt:PediatricNutritionalsMember2024-01-012024-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:NutritionalProductsMemberabt:PediatricNutritionalsMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMemberabt:PediatricNutritionalsMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMembercountry:USabt:PediatricNutritionalsMember2023-01-012023-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:NutritionalProductsMemberabt:PediatricNutritionalsMember2023-01-012023-03-310000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMemberabt:PediatricNutritionalsMember2023-01-012023-03-310000001800abt:AdultNutritionalsMemberus-gaap:OperatingSegmentsMemberabt:NutritionalProductsMembercountry:US2024-01-012024-03-310000001800us-gaap:NonUsMemberabt:AdultNutritionalsMemberus-gaap:OperatingSegmentsMemberabt:NutritionalProductsMember2024-01-012024-03-310000001800abt:AdultNutritionalsMemberus-gaap:OperatingSegmentsMemberabt:NutritionalProductsMember2024-01-012024-03-310000001800abt:AdultNutritionalsMemberus-gaap:OperatingSegmentsMemberabt:NutritionalProductsMembercountry:US2023-01-012023-03-310000001800us-gaap:NonUsMemberabt:AdultNutritionalsMemberus-gaap:OperatingSegmentsMemberabt:NutritionalProductsMember2023-01-012023-03-310000001800abt:AdultNutritionalsMemberus-gaap:OperatingSegmentsMemberabt:NutritionalProductsMember2023-01-012023-03-310000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMembercountry:US2024-01-012024-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:NutritionalProductsMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMembercountry:US2023-01-012023-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:NutritionalProductsMember2023-01-012023-03-310000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMember2023-01-012023-03-310000001800us-gaap:OperatingSegmentsMemberabt:CoreLaboratoryMemberabt:DiagnosticProductsMembercountry:US2024-01-012024-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:CoreLaboratoryMemberabt:DiagnosticProductsMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:CoreLaboratoryMemberabt:DiagnosticProductsMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:CoreLaboratoryMemberabt:DiagnosticProductsMembercountry:US2023-01-012023-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:CoreLaboratoryMemberabt:DiagnosticProductsMember2023-01-012023-03-310000001800us-gaap:OperatingSegmentsMemberabt:CoreLaboratoryMemberabt:DiagnosticProductsMember2023-01-012023-03-310000001800us-gaap:OperatingSegmentsMemberabt:MolecularMemberabt:DiagnosticProductsMembercountry:US2024-01-012024-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:MolecularMemberabt:DiagnosticProductsMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:MolecularMemberabt:DiagnosticProductsMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:MolecularMemberabt:DiagnosticProductsMembercountry:US2023-01-012023-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:MolecularMemberabt:DiagnosticProductsMember2023-01-012023-03-310000001800us-gaap:OperatingSegmentsMemberabt:MolecularMemberabt:DiagnosticProductsMember2023-01-012023-03-310000001800us-gaap:OperatingSegmentsMemberabt:PointOfCareMemberabt:DiagnosticProductsMembercountry:US2024-01-012024-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:PointOfCareMemberabt:DiagnosticProductsMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:PointOfCareMemberabt:DiagnosticProductsMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:PointOfCareMemberabt:DiagnosticProductsMembercountry:US2023-01-012023-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:PointOfCareMemberabt:DiagnosticProductsMember2023-01-012023-03-310000001800us-gaap:OperatingSegmentsMemberabt:PointOfCareMemberabt:DiagnosticProductsMember2023-01-012023-03-310000001800abt:RapidDiagnosticsMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMembercountry:US2024-01-012024-03-310000001800us-gaap:NonUsMemberabt:RapidDiagnosticsMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2024-01-012024-03-310000001800abt:RapidDiagnosticsMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2024-01-012024-03-310000001800abt:RapidDiagnosticsMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMembercountry:US2023-01-012023-03-310000001800us-gaap:NonUsMemberabt:RapidDiagnosticsMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2023-01-012023-03-310000001800abt:RapidDiagnosticsMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2023-01-012023-03-310000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMembercountry:US2024-01-012024-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMembercountry:US2023-01-012023-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2023-01-012023-03-310000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2023-01-012023-03-310000001800us-gaap:OperatingSegmentsMemberabt:RhythmManagementMemberabt:MedicalDevicesMembercountry:US2024-01-012024-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:RhythmManagementMemberabt:MedicalDevicesMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:RhythmManagementMemberabt:MedicalDevicesMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:RhythmManagementMemberabt:MedicalDevicesMembercountry:US2023-01-012023-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:RhythmManagementMemberabt:MedicalDevicesMember2023-01-012023-03-310000001800us-gaap:OperatingSegmentsMemberabt:RhythmManagementMemberabt:MedicalDevicesMember2023-01-012023-03-310000001800us-gaap:OperatingSegmentsMemberabt:ElectrophysiologyMemberabt:MedicalDevicesMembercountry:US2024-01-012024-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:ElectrophysiologyMemberabt:MedicalDevicesMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:ElectrophysiologyMemberabt:MedicalDevicesMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:ElectrophysiologyMemberabt:MedicalDevicesMembercountry:US2023-01-012023-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:ElectrophysiologyMemberabt:MedicalDevicesMember2023-01-012023-03-310000001800us-gaap:OperatingSegmentsMemberabt:ElectrophysiologyMemberabt:MedicalDevicesMember2023-01-012023-03-310000001800us-gaap:OperatingSegmentsMemberabt:HeartFailureMemberabt:MedicalDevicesMembercountry:US2024-01-012024-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:HeartFailureMemberabt:MedicalDevicesMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:HeartFailureMemberabt:MedicalDevicesMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:HeartFailureMemberabt:MedicalDevicesMembercountry:US2023-01-012023-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:HeartFailureMemberabt:MedicalDevicesMember2023-01-012023-03-310000001800us-gaap:OperatingSegmentsMemberabt:HeartFailureMemberabt:MedicalDevicesMember2023-01-012023-03-310000001800us-gaap:OperatingSegmentsMemberabt:VascularMemberabt:MedicalDevicesMembercountry:US2024-01-012024-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:VascularMemberabt:MedicalDevicesMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:VascularMemberabt:MedicalDevicesMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:VascularMemberabt:MedicalDevicesMembercountry:US2023-01-012023-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:VascularMemberabt:MedicalDevicesMember2023-01-012023-03-310000001800us-gaap:OperatingSegmentsMemberabt:VascularMemberabt:MedicalDevicesMember2023-01-012023-03-310000001800us-gaap:OperatingSegmentsMemberabt:StructuralHeartMemberabt:MedicalDevicesMembercountry:US2024-01-012024-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:StructuralHeartMemberabt:MedicalDevicesMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:StructuralHeartMemberabt:MedicalDevicesMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:StructuralHeartMemberabt:MedicalDevicesMembercountry:US2023-01-012023-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:StructuralHeartMemberabt:MedicalDevicesMember2023-01-012023-03-310000001800us-gaap:OperatingSegmentsMemberabt:StructuralHeartMemberabt:MedicalDevicesMember2023-01-012023-03-310000001800us-gaap:OperatingSegmentsMemberabt:NeuromodulationMemberabt:MedicalDevicesMembercountry:US2024-01-012024-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:NeuromodulationMemberabt:MedicalDevicesMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:NeuromodulationMemberabt:MedicalDevicesMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:NeuromodulationMemberabt:MedicalDevicesMembercountry:US2023-01-012023-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:NeuromodulationMemberabt:MedicalDevicesMember2023-01-012023-03-310000001800us-gaap:OperatingSegmentsMemberabt:NeuromodulationMemberabt:MedicalDevicesMember2023-01-012023-03-310000001800us-gaap:OperatingSegmentsMemberabt:DiabetesCareMemberabt:MedicalDevicesMembercountry:US2024-01-012024-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:DiabetesCareMemberabt:MedicalDevicesMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:DiabetesCareMemberabt:MedicalDevicesMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:DiabetesCareMemberabt:MedicalDevicesMembercountry:US2023-01-012023-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:DiabetesCareMemberabt:MedicalDevicesMember2023-01-012023-03-310000001800us-gaap:OperatingSegmentsMemberabt:DiabetesCareMemberabt:MedicalDevicesMember2023-01-012023-03-310000001800us-gaap:OperatingSegmentsMemberabt:MedicalDevicesMembercountry:US2024-01-012024-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMemberabt:MedicalDevicesMembercountry:US2023-01-012023-03-310000001800us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2023-01-012023-03-310000001800us-gaap:OperatingSegmentsMemberabt:MedicalDevicesMember2023-01-012023-03-310000001800us-gaap:CorporateNonSegmentMembercountry:US2024-01-012024-03-310000001800us-gaap:NonUsMemberus-gaap:CorporateNonSegmentMember2024-01-012024-03-310000001800us-gaap:CorporateNonSegmentMember2024-01-012024-03-310000001800us-gaap:CorporateNonSegmentMembercountry:US2023-01-012023-03-310000001800us-gaap:NonUsMemberus-gaap:CorporateNonSegmentMember2023-01-012023-03-310000001800us-gaap:CorporateNonSegmentMember2023-01-012023-03-310000001800country:US2024-01-012024-03-310000001800us-gaap:NonUsMember2024-01-012024-03-310000001800country:US2023-01-012023-03-310000001800us-gaap:NonUsMember2023-01-012023-03-310000001800abt:COVID19TestingMemberabt:DiagnosticProductsMember2024-01-012024-03-310000001800abt:COVID19TestingMemberabt:DiagnosticProductsMember2023-01-012023-03-310000001800abt:DiagnosticProductsMember2024-03-310000001800abt:MedicalDevicesMember2024-03-3100000018002024-04-012024-01-012024-03-31xbrli:pure00000018002024-04-012024-03-3100000018002026-04-012024-01-012024-03-3100000018002026-04-012024-03-310000001800us-gaap:PensionPlansDefinedBenefitMember2024-01-012024-03-310000001800us-gaap:PensionPlansDefinedBenefitMember2023-01-012023-03-310000001800us-gaap:EquitySecuritiesMember2024-03-310000001800us-gaap:EquitySecuritiesMember2023-12-310000001800us-gaap:OtherInvestmentsMember2024-03-310000001800us-gaap:OtherInvestmentsMember2023-12-310000001800abt:StJudeMedicalMember2024-03-310000001800us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000001800us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-310000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310000001800us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-03-310000001800us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-03-310000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-03-310000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-03-310000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-03-310000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-03-310000001800us-gaap:AccumulatedTranslationAdjustmentMember2024-03-310000001800us-gaap:AccumulatedTranslationAdjustmentMember2023-03-310000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-03-310000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-03-310000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-03-310000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-03-310000001800abt:CardiovascularSystemsIncMember2023-04-270000001800abt:CardiovascularSystemsIncMember2023-04-272023-04-27abt:intangibleAsset0000001800abt:EstablishedPharmaceuticalProductsMember2024-03-310000001800abt:NutritionalProductsMember2024-03-310000001800abt:A2024RestructuringPlanMember2024-01-012024-03-310000001800abt:CostOfGoodsAndServicesSoldMemberabt:A2024RestructuringPlanMember2024-01-012024-03-310000001800us-gaap:ResearchAndDevelopmentExpenseMemberabt:A2024RestructuringPlanMember2024-01-012024-03-310000001800us-gaap:SellingGeneralAndAdministrativeExpensesMemberabt:A2024RestructuringPlanMember2024-01-012024-03-310000001800abt:A2024RestructuringPlanMember2024-03-310000001800abt:A2022And2023RestructuringPlanMember2023-12-310000001800abt:A2022And2023RestructuringPlanMember2024-01-012024-03-310000001800abt:A2022And2023RestructuringPlanMember2024-03-310000001800us-gaap:EmployeeStockOptionMember2024-01-012024-03-310000001800abt:RestrictedStockAwardsMember2024-01-012024-03-310000001800us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310000001800us-gaap:EmployeeStockOptionMember2024-03-310000001800abt:A2024FiveYearCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2024-03-310000001800abt:A2020FiveYearCreditAgreementMemberus-gaap:LineOfCreditMember2020-11-122020-11-120000001800abt:A2024FiveYearCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2024-01-292024-01-290000001800abt:A2020FiveYearCreditAgreementMemberus-gaap:LineOfCreditMember2024-01-290000001800us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000001800us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000001800us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-01-012024-03-310000001800us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2024-03-310000001800us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2023-12-310000001800us-gaap:NetInvestmentHedgingMemberabt:FiveYearTermLoanDue2024Memberus-gaap:DesignatedAsHedgingInstrumentMember2024-01-012024-03-310000001800us-gaap:NetInvestmentHedgingMemberabt:FiveYearTermLoanDue2024Memberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-12-310000001800us-gaap:NetInvestmentHedgingMemberabt:FiveYearTermLoanDue2024Memberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000001800us-gaap:NetInvestmentHedgingMemberabt:FiveYearTermLoanDue2024Memberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000001800us-gaap:FairValueHedgingMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000001800us-gaap:FairValueHedgingMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000001800us-gaap:FairValueHedgingMemberabt:DeferredIncomeTaxesAndOtherAssetsNoncurrentMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000001800us-gaap:FairValueHedgingMemberabt:DeferredIncomeTaxesAndOtherAssetsNoncurrentMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000001800us-gaap:FairValueHedgingMemberabt:PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000001800us-gaap:FairValueHedgingMemberabt:PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000001800us-gaap:FairValueHedgingMemberus-gaap:InterestRateSwapMemberabt:PrepaidExpensesAndOtherReceivablesCurrentMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000001800us-gaap:FairValueHedgingMemberus-gaap:InterestRateSwapMemberabt:PrepaidExpensesAndOtherReceivablesCurrentMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000001800us-gaap:FairValueHedgingMemberus-gaap:InterestRateSwapMemberabt:OtherAccruedLiabilitiesCurrentMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000001800us-gaap:FairValueHedgingMemberus-gaap:InterestRateSwapMemberabt:OtherAccruedLiabilitiesCurrentMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000001800abt:PrepaidExpenseAndOtherReceivablesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000001800abt:PrepaidExpenseAndOtherReceivablesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000001800abt:OtherAccruedLiabilitiesCurrentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000001800abt:OtherAccruedLiabilitiesCurrentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000001800abt:PrepaidExpenseAndOtherReceivablesMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2024-03-310000001800abt:PrepaidExpenseAndOtherReceivablesMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2023-12-310000001800abt:OtherAccruedLiabilitiesCurrentMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2024-03-310000001800abt:OtherAccruedLiabilitiesCurrentMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2023-12-310000001800us-gaap:DebtMemberabt:LongTermDebtCurrentMaturitiesMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-310000001800us-gaap:DebtMemberabt:LongTermDebtCurrentMaturitiesMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000001800abt:CostOfGoodsAndServicesSoldMemberus-gaap:ForeignExchangeForwardMember2024-01-012024-03-310000001800abt:CostOfGoodsAndServicesSoldMemberus-gaap:ForeignExchangeForwardMember2023-01-012023-03-310000001800us-gaap:DebtMember2024-01-012024-03-310000001800us-gaap:DebtMember2023-01-012023-03-310000001800us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2024-01-012024-03-310000001800us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2023-01-012023-03-310000001800us-gaap:EquitySecuritiesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2024-03-310000001800us-gaap:EquitySecuritiesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-03-310000001800us-gaap:EquitySecuritiesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310000001800us-gaap:EquitySecuritiesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310000001800us-gaap:OtherAggregatedInvestmentsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2024-03-310000001800us-gaap:OtherAggregatedInvestmentsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-03-310000001800us-gaap:OtherAggregatedInvestmentsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310000001800us-gaap:OtherAggregatedInvestmentsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310000001800us-gaap:CarryingReportedAmountFairValueDisclosureMember2024-03-310000001800us-gaap:EstimateOfFairValueFairValueDisclosureMember2024-03-310000001800us-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310000001800us-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310000001800us-gaap:ForeignExchangeForwardMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2024-03-310000001800us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ForeignExchangeForwardMember2024-03-310000001800us-gaap:ForeignExchangeForwardMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310000001800us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ForeignExchangeForwardMember2023-12-310000001800us-gaap:InterestRateSwapMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2024-03-310000001800us-gaap:InterestRateSwapMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-03-310000001800us-gaap:InterestRateSwapMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310000001800us-gaap:InterestRateSwapMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310000001800us-gaap:FairValueMeasurementsRecurringMember2024-03-310000001800us-gaap:FairValueInputsLevel1Member2024-03-310000001800us-gaap:FairValueInputsLevel2Member2024-03-310000001800us-gaap:FairValueInputsLevel3Member2024-03-310000001800us-gaap:FairValueMeasurementsRecurringMember2023-12-310000001800us-gaap:FairValueInputsLevel1Member2023-12-310000001800us-gaap:FairValueInputsLevel2Member2023-12-310000001800us-gaap:FairValueInputsLevel3Member2023-12-310000001800abt:VariousBusinessAcquisitionsMember2024-03-310000001800abt:LegalProceedingsAndEnvironmentalExposuresMembersrt:MinimumMember2024-03-310000001800abt:LegalProceedingsAndEnvironmentalExposuresMembersrt:MaximumMember2024-03-310000001800abt:LegalProceedingsAndEnvironmentalExposuresMember2024-03-310000001800us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-01-012024-03-310000001800us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-01-012023-03-3100000018002023-09-300000001800us-gaap:OperatingSegmentsMember2024-01-012024-03-310000001800us-gaap:OperatingSegmentsMember2023-01-012023-03-310000001800us-gaap:MaterialReconcilingItemsMember2024-01-012024-03-310000001800us-gaap:MaterialReconcilingItemsMember2023-01-012023-03-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2024
OR
oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to
Commission File No. 1-2189
ABBOTT LABORATORIES
An Illinois Corporation
I.R.S. Employer Identification No.
36-0698440
100 Abbott Park Road
Abbott Park, Illinois 60064-6400
Telephone: (224) 667-6100
Securities Registered Pursuant to Section 12(b) of the Act:
Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered
Common Shares, Without Par ValueABT
New York Stock Exchange
Chicago Stock Exchange, Inc.
Indicate by check mark whether the registrant: (l) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of l934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer x
Accelerated Filer o
Non-Accelerated Filer o
Smaller reporting company o
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
As of March 31, 2024, Abbott Laboratories had 1,739,633,759 common shares without par value outstanding.

Abbott Laboratories
Table of Contents
2


Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited)
(dollars in millions except per share data; shares in thousands)
Three Months Ended
March 31
20242023
Net sales$9,964 $9,747 
Cost of products sold, excluding amortization of intangible assets4,463 4,331 
Amortization of intangible assets472 491 
Research and development684 654 
Selling, general and administrative2,959 2,762 
Total operating cost and expenses8,578 8,238 
Operating earnings1,386 1,509 
Interest expense141 153 
Interest (income)(80)(101)
Net foreign exchange (gain) loss— 6 
Other (income) expense, net(111)(111)
Earnings before taxes1,436 1,562 
Taxes on earnings211 244 
Net Earnings$1,225 $1,318 
Basic Earnings Per Common Share$0.70 $0.75 
Diluted Earnings Per Common Share$0.70 $0.75 
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share1,740,203 1,741,738 
Dilutive Common Stock Options9,449 9,977 
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options1,749,652 1,751,715 
Outstanding Common Stock Options Having No Dilutive Effect6,892 7,332 
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
3
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Comprehensive Income
(Unaudited)
(dollars in millions)
Three Months Ended
March 31
20242023
Net Earnings$1,225 $1,318 
Foreign currency translation gain (loss) adjustments(386)139 
Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $1 in 2024 and $— in 2023
4 2 
Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $30 in 2024 and $(58) in 2023
55 (129)
Other comprehensive income (loss)(327)12 
Comprehensive Income$898 $1,330 
March 31,
2024		December 31,
2023
Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:
Cumulative foreign currency translation (loss) adjustments$(6,890)$(6,504)
Net actuarial (losses) and prior service (costs) and credits(1,372)(1,376)
Cumulative gains (losses) on derivative instruments designated as cash flow hedges96 41 
Accumulated Other Comprehensive Income (Loss)$(8,166)$(7,839)
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
4
Abbott Laboratories and Subsidiaries
Condensed Consolidated Balance Sheet
(Unaudited)
(dollars in millions)
March 31,
2024		December 31,
2023
Assets
Current Assets:
Cash and cash equivalents$6,284 $6,896 
Short-term investments367 383 
Trade receivables, less allowances of $439 in 2024 and $444 in 2023
6,605 6,565 
Inventories:
Finished products4,063 3,946 
Work in process881 807 
Materials1,883 1,817 
Total inventories6,827 6,570 
Prepaid expenses and other receivables2,293 2,256 
Total Current Assets22,376 22,670 
Investments818 799 
Property and equipment, at cost22,055 21,933 
Less: accumulated depreciation and amortization11,948 11,779 
Net property and equipment10,107 10,154 
Intangible assets, net of amortization8,296 8,815 
Goodwill23,383 23,679 
Deferred income taxes and other assets7,487 7,097 
$72,467 $73,214 
Liabilities and Shareholders’ Investment
Current Liabilities:
Trade accounts payable$4,178 $4,295 
Salaries, wages and commissions1,092 1,597 
Other accrued liabilities5,220 5,422 
Dividends payable959 955 
Income taxes payable562 492 
Current portion of long-term debt2,010 1,080 
Total Current Liabilities14,021 13,841 
Long-term debt12,576 13,599 
Post-employment obligations, deferred income taxes and other long-term liabilities6,827 6,947 
Commitments and Contingencies
Shareholders’ Investment:
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued
— — 
Common shares, without par value Authorized — 2,400,000,000 shares
Issued at stated capital amount — Shares: 2024: 1,989,789,999; 2023: 1,987,883,852
24,726 24,869 
Common shares held in treasury, at cost — Shares: 2024: 250,155,515; 2023: 253,807,494
(15,761)(15,981)
Earnings employed in the business38,011 37,554 
Accumulated other comprehensive income (loss)(8,166)(7,839)
Total Abbott Shareholders’ Investment38,810 38,603 
Noncontrolling Interests in Subsidiaries233 224 
Total Shareholders’ Investment39,043 38,827 
$72,467 $73,214 
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
5
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Shareholders’ Investment
(Unaudited)
(in millions except shares and per share data)
Three Months Ended March 31
20242023
Common Shares:
Balance at January 1
Shares: 2024: 1,987,883,852; 2023: 1,986,519,278
$24,869 $24,709 
Issued under incentive stock programs  
Shares: 2024: 1,906,147; 2023: 384,892
87 16 
Share-based compensation322 296 
Issuance of restricted stock awards(552)(533)
Balance at March 31  
Shares: 2024: 1,989,789,999; 2023: 1,986,904,170
$24,726 $24,488 
Common Shares Held in Treasury:
Balance at January 1
Shares: 2024: 253,807,494; 2023: 248,724,257
$(15,981)$(15,229)
Issued under incentive stock programs  
Shares: 2024: 3,838,255; 2023: 3,933,165
242 242 
Purchased  
Shares: 2024: 186,276; 2023: 3,166,279
(22)(320)
Balance at March 31  
Shares: 2024: 250,155,515; 2023: 247,957,371
$(15,761)$(15,307)
Earnings Employed in the Business:
Balance at January 1$37,554 $35,257 
Net earnings1,225 1,318 
Cash dividends declared on common shares (per share — 2024: $0.55; 2023: $0.51)
(960)(890)
Effect of common and treasury share transactions192 183 
Balance at March 31$38,011 $35,868 
Accumulated Other Comprehensive Income (Loss):
Balance at January 1$(7,839)$(8,051)
Other comprehensive income (loss)(327)12 
Balance at March 31$(8,166)$(8,039)
Noncontrolling Interests in Subsidiaries:
Balance at January 1$224 $219 
Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases9 3 
Balance at March 31$233 $222 
The accompanying notes to condensed consolidated financial statements are an integral part of this statement.
6
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Cash Flows
(Unaudited)
(dollars in millions)
Three Months Ended March 31
20242023
Cash Flow From (Used in) Operating Activities:
Net earnings$1,225 $1,318 
Adjustments to reconcile net earnings to net cash from operating activities —
Depreciation333 315 
Amortization of intangible assets472 491 
Share-based compensation304 281 
Trade receivables(151)233 
Inventories(410)(419)
Other, net(748)(1,076)
Net Cash From Operating Activities1,025 1,143 
Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment(398)(380)
Sales (purchases) of other investment securities, net(28)(86)
Other1 4 
Net Cash From (Used in) Investing Activities(425)(462)
Cash Flow From (Used in) Financing Activities:
Net borrowings (repayments) of short-term debt and other(127)(42)
Purchases of common shares(226)(540)
Proceeds from stock options exercised134 62 
Dividends paid(957)(890)
Net Cash From (Used in) Financing Activities(1,176)(1,410)
Effect of exchange rate changes on cash and cash equivalents(36)8 
Net Increase (Decrease) in Cash and Cash Equivalents(612)(721)
Cash and Cash Equivalents, Beginning of Year6,896 9,882 
Cash and Cash Equivalents, End of Period$6,284 $9,161 
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
7
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2024
(Unaudited)

Note 1 — Basis of Presentation

The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s Annual Report on Form 10-K for the year ended December 31, 2023. The condensed consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions.

Note 2 — New Accounting Standards

Recent Accounting Standards Not Yet Adopted

In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which expands the breadth and frequency of required segment disclosures. The guidance is required to be applied retrospectively to all periods presented in the financial statements. The standard becomes effective for Abbott for full year 2024 reporting and for interim periods beginning in the first quarter of 2025. Abbott is currently evaluating the impact of this new standard on its consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires an entity to disclose annually additional information related to the company's income tax rate reconciliation and income taxes paid during the period. The guidance should be applied prospectively with the option to apply the standard retrospectively. The standard becomes effective for Abbott for full year 2025 reporting. Abbott is currently evaluating the impact of this new standard on its consolidated financial statements.
8
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2024
(Unaudited)
Note 3 — Revenue

Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

The following tables provide detail by sales category:

Three Months Ended March 31, 2024Three Months Ended March 31, 2023
(in millions)U.S.Int’lTotalU.S.Int’lTotal
Established Pharmaceutical Products —
Key Emerging Markets$— $928 $928 $— $912 $912 
Other— 298 298 — 277 277 
Total— 1,226 1,226 — 1,189 1,189 
Nutritionals —    
Pediatric Nutritionals514 495 1,009 459 465 924 
Adult Nutritionals364 695 1,059 353 690 1,043 
Total878 1,190 2,068 812 1,155 1,967 
Diagnostics —     
Core Laboratory310 895 1,205 289 893 1,182 
Molecular42 87 129 47 100 147 
Point of Care98 41 139 93 41 134 
Rapid Diagnostics481 260 741 906 319 1,225 
Total931 1,283 2,214 1,335 1,353 2,688 
Medical Devices —    
Rhythm Management271 291 562 260 267 527 
Electrophysiology269 318 587 238 267 505 
Heart Failure237 68 305 218 63 281 
Vascular254 435 689 218 399 617 
Structural Heart233 282 515 210 251 461 
Neuromodulation181 45 226 155 41 196 
Diabetes Care 589 980 1,569 479 834 1,313 
Total2,034 2,419 4,453 1,778 2,122 3,900 
Other3 — 3 3 — 3 
Total$3,846 $6,118 $9,964 $3,928 $5,819 $9,747 

Products sold by the Diagnostics segment include various types of diagnostic tests to detect the COVID-19 coronavirus. In the first three months of 2024 and 2023, Abbott’s COVID-19 testing-related sales totaled $204 million and $730 million, respectively.


9
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2024
(Unaudited)
Note 3 — Revenue (Continued)
Remaining Performance Obligations

As of March 31, 2024, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was approximately $4.5 billion in the Diagnostics segment and approximately $495 million in the Medical Devices segment. Abbott expects to recognize revenue on approximately 59 percent of these remaining performance obligations over the next 24 months, approximately 16 percent over the subsequent 12 months and the remainder thereafter.

These performance obligations primarily reflect the future sale of reagents/consumables in contracts with minimum purchase obligations, extended warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has applied the practical expedient described in FASB Accounting Standards Codification (ASC) 606-10-50-14 and has not included remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.

Other Contract Assets and Liabilities

Abbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at the net amount expected to be collected. Contract assets primarily relate to Abbott’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were not significant.

Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott’s contract liabilities arise primarily in the Medical Devices reportable segment when payment is received upfront for various multi-period extended service arrangements.

Changes in the contract liabilities during the period are as follows:

(in millions)
Contract Liabilities:
Balance at December 31, 2023$545 
Unearned revenue from cash received during the period120 
Revenue recognized related to contract liability balance(116)
Balance at March 31, 2024$549 

Note 4 — Supplemental Financial Information

Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Net earnings allocated to common shares for the three months ended March 31, 2024 and 2023 were $1.220 billion and $1.313 billion, respectively.

Other, net in Net cash from operating activities in the Condensed Consolidated Statement of Cash Flows for the first three months of 2024 includes $280 million of pension contributions and the payment of cash taxes of approximately $225 million. The first three months of 2023 includes $282 million of pension contributions and the payment of cash taxes of approximately $122 million.

10
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2024
(Unaudited)
Note 4 — Supplemental Financial Information (Continued)
The following summarizes the activity for the first three months of 2024 related to the allowance for doubtful accounts as of March 31, 2024:

(in millions)
Allowance for Doubtful Accounts:
Balance at December 31, 2023$241 
Provisions/charges to income14 
Amounts charged off and other adjustments(8)
Balance at March 31, 2024$247 

The allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivable. Abbott considers various factors in establishing, monitoring, and adjusting its allowance for doubtful accounts, including the aging of the accounts and aging trends, the historical level of charge-offs, and specific exposures related to particular customers. Abbott also monitors other risk factors and forward-looking information, such as country risk, when determining credit limits for customers and establishing adequate allowances.

The components of long-term investments as of March 31, 2024 and December 31, 2023 are as follows:

(in millions)March 31,
2024		December 31,
2023
Long-term Investments:
Equity securities$547 $555 
Other271 244 
Total$818 $799 

The increase in Abbott’s long-term investments as of March 31, 2024 versus the balance as of December 31, 2023 primarily relates to additional investments and earnings from equity method investments, partially offset by the impairment of certain securities.

Abbott’s equity securities as of March 31, 2024, include $317 million of investments in mutual funds that are held in a rabbi trust. These investments, which are specifically designated as available for the purpose of paying benefits under a deferred compensation plan, are not available for general corporate purposes and are subject to creditor claims in the event of insolvency.

Abbott also holds certain investments as of March 31, 2024 with a carrying value of $154 million that are accounted for under the equity method of accounting and other equity investments with a carrying value of approximately $66 million that do not have a readily determinable fair value.

11
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2024
(Unaudited)
Note 5 — Changes In Accumulated Other Comprehensive Income (Loss)

The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:

Three Months Ended March 31
Cumulative Foreign
Currency Translation
(Loss) Adjustments		Net Actuarial (Losses) and
Prior Service (Costs) and
Credits		Cumulative Gains (Losses)
on Derivative Instruments
Designated as Cash Flow
Hedges and Other
(in millions)202420232024202320242023
Balance at January 1$(6,504)$(6,733)$(1,376)$(1,493)$41 $175 
Other comprehensive income (loss) before reclassifications(386)139 2 2 68 (42)
Amounts reclassified from accumulated other comprehensive income— — 2 — (13)(87)
Net current period comprehensive income (loss)(386)139 4 2 55 (129)
Balance at March 31$(6,890)$(6,594)$(1,372)$(1,491)$96 $46 

Reclassified amounts for cash flow hedges are recorded as Cost of products sold. Net actuarial losses and prior service cost are included as a component of net periodic benefit costs; see Note 13 for additional details.

Note 6 — Business Acquisitions

On September 22, 2023, Abbott completed the acquisition of Bigfoot Biomedical, Inc. (Bigfoot), which will further Abbott's efforts to develop connected solutions for making diabetes management more personal and precise. The purchase price, the preliminary allocation of acquired assets and liabilities, and the revenue and net income contributed by Bigfoot since the date of acquisition are not material to Abbott's condensed consolidated financial statements.

On April 27, 2023, Abbott completed the acquisition of Cardiovascular Systems, Inc. (CSI) for $20 per common share, which equated to a purchase price of $851 million. The transaction was funded with cash on hand and accounted for as a business combination. CSI's atherectomy system, which is used in treating peripheral and coronary artery disease, adds complementary technologies to Abbott's portfolio of vascular device offerings.

The final allocation of the purchase price of the CSI acquisition resulted in the recording of two non-deductible developed technology intangible assets totaling $305 million; non-deductible in-process research and development asset of $15 million, which will be accounted for as an indefinite-lived intangible asset until regulatory approval or discontinuation; non-deductible goodwill of $369 million; net deferred tax assets of $46 million and other net assets of $116 million. The goodwill is identifiable to the Medical Devices reportable segment and is attributable to expected synergies from combining operations, as well as intangible assets that do not qualify for separate recognition. Revenues and earnings of CSI included in Abbott's condensed consolidated financial statements since the acquisition date are not material to Abbott's consolidated revenue and earnings.

Note 7 — Goodwill and Intangible Assets

The total amount of goodwill reported was $23.4 billion at March 31, 2024 and $23.7 billion at December 31, 2023. Foreign currency translation adjustments decreased goodwill by approximately $294 million in the first three months of 2024. The amount of goodwill related to reportable segments at March 31, 2024 was $2.7 billion for the Established Pharmaceutical Products segment, $285 million for the Nutritional Products segment, $3.5 billion for the Diagnostic Products segment, and $16.9 billion for the Medical Devices segment. There was no reduction of goodwill relating to impairments in the first three months of 2024.
12
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2024
(Unaudited)
Note 7 — Goodwill and Intangible Assets (Continued)
The gross amount of amortizable intangible assets, primarily product rights and technology, was $27.5 billion and $27.7 billion as of March 31, 2024 and December 31, 2023, respectively. Accumulated amortization was $20.0 billion and $19.7 billion as of March 31, 2024 and December 31, 2023, respectively. In the first three months of 2024, intangible assets decreased $38 million due to foreign currency translation and $8 million due to an impairment charge. Abbott’s estimated annual amortization expense for intangible assets is approximately $1.9 billion in 2024, $1.7 billion in 2025, $1.6 billion in 2026, $1.3 billion in 2027 and $0.7 billion in 2028.

Indefinite-lived intangible assets, which relate to in-process R&D (IPR&D) acquired in a business combination, were approximately $787 million as of March 31, 2024 and as of December 31, 2023.

Note 8 — Restructuring Plans

In 2024, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in its nutritional business, including the discontinuation of its ZonePerfect® product line, and in its medical devices segment. In the first three months of 2024, Abbott recorded employee related severance and other charges of approximately $17 million, of which approximately $11 million was recorded in Cost of products sold, approximately $1 million was recorded in Research and development and approximately $5 million was recorded in Selling, general and administrative expenses. Payments related to these actions totaled $3 million in the first three months of 2024 and the remaining liabilities totaled $14 million at March 31, 2024. In addition, Abbott recognized asset impairment charges of approximately $30 million related to these restructuring plans.

In 2023 and 2022, Abbott management approved plans to restructure or streamline various operations in order to reduce costs in its medical devices, diagnostic, nutritional and established pharmaceutical businesses. The following summarizes the 2024 activity related to these restructuring actions and the status of the related accruals as of March 31, 2024:

(in millions)
Accrued balance at December 31, 2023$137 
Payments and other adjustments(41)
Accrued balance at March 31, 2024$96 

Note 9 — Incentive Stock Programs

In the first three months of 2024, Abbott granted 1,666,566 stock options, 404,597 restricted stock awards and 5,189,560 restricted stock units under its incentive stock program. At March 31, 2024, approximately 60 million shares were reserved for future grants. Information regarding the number of options outstanding and exercisable at March 31, 2024 is as follows:

OutstandingExercisable
Number of shares 28,281,501 24,296,425 
Weighted average remaining life (years)
5.14.4
Weighted average exercise price $78.71 $73.05 
Aggregate intrinsic value (in millions)
$1,031 $1,020 

The total unrecognized share-based compensation cost at March 31, 2024 amounted to approximately $787 million, which is expected to be recognized over the next three years.

13
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2024
(Unaudited)
Note 10 — Debt and Lines of Credit

Abbott has readily available financial resources, including unused lines of credit that support commercial paper borrowing arrangements and provide Abbott with the ability to borrow up to $5 billion on an unsecured basis. On January 29, 2024, Abbott terminated its 2020 Five Year Credit Agreement (2020 Agreement) and entered into a new Five Year Credit Agreement (Revolving Credit Agreement). There were no outstanding borrowings under the 2020 Agreement at the time of its termination. Any borrowings under the Revolving Credit Agreement will mature and be payable on January 29, 2029 and will bear interest, at Abbott’s option, based on either a base rate or Secured Overnight Financing Rate (SOFR), plus an applicable margin based on Abbott’s credit ratings.

Note 11 — Financial Instruments, Derivatives and Fair Value Measures

Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates, primarily for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross notional amounts totaling $7.3 billion at March 31, 2024 and at December 31, 2023, are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of March 31, 2024 will be included in Cost of products sold at the time the products are sold, generally through the next twelve to eighteen months.

Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar and European currencies. At March 31, 2024 and December 31, 2023, Abbott held gross notional amounts of $14.5 billion and $13.8 billion, respectively, of such foreign currency forward exchange contracts.

Abbott has designated a yen-denominated, 5-year term loan, scheduled to mature in November 2024, of approximately $395 million and $419 million as of March 31, 2024 and December 31, 2023, respectively, as a hedge of the net investment in certain foreign subsidiaries. The change in the value of the debt, which is due to changes in foreign exchange rates, is recorded in Accumulated other comprehensive income (loss), net of tax.

Abbott is a party to interest rate hedge contracts totaling approximately $2.2 billion at March 31, 2024 and December 31, 2023 to manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.

14
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2024
(Unaudited)
Note 11 — Financial Instruments, Derivatives and Fair Value Measures (Continued)
The following table summarizes the amounts and location of certain derivative financial instruments as of March 31, 2024 and December 31, 2023:

Fair Value - AssetsFair Value - Liabilities
(in millions)March 31,
2024		December 31,
2023		Balance Sheet CaptionMarch 31,
2024		December 31,
2023		Balance Sheet Caption
Interest rate swaps designated as fair value hedges:
Non-current $— $— Deferred income taxes and other assets$88 $95 Post-employment obligations, deferred income taxes and other long-term liabilities
Current— — Prepaid expenses and other receivables31 — Other accrued liabilities
Foreign currency forward exchange contracts:
Hedging instruments118 88 Prepaid expenses and other receivables61 134 Other accrued liabilities
Others not designated as hedges52 81 Prepaid expenses and other receivables39 97 Other accrued liabilities
Debt designated as a hedge of net investment in a foreign subsidiary— — n/a395 419 Current portion of long-term debt
$170 $169 $614 $745 

The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three months ended March 31, 2024 and 2023.

Gain (loss) Recognized in Other Comprehensive Income (loss)Income (expense) and
 Gain (loss) Reclassified into Income
Three Months
Ended March 31		Three Months
Ended March 31
(in millions)2024202320242023Income Statement Caption
Foreign currency forward exchange contracts designated as cash flow hedges$127 $(63)$18 $126 Cost of products sold
Debt designated as a hedge of net investment in a foreign subsidiary24 (5)— — n/a
Interest rate swaps designated as fair value hedgesn/an/a(24)9 Interest expense

15
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2024
(Unaudited)
Note 11 — Financial Instruments, Derivatives and Fair Value Measures (Continued)
Gains of $92 million and losses of $103 million were recognized in the three months ended March 31, 2024 and 2023, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net foreign exchange (gain) loss line.

The carrying values and fair values of certain financial instruments as of March 31, 2024 and December 31, 2023 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.

March 31, 2024December 31, 2023
(in millions)Carrying
Value		Fair
Value		Carrying
Value		Fair
Value
Long-term Investment Securities:
Equity securities$547 $547 $555 $555 
Other271 271 244 244 
Total Long-term Debt(14,586)(14,299)(14,679)(14,769)
Foreign Currency Forward Exchange Contracts:   
Receivable position170 170 169 169 
(Payable) position(100)(100)(231)(231)
Interest Rate Hedge Contracts:    
(Payable) position(119)(119)(95)(95)

The fair value of the debt was determined based on significant other observable inputs, including current interest rates.

16
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2024
(Unaudited)
Note 11 — Financial Instruments, Derivatives and Fair Value Measures (Continued)
The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:

Basis of Fair Value Measurement
(in millions)Outstanding
Balances		Quoted
Prices in
Active
Markets		Significant
Other
Observable
Inputs		Significant
Unobservable
Inputs
March 31, 2024:
Equity securities$327 $327 $— $— 
Foreign currency forward exchange contracts170 — 170 — 
Total Assets$497 $327 $170 $— 
Fair value of hedged long-term debt$2,046 $— $2,046 $— 
Interest rate swap derivative financial instruments119 — 119 — 
Foreign currency forward exchange contracts100 — 100 — 
Contingent consideration related to business combinations59 — — 59 
Total Liabilities$2,324 $— $2,265 $59 
December 31, 2023:
Equity securities$326 $326 $— $— 
Foreign currency forward exchange contracts169 — 169 — 
Total Assets$495 $326 $169 $— 
Fair value of hedged long-term debt$2,052 $— $2,052 $— 
Interest rate swap derivative financial instruments95 — 95 — 
Foreign currency forward exchange contracts231 — 231 — 
Contingent consideration related to business combinations112 — — 112 
Total Liabilities$2,490 $— $2,378 $112 

The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis using significant other observable inputs. The fair value of the contingent consideration was determined based on independent appraisals at the time of acquisition, adjusted for the time value of money and other changes in fair value. The decrease in the amount of contingent consideration from December 31, 2023 reflects a payment of $40 million and a $13 million change in the fair value of the remaining contingent consideration.

The maximum amount for certain contingent consideration is not determinable as it is based on a percent of certain sales. Excluding such contingent consideration, the maximum amount that may be due under the other contingent consideration arrangements was estimated at March 31, 2024 to be approximately $135 million, which is dependent upon attaining certain sales thresholds or upon the occurrence of certain events, such as regulatory approvals.

17
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2024
(Unaudited)

Note 12 — Litigation and Environmental Matters

Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million.

Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately $45 million to $60 million. The recorded accrual balance at March 31, 2024 for these proceedings and exposures was approximately $55 million. This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.” Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations.

Note 13 — Post-Employment Benefits

Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net periodic benefit costs, other than service costs, are recognized in the Other (income) expense, net line of the Condensed Consolidated Statement of Earnings. Net cost recognized for the three months ended March 31 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:

Defined Benefit PlansMedical and Dental Plans
Three Months
Ended March 31		Three Months
Ended March 31
(in millions)2024202320242023
Service cost - benefits earned during the period$61 $60 $10 $9 
Interest cost on projected benefit obligations118 114 15 14 
Expected return on plan assets(262)(242)(6)(6)
Net amortization of:
Actuarial loss, net6 3 — — 
Prior service cost (credit)— — (3)(3)
Net cost (credit)$(77)$(65)$16 $14 

Abbott funds its domestic defined benefit plans according to Internal Revenue Service funding limitations. International pension plans are funded according to similar regulations. In the first three months of 2024 and 2023, $280 million and $282 million, respectively, were contributed to defined benefit plans. In the first three months of 2024 and 2023, $28 million was contributed in each year to the post-employment medical and dental plans.

18
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2024
(Unaudited)
Note 14 — Taxes on Earnings

Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first three months of 2024 and 2023, taxes on earnings include approximately $25 million and $3 million, respectively, in excess tax benefits associated with share-based compensation. In the first three months of 2024 and 2023, taxes on earnings also include approximately $10 million and $22 million, respectively, of tax expense as the result of the resolution of various tax positions related to prior years.

Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease approximately $82 million to $1.34 billion, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters.

In September 2023, Abbott received a Statutory Notice of Deficiency (SNOD) from the U.S. Internal Revenue Service (IRS) for the 2019 Federal tax year in the amount of $417 million. The primary adjustments proposed in the SNOD relate to the reallocation of income between Abbott’s U.S. entities and its foreign affiliates. Abbott believes that the income reallocation adjustments proposed in the SNOD are without merit, in part because certain adjustments contradict methods that were agreed to with the IRS in prior audit periods. The SNOD also contains other proposed adjustments that Abbott believes are erroneous and unsupported. Abbott filed a petition with the U.S. Tax Court contesting the SNOD in December 2023.

Abbott’s 2017 and 2018 Federal tax years are also currently under examination by the IRS with respect to income reallocation issues similar to those included in the 2019 Federal tax year. Abbott intends to vigorously defend its filing positions through ongoing discussions with the IRS, the IRS independent appeals process and/or through litigation as necessary.

Abbott reserves for uncertain tax positions related to unresolved matters with the IRS and other taxing authorities. Abbott continues to believe that its reserves for uncertain tax positions are appropriate.

The Organization for Economic Cooperation & Development (OECD) has proposed a two-pillared plan for a revised international tax system. Pillar 1 proposes to reallocate taxing rights among the jurisdictions in which in-scope multinational corporations operate. Abbott is continuing to analyze the Pillar 1 proposal. Pillar 2 proposes to assess a 15 percent minimum tax on the earnings of in-scope multinational corporations on a country-by-country basis. Numerous countries have enacted legislation to adopt the Pillar 2 model rules. A subset of the rules became effective January 1, 2024, and the remaining rules become effective January 1, 2025 or later. Abbott continues to analyze the Pillar 2 model rules. The full implementation of the model rules may have a material impact on Abbott’s condensed consolidated financial statements in the future.
19
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2024
(Unaudited)
Note 15 — Segment Information

Abbott’s principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices and government agencies throughout the world.

Abbott’s reportable segments are as follows:

Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical products.

Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products.

Diagnostic Products — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. For segment reporting purposes, the Core Laboratory Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care Diagnostics businesses are aggregated and reported as the Diagnostic Products segment.

Medical Devices — Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. For segment reporting purposes, the Cardiac Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, Neuromodulation and Diabetes Care divisions are aggregated and reported as the Medical Devices segment.

Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. Intersegment transfers of inventory are recorded at standard cost and are not a measure of segment operating earnings. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.

20
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2024
(Unaudited)
Note 15 — Segment Information (Continued)
The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the condensed consolidated financial statements.

 Net Sales to External CustomersOperating Earnings
Three Months
Ended March 31		Three Months
Ended March 31
(in millions)202420232024 2023
Established Pharmaceutical Products$1,226 $1,189 $267 $300 
Nutritional Products2,068 1,967 377 380 
Diagnostic Products2,214 2,688 474 651 
Medical Devices4,453 3,900 1,360 1,078 
Total Reportable Segments9,961 9,744 2,478 2,409 
Other 3 3 
Net sales$9,964 $9,747 
Corporate functions and benefit plan costs(66)(77)
Net interest expense (61)(52)
Share-based compensation (a) (304)(281)
Amortization of intangible assets(472)(491)
Other, net (b)(139)54 
Earnings before taxes$1,436 $1,562 
______________________________________
(a)
Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.
(b)
Other, net for the three months ended March 31, 2024 and March 31, 2023 includes charges related to restructuring actions. Other, net for the three months ended March 31, 2024 also includes integration costs associated with the acquisition of CSI and $38 million related to various investment impairments.
21
Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations

Financial Review — Results of Operations

Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Patent protection and licenses, technological and performance features, and inclusion of Abbott’s products under a contract most impact which products are sold; price controls, competition and rebates most impact the net selling prices of products; and foreign currency translation impacts the measurement of net sales and costs. Abbott’s primary products are medical devices, diagnostic testing products, nutritional products and branded generic pharmaceuticals.

The following tables detail sales by reportable segment for the three months ended March 31. Percent changes are versus the prior year and are based on unrounded numbers.

Net Sales to External Customers
(in millions)Three Months Ended
March 31, 2024		Three Months Ended
March 31, 2023		Total
Change		Impact of
Foreign
Exchange		Total Change
Excl. Foreign
Exchange
Established Pharmaceutical Products$1,226 $1,189 3.1 %(10.6)%13.7 %
Nutritional Products2,068 1,967 5.1 (2.6)7.7 
Diagnostic Products2,214 2,688 (17.6)(2.1)(15.5)
Medical Devices4,453 3,900 14.2 (1.2)15.4 
Total Reportable Segments9,961 9,744 2.2 (2.9)5.1 
Other3 3 ———
Net Sales$9,964 $9,747 2.2 (2.9)5.1 
Total U.S.$3,846 $3,928 (2.1)— (2.1)
Total International$6,118 $5,819 5.2 (4.8)10.0 
______________________________________
Notes:In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

The 5.1 percent increase in total net sales during the first three months of 2024, excluding the impact of foreign exchange, reflected higher sales primarily in the Medical Devices and Established Pharmaceuticals segments, partially offset by a decrease in demand for Abbott’s rapid diagnostic tests to detect COVID-19. Abbott’s COVID-19 testing-related sales totaled $204 million during the first quarter of 2024 and $730 million during the first quarter of 2023. Excluding the impact of COVID-19 testing-related sales, Abbott’s total net sales increased 8.2 percent. Excluding the impacts of COVID-19 testing-related sales and foreign exchange, Abbott’s total net sales increased 11.3 percent. In the first quarter of 2024, Abbott’s net sales were unfavorably impacted by changes in foreign exchange rates as the relatively stronger U.S. dollar decreased total international sales by 4.8 percent and total sales by 2.9 percent.



22
The table below provides detail by sales category for the three months ended March 31. Percent changes are versus the prior year and are based on unrounded numbers.

(in millions)March 31,
2024		March 31,
2023		Total
Change		Impact of
Foreign
Exchange		Total Change
Excl. Foreign
Exchange
Established Pharmaceutical Products —
Key Emerging Markets$928 $912 1.7 %(13.7)%15.4 %
Other Emerging Markets298 277 7.6 (0.6)8.2 
Nutritionals —
International Pediatric Nutritionals495 465 6.4 (2.5)8.9 
U.S. Pediatric Nutritionals514 459 12.0 — 12.0 
International Adult Nutritionals695 690 0.8 (5.6)6.4 
U.S. Adult Nutritionals364 353 3.0 — 3.0 
Diagnostics —
Core Laboratory1,205 1,182 2.0 (3.9)5.9 
Molecular129 147 (11.9)(0.2)(11.7)
Point of Care139 134 3.7 0.1 3.6 
Rapid Diagnostics741 1,225 (39.5)(0.8)(38.7)
Medical Devices —
Rhythm Management562 527 6.8 (0.7)7.5 
Electrophysiology587 505 16.2 (2.2)18.4 
Heart Failure305 281 8.5 0.1 8.4 
Vascular689 617 11.7 (1.0)12.7 
Structural Heart515 461 11.7 (1.3)13.0 
Neuromodulation226 196 15.3 (2.1)17.4 
Diabetes Care1,569 1,313 19.5 (1.2)20.7 

23
Excluding the unfavorable effect of foreign exchange, sales in the Key Emerging Markets for Established Pharmaceutical Products increased 15.4 percent in the first three months of 2024, led by growth in several countries and across several therapeutic areas, including respiratory, women's health, and central nervous system/pain management. Other Emerging Markets, excluding the effect of foreign exchange, increased by 8.2 percent in the first three months of 2024.

Excluding the impact of foreign exchange, total Nutritional Products sales in the first three months of 2024 increased 7.7 percent. In U.S. Pediatric Nutritionals, the 12.0 percent increase in sales in the first three months of 2024 reflects the continued progress in recovering market share following the voluntary recall of certain infant formula products in the first quarter of 2022, partially offset by a decrease in PediaSure® and Pedialyte® sales. Excluding the effect of foreign exchange, the 8.9 percent increase in International Pediatric Nutritional sales in the first three months of 2024 primarily reflects growth in Canada and several countries in Asia Pacific and Latin America.

Excluding the effect of foreign exchange, the increases of 3.0 percent in U.S. Adult Nutritionals and 6.4 percent in International Adult Nutritionals in the first three months of 2024 reflect growth of Ensure® and Glucerna® product sales.
The 15.5 percent decrease in Diagnostic Products sales in the first three months of 2024, excluding the impact of foreign exchange, was primarily driven by lower demand for COVID-19 tests. In Rapid Diagnostics, sales decreased 38.7 percent in the first three months of 2024, excluding the effect of foreign exchange, due to lower demand for COVID-19 tests. In the first three months of 2024 and 2023, Rapid Diagnostics COVID-19 testing-related sales were $197 million and $704 million, respectively. In the first three months of 2024, Rapid Diagnostics sales increased 4.4 percent, excluding COVID-19 testing-related sales, and increased 5.6 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.
In Core Laboratory Diagnostics, sales increased 5.9 percent in the first three months of 2024, excluding the effect of foreign exchange, due to the continued deployment of Abbott's Alinity® testing platform and higher volume of routine diagnostic testing performed in hospitals and other laboratories, partially offset by lower test sales for the detection of COVID-19 IgG and IgM antibodies. In the first three months of 2024 and 2023, Core Laboratory Diagnostics COVID-19 testing-related sales were $3 million and $6 million, respectively. In the first three months of 2024, Core Laboratory Diagnostics sales increased 2.2 percent, excluding COVID-19 testing-related sales, and increased 6.2 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.

The 11.7 percent decrease in Molecular Diagnostics sales in the first three months of 2024, excluding the effect of foreign exchange, was primarily driven by lower demand for laboratory-based molecular tests for COVID-19. In the first three months of 2024 and 2023, Molecular Diagnostics COVID-19 testing-related sales were $4 million and $20 million, respectively. In the first three months of 2024, Molecular Diagnostics sales decreased 1.1 percent, excluding COVID-19 testing-related sales, and decreased 0.8 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.

Excluding the effect of foreign exchange, total Medical Devices sales increased 15.4 percent in the first three months of 2024, led by double-digit growth in Diabetes Care, Electrophysiology, Vascular, Structural Heart and Neuromodulation. Higher Diabetes Care sales were driven by continued growth of FreeStyle Libre®, Abbott’s continuous glucose monitoring system, in the U.S. and internationally. FreeStyle Libre sales totaled $1.5 billion in the first three months of 2024, which reflected a 23.3 percent increase, excluding the effect of foreign exchange, over the first three months of 2023 when FreeStyle Libre sales totaled $1.2 billion.

In January 2024, Abbott announced that Tandem Diabetes Care, Inc.'s t:slim X2™ insulin pump is the first automated insulin delivery system in the U.S. to integrate with Abbott's FreeStyle Libre 2 Plus sensor for treating diabetes. In February 2024, Insulet's Omnipod® 5 Automated Insulin Delivery System received CE Mark approval to be offered as an integrated solution with Abbott's FreeStyle Libre 2 Plus sensor.

During the first three months of 2024, procedure volumes continued to increase across the cardiovascular and neuromodulation businesses. In Structural Heart, the 13.0 percent increase in sales, excluding the effect of foreign exchange, primarily reflects continued growth of the MitraClip® and Navitor® products, as well as various structural intervention products. In Vascular, the 12.7 percent increase in sales, excluding the impact of foreign exchange, during the first three months of 2024 was primarily due to the acquisition of Cardiovascular Systems, Inc. (CSI) in April 2023 and double-digit growth in other endovascular sales.

24
In Electrophysiology, the 18.4 percent increase in sales, excluding the effect of foreign exchange, primarily reflects higher procedure volumes in the U.S., the Asia Pacific region and various European countries. In Neuromodulation, the 17.4 percent increase in sales, excluding the effect of foreign exchange, was driven by the EternaTM rechargeable spinal cord stimulation system for the treatment of chronic pain.

Abbott's gross profit margin percentage remained at 50.5 percent for the first quarter of 2024 compared to the first quarter of 2023 as the unfavorable effect of foreign exchange was offset by the favorable impacts of gross margin improvement initiatives, higher pricing in various businesses and product mix.

Research and development (R&D) expenses increased $30 million, or 4.5 percent, in the first quarter of 2024 compared to the prior year. The increase in R&D expenses in the first quarter of 2024 was driven by higher spending on various projects.

Selling, general and administrative (SG&A) expenses increased $197 million, or 7.1 percent, in the first quarter of 2024 compared to the prior year as higher SG&A spending to drive growth across various businesses was partially offset by the favorable impact of foreign exchange.

Restructuring Plans

In 2024, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in its nutritional business, including the discontinuation of its ZonePerfect® product line, and in its medical devices segment. In the first three months of 2024, Abbott recorded employee related severance and other charges of approximately $17 million, of which approximately $11 million was recorded in Cost of products sold, approximately $1 million was recorded in Research and development and approximately $5 million was recorded in Selling, general and administrative expenses. Payments related to these actions totaled $3 million in the first three months of 2024 and the remaining liabilities totaled $14 million at March 31, 2024. In addition, Abbott recognized asset impairment charges of approximately $30 million related to these restructuring plans.

Other (Income) Expense, net

Other income, net totaled $111 million in the first quarter of 2024 and 2023. An increase in income associated with the non-service cost components of net pension and post-retirement medical benefit costs and a favorable change in the fair value of contingent consideration liabilities were offset by charges related to investment impairments.

Interest Expense, net

Interest expense, net increased from $52 million in the first quarter of 2023 to $61 million in the first quarter of 2024 as interest income decreased from $101 million to $80 million due to a lower average cash balance in the first quarter of 2024 versus the first quarter of 2023. The decrease in interest income was partially offset by lower interest expense due to the repayment of approximately $2.25 billion of long-term debt in September and November of 2023.

Taxes on Earnings

Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first three months of 2024 and 2023, taxes on earnings include approximately $25 million and $3 million, respectively, in excess tax benefits associated with share-based compensation. In the first three months of 2024 and 2023, taxes on earnings also include approximately $10 million and $22 million, respectively, of tax expense as the result of the resolution of various tax positions related to prior years.

Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease approximately $82 million to $1.34 billion, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters.

25
In September 2023, Abbott received a Statutory Notice of Deficiency (SNOD) from the IRS for the 2019 Federal tax year in the amount of $417 million. The primary adjustments proposed in the SNOD relate to the reallocation of income between Abbott’s U.S. entities and its foreign affiliates. Abbott believes that the income reallocation adjustments proposed in the SNOD are without merit, in part because certain adjustments contradict methods that were agreed to with the IRS in prior audit periods. The SNOD also contains other proposed adjustments that Abbott believes are erroneous and unsupported. Abbott filed a petition with the U.S. Tax Court contesting the SNOD in December 2023.

Abbott’s 2017 and 2018 Federal tax years are also currently under examination by the IRS with respect to income reallocation issues similar to those included in the 2019 Federal tax year. Abbott intends to vigorously defend its filing positions through ongoing discussions with the IRS, the IRS independent appeals process and/or through litigation as necessary.

Abbott reserves for uncertain tax positions related to unresolved matters with the IRS and other taxing authorities. Abbott continues to believe that its reserves for uncertain tax positions are appropriate.

The Organization for Economic Cooperation & Development (OECD) has proposed a two-pillared plan for a revised international tax system. Pillar 1 proposes to reallocate taxing rights among the jurisdictions in which in-scope multinational corporations operate. Abbott is continuing to analyze the Pillar 1 proposal. Pillar 2 proposes to assess a 15 percent minimum tax on the earnings of in-scope multinational corporations on a country-by-country basis. Numerous countries have enacted legislation to adopt the Pillar 2 model rules. A subset of the rules became effective January 1, 2024, and the remaining rules become effective January 1, 2025 or later. Abbott continues to analyze the Pillar 2 model rules. The full implementation of the model rules may have a material impact on Abbott’s condensed consolidated financial statements in the future.

Liquidity and Capital Resources

The decrease in cash and cash equivalents from $6.9 billion at December 31, 2023 to $6.3 billion at March 31, 2024 primarily reflects the payment of dividends and capital expenditures, partially offset by the cash generated from operations in the first three months of 2024. Working capital was $8.4 billion at March 31, 2024 and $8.8 billion at December 31, 2023. The decrease in working capital in 2024 primarily reflects a decrease in cash and cash equivalents, as well as an increase in the current portion of long-term debt, partially offset by decreases in accrued salaries and accounts payable.

In the Condensed Consolidated Statement of Cash Flows, Net cash from operating activities for the first three months of 2024 totaled approximately $1.0 billion, which reflects a decrease of $118 million from the prior year. The decrease reflects lower operating earnings and an increase in trade receivables in 2024. In the first three months of 2024, Net cash from operating activities includes $280 million of pension contributions and the payment of cash taxes of approximately $225 million. In the first three months of 2023, Net cash from operating activities includes $282 million of pension contributions and the payment of cash taxes of approximately $122 million.

At March 31, 2024, Abbott’s long-term debt rating was AA- by S&P Global Ratings and Aa3 by Moody’s Investors Service. Abbott expects to maintain an investment grade rating.

Abbott has readily available financial resources, including unused lines of credit that support commercial paper borrowing arrangements and provide Abbott with the ability to borrow up to $5 billion on an unsecured basis. On January 29, 2024, Abbott terminated its 2020 Five Year Credit Agreement (2020 Agreement) and entered into a new Five Year Credit Agreement (Revolving Credit Agreement). There were no outstanding borrowings under the 2020 Agreement at the time of its termination. Any borrowings under the Revolving Credit Agreement will mature and be payable on January 29, 2029 and will bear interest, at Abbott’s option, based on either a base rate or Secured Overnight Financing Rate (SOFR), plus an applicable margin based on Abbott’s credit ratings.

In the first quarter of 2024, Abbott declared a quarterly dividend of $0.55 per share on its common shares, which represents an increase of 7.8 percent over the $0.51 per share dividend declared in the first quarter of 2023.

26
Business Acquisition

On September 22, 2023, Abbott completed the acquisition of Bigfoot Biomedical, Inc. (Bigfoot), which will further Abbott's efforts to develop connected solutions for making diabetes management more personal and precise. The purchase price, the preliminary allocation of acquired assets and liabilities, and the revenue and net income contributed by Bigfoot since the date of acquisition are not material to Abbott's condensed consolidated financial statements.

On April 27, 2023, Abbott completed the acquisition of CSI for $20 per common share, which equated to a purchase price of $851 million. The transaction was funded with cash on hand and accounted for as a business combination. CSI's atherectomy system, which is used in treating peripheral and coronary artery disease, adds complementary technologies to Abbott's portfolio of vascular device offerings.

The final allocation of the purchase price of the CSI acquisition resulted in the recording of two non-deductible developed technology intangible assets totaling $305 million; non-deductible in-process research and development of $15 million, which will be accounted for as an indefinite-lived intangible asset until regulatory approval or discontinuation; non-deductible goodwill of $369 million; net deferred tax assets of $46 million and other net assets of $116 million. The goodwill is identifiable to the Medical Devices reportable segment and is attributable to expected synergies from combining operations, as well as intangible assets that do not qualify for separate recognition. Revenues and earnings of CSI included in Abbott's condensed consolidated financial statements since the acquisition date are not material to Abbott's consolidated revenue and earnings.

Legislative Issues

Abbott’s primary markets are highly competitive and subject to substantial government regulations throughout the world. Abbott expects debate to continue over the availability, method of delivery, and payment for health care products and services. It is not possible to predict the extent to which Abbott or the health care industry in general might be adversely affected by these factors in the future. A more complete discussion of these factors is contained in Item 1, Business, and Item 1A, Risk Factors, in the 2023 Annual Report on Form 10-K.

Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements

Under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Abbott cautions that any forward-looking statements made by Abbott are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

27
PART I. FINANCIAL INFORMATION

Item 4.     Controls and Procedures

(a)Evaluation of disclosure controls and procedures. The Chief Executive Officer, Robert B. Ford, and Chief Financial Officer, Philip P. Boudreau, evaluated the effectiveness of Abbott Laboratories’ disclosure controls and procedures as of the end of the period covered by this report, and concluded that Abbott Laboratories’ disclosure controls and procedures were effective to ensure that information Abbott is required to disclose in the reports that it files or submits with the Securities and Exchange Commission (the “Commission”) under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms, and to ensure that information required to be disclosed by Abbott in the reports that it files or submits under the Exchange Act is accumulated and communicated to Abbott’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

(b)Changes in internal control over financial reporting. During the quarter ended March 31, 2024, there were no changes in Abbott’s internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, Abbott’s internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1.     Legal Proceedings

Abbott is involved in various claims, legal proceedings and investigations as described in our Annual Report on Form 10-K for the year ended December 31, 2023, including those described below (as of March 31, 2024, except where noted below). While it is not feasible to predict the outcome of such pending claims, proceedings, and investigations with certainty, management is of the opinion that their ultimate resolution should not have a material adverse effect on Abbott's financial position, cash flows, or results of operations.

In its 2023 Annual Report on Form 10-K, Abbott reported that its first U.S. patent infringement trial against DexCom, Inc. (DexCom) was scheduled for March 2024. In March 2024, the trial occurred, with the jury finding that DexCom's G6 products infringe one of Abbott's inserter patents. A further trial to determine damages will occur at a future date.

Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds

(c)Issuer Purchases of Equity Securities

Period(a) Total
Number of
Shares (or
Units)
Purchased		(b) Average
Price Paid per
Share (or
Unit)		(c) Total Number
of Shares (or
Units) Purchased
as Part of
Publicly
Announced Plans
or Programs		(d) Maximum
Number (or
Approximate
Dollar Value) of
Shares (or Units)
that May Yet Be
Purchased Under
the Plans or
Programs
January 1, 2024 - January 31, 2024— 
(1)
$— — $1,409,092,884 
(2)
February 1, 2024 - February 29, 2024— 
(1)
— — 1,409,092,884 
(2)
March 1, 2024 - March 31, 2024— 
(1)
— — 1,409,092,884 
(2)
Total— 
(1)
$— — $1,409,092,884 
(2)
______________________________________
1.These shares do not include the shares surrendered to Abbott to satisfy tax withholding obligations in connection with the vesting of restricted stock or restricted stock units.
2.On December 10, 2021, the board of directors authorized the repurchase of up to $5 billion of Abbott common shares, from time to time.

28
Item 6.     Exhibits
Exhibit No.Exhibit
31.1
31.2
Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed” under the Securities Exchange Act of 1934.
32.1
32.2
101The following financial statements and notes from the Abbott Laboratories Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, formatted in Inline XBRL: (i) Condensed Consolidated Statement of Earnings; (ii) Condensed Consolidated Statement of Comprehensive Income; (iii) Condensed Consolidated Balance Sheet; (iv) Condensed Consolidated Statement of Shareholders’ Investment; (v) Condensed Consolidated Statement of Cash Flows; and (vi) Notes to the Condensed Consolidated Financial Statements.
104Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document and included in Exhibit 101).
29
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ABBOTT LABORATORIES
By:/s/ PHILIP P. BOUDREAU
Philip P. Boudreau
Senior Vice President, Finance
and Chief Financial Officer
Date: May 2, 2024
30
 EX-31.1 2 q1202410qex311.htm EX-31.1 Document

Exhibit 31.1
Certification of Chief Executive Officer
Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))
I, Robert B. Ford, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Abbott Laboratories;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of Abbott as of, and for, the periods presented in this report;
4.Abbott’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for Abbott and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to Abbott, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of Abbott’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in Abbott’s internal control over financial reporting that occurred during Abbott’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, Abbott’s internal control over financial reporting; and
5.Abbott’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to Abbott’s auditors and the audit committee of Abbott’s board of directors:
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect Abbott’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in Abbott’s internal control over financial reporting.
Date: May 2, 2024/s/ ROBERT B. FORD
Robert B. Ford
Chairman of the Board and Chief Executive Officer

 EX-31.2 3 q1202410qex312.htm EX-31.2 Document

Exhibit 31.2
Certification of Chief Financial Officer
Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))
I, Philip P. Boudreau, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Abbott Laboratories;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of Abbott as of, and for, the periods presented in this report;
4.Abbott’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for Abbott and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to Abbott, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of Abbott’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in Abbott’s internal control over financial reporting that occurred during Abbott’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, Abbott’s internal control over financial reporting; and
5.Abbott’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to Abbott’s auditors and the audit committee of Abbott’s board of directors:
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect Abbott’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in Abbott’s internal control over financial reporting.
Date: May 2, 2024/s/ PHILIP P. BOUDREAU
Philip P. Boudreau
Senior Vice President, Finance
and Chief Financial Officer

 EX-32.1 4 q1202410qex321.htm EX-32.1 Document

Exhibit 32.1
Certification Pursuant To
18 U.S.C. Section 1350
As Adopted Pursuant To
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report of Abbott Laboratories (the “Company”) on Form 10-Q for the period ended March 31, 2024 as filed with the Securities and Exchange Commission (the “Report”), I, Robert B. Ford, Chairman of the Board and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ ROBERT B. FORD
Robert B. Ford
Chairman of the Board and Chief Executive Officer
May 2, 2024
A signed original of this written statement required by Section 906 has been provided to Abbott Laboratories and will be retained by Abbott Laboratories and furnished to the Securities and Exchange Commission or its staff upon request.

 EX-32.2 5 q1202410qex322.htm EX-32.2 Document

Exhibit 32.2
Certification Pursuant To
18 U.S.C. Section 1350
As Adopted Pursuant To
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report of Abbott Laboratories (the “Company”) on Form 10-Q for the period ended March 31, 2024 as filed with the Securities and Exchange Commission (the “Report”), I, Philip P. Boudreau, Senior Vice President, Finance and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ PHILIP P. BOUDREAU
Philip P. Boudreau
Senior Vice President, Finance
and Chief Financial Officer
May 2, 2024
A signed original of this written statement required by Section 906 has been provided to Abbott Laboratories and will be retained by Abbott Laboratories and furnished to the Securities and Exchange Commission or its staff upon request.

 EX-101.SCH 6 abt-20240331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Statement of Earnings (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Statement of Comprehensive Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Balance Sheet (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statement of Shareholders' Investment (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Condensed Consolidated Statement of Shareholders' Investment (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000009 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - New Accounting Standards link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Supplemental Financial Information link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Changes In Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Business Acquisitions link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Restructuring Plans link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Incentive Stock Programs link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Debt and Lines of Credit link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Litigation and Environmental Matters link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Post-Employment Benefits link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Taxes on Earnings link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - New Accounting Standards (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Supplemental Financial Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Changes In Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Restructuring Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Incentive Stock Programs (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Post-Employment Benefits (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Revenue - Summary of Revenue by Sales Category (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Revenue - Schedule of Changes in Contract Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Supplemental Financial Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Supplemental Financial Information - Allowance for Doubtful Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Supplemental Financial Information - Long-Term Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Changes In Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Business Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Goodwill and Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Restructuring Plans - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Restructuring Plans - Restructuring Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Incentive Stock Programs - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Incentive Stock Programs - Options (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Debt and Lines of Credit (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Amounts and Location of Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Schedule of Derivatives Gain (Loss) in OCI and Income (Expense) (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Litigation and Environmental Matters (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Post-Employment Benefits - Schedule of Net Periodic Cost (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Post-Employment Benefits - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Taxes on Earnings (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 abt-20240331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 abt-20240331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 abt-20240331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Statistical Measurement [Domain] Statistical Measurement [Domain] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Research and development Research and Development Expense Award Type [Domain] Award Type [Domain] Expected timing of satisfaction period (in months) Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Prepaid expenses and other receivables Prepaid Expense and Other Receivables [Member] The Other Prepaid Expenses and Receivables line item in the statement of financial position in which the amounts are included. Impairment charge Impairment of Intangible Assets (Excluding Goodwill) Debt and Lines of Credit Debt Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Neuromodulation Neuromodulation [Member] It represents the neuromodulation, segment of the entity. Revolving Credit Facility Revolving Credit Facility [Member] Net actuarial (losses) and prior service (costs) and credits Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax Segment Reporting [Abstract] Segment Reporting [Abstract] Exercisable, weighted-average remaining life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Pediatric Nutritionals Pediatric Nutritionals [Member] It represents the pediatric nutritionals, segment of the entity. Commitments and Contingencies Commitments and Contingencies 2024 Five Year Credit Agreement 2024 Five Year Credit Agreement [Member] 2024 Five Year Credit Agreement Exercisable, number of shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases Noncontrolling Interests Share of Income Net of Distributions and Share Repurchases and Business Combinations This element represent Noncontrolling Interests' share of income, net of distributions, share repurchases and business combinations. Geographical [Axis] Geographical [Axis] Taxes on Earnings Income Tax Disclosure [Text Block] Current Liabilities: Liabilities, Current [Abstract] Preferred shares, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued Preferred Stock, Value, Issued Business Acquisition [Line Items] Business Acquisition [Line Items] Investments in mutual funds held in a rabbi trust Common Stock, Shares Held in Employee Trust Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Payment for contingent consideration Payment for Contingent Consideration Liability, Financing Activities Inventories: Inventory, Net [Abstract] Dividends paid Payments of Ordinary Dividends, Common Stock Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Diluted Earnings Per Common Share (in dollars per share) Earnings Per Share, Diluted Yen-denominated term loan Fair Value - Liabilities (Payable) position Derivative Liability, Subject to Master Netting Arrangement, before Offset Hedging Relationship [Axis] Hedging Relationship [Axis] Trade receivables, less allowances of $439 in 2024 and $444 in 2023 Accounts Receivable, after Allowance for Credit Loss, Current Deferred income taxes and other assets Deferred Income Taxes and Other Assets, Noncurrent [Member] The Deferred Income Taxes and Other Assets line item in the statement of financial position in which the amounts are included. Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $30 in 2024 and $(58) in 2023 Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Acquisition share price (in dollars per share) Business Acquisition, Share Price Significant Unobservable Inputs Fair Value, Inputs, Level 3 [Member] Common shares held in treasury (in shares) Beginning balance, treasury stock, common (in shares) Ending balance, treasury stock, common (in shares) Treasury Stock, Common, Shares Line of Credit Line of Credit [Member] Condensed Cash Flow Statement [Table] Condensed Cash Flow Statement [Table] Molecular Molecular [Member] It represents the molecular, segment of the entity. Outstanding, number of shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Schedule of Net Periodic Cost Schedule of Net Benefit Costs [Table Text Block] Trading Symbol Trading Symbol Five Year Term Loan due 2024 Five Year Term Loan due 2024 [Member] Represents the term loan. Restructuring Plan [Domain] Restructuring Plan [Domain] Net Earnings Net Earnings Net earnings Net Income (Loss) Total Current Liabilities Liabilities, Current Derivative Contract [Domain] Derivative Contract [Domain] Liabilities and Shareholders’ Investment Liabilities and Equity [Abstract] Sales (purchases) of other investment securities, net Payments for (Proceeds from) Investments Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] 2020 Five Year Credit Agreement 2020 Five Year Credit Agreement [Member] This member stands for 2020 Five Year Credit Agreement. Cost of products sold Cost of Goods and Services Sold [Member] Cost of Goods and Services Sold Beginning balance Ending balance Contract with Customer, Liability Gain (loss) recognized in other comprehensive income (loss), foreign currency forward exchange contracts designated as cash flow hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Cost of products sold, excluding amortization of intangible assets Cost of Goods and Services Sold Service cost - benefits earned during the period Defined Benefit Plan, Service Cost Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Gain (loss) from foreign currency forward exchange contracts not designated as hedges Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Quoted Prices in Active Markets Fair Value, Inputs, Level 1 [Member] Debt Debt [Member] Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $1 in 2024 and $— in 2023 Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Carrying Value Reported Value Measurement [Member] Goodwill Goodwill Equity Components [Axis] Equity Components [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Incentive stock program, shares reserved for future grants (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Investment Type [Axis] Investment Type [Axis] Measurement Basis [Axis] Measurement Basis [Axis] Stock options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Entity Small Business Entity Small Business Maximum length of time over which accumulated gains and losses will be recognized in Cost of products sold Maximum Length of Time Hedged in Cash Flow Hedge Estimated annual amortization expense, intangible assets, year four Finite-Lived Intangible Asset, Expected Amortization, Year Four Investments [Domain] Investments [Domain] Changes In Accumulated Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Local Phone Number Local Phone Number Trade receivables Increase (Decrease) in Accounts Receivable Fair Value Measurement [Domain] Fair Value Measurement [Domain] Tax expense from prior year tax positions Tax Adjustments, Settlements, and Unusual Provisions Derivative, notional amount Derivative, Notional Amount Selling, general and administrative expenses Selling, General and Administrative Expenses [Member] Cash dividends declared on common shares (in dollars per share) Common Stock, Dividends, Per Share, Declared Measurement Frequency [Axis] Measurement Frequency [Axis] Prepaid expenses and other receivables, current Prepaid Expenses and Other Receivables, Current [Member] Prepaid Expenses and Other Receivables, Current Retirement Plan Type [Domain] Retirement Plan Type [Domain] Diabetes Care Diabetes Care [Member] It represents the Diabetes Care, segment of the entity. Various Business Acquisitions Various Business Acquisitions [Member] Represents the aggregation and reporting of combined amounts of various business acquisitions. Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Debt instrument, term Debt Instrument, Term Effect of common and treasury share transactions Effect of Common and Treasury Share Transactions This element represents the effect on retained earning due to common and treasury stock transactions. Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Depreciation Depreciation 2022 and 2023 Restructuring Plan 2022 and 2023 Restructuring Plan [Member] The entity's 2022 and 2023 restructuring plans to streamline various commercial operations in order to reduce costs and improve efficiencies in the entity's core diagnostics, established pharmaceuticals and nutritionals businesses. Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] St. Jude Medical St Jude Medical [Member] Represents information relating to acquisition of St. Jude Medical, Inc. Income Statement Location [Axis] Income Statement Location [Axis] Foreign Currency Forward Exchange Contracts Foreign Exchange Forward [Member] Structural Heart Structural Heart [Member] It represents the structural heart, segment of the entity. Heart Failure Heart Failure [Member] It represents the Heart Failure, segment of the entity. Income taxes payable Accrued Income Taxes, Current Schedule of Carrying Values and Fair Values of Financial Instruments Fair Value, by Balance Sheet Grouping [Table Text Block] 2024 Restructuring Plan 2024 Restructuring Plan [Member] 2024 Restructuring Plan Rhythm Management Rhythm Management [Member] It represents the rhythm management, segment of the entity. Product and Service [Domain] Product and Service [Domain] Inventories Increase (Decrease) in Inventories Research and development Research and Development Expense [Member] Cash Flow From (Used in) Investing Activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Remaining liabilities Accrued balance at beginning of the period Accrued balance at end of the period Restructuring Reserve COVID-19 Testing COVID-19 Testing [Member] COVID-19 Testing Award Type [Axis] Award Type [Axis] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Outstanding Common Stock Options Having No Dilutive Effect (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Restricted stock awards granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Document Quarterly Report Document Quarterly Report Interest expense Interest Expense Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Supplemental Financial Information Additional Financial Information Disclosure [Text Block] Hedging Designation [Axis] Hedging Designation [Axis] Property and equipment, at cost Property, Plant and Equipment, Gross Outstanding, weighted-average remaining life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Key Emerging Markets Key Emerging Markets [Member] It represents the key emerging markets, segment of the entity. Gain (loss) recognized in other comprehensive income (loss), debt designated as a hedge of net investment in a foreign subsidiary Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Estimated annual amortization expense, intangible assets, remainder of year Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Issued under incentive stock programs Stock Issued During Period, Value, Incentive Stock Programs Stock Issued During Period, Value, Incentive Stock Programs Pension contributions Company contributions Defined Benefit Plan, Plan Assets, Contributions by Employer Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Entity File Number Entity File Number Loss Contingencies [Table] Loss Contingencies [Table] Income (expense) and gain (loss) reclassified into income, interest rate swaps designated as fair value hedges Other Comprehensive Income (Loss), Fair Value Hedge, Gain (Loss), Reclassification, before Tax Other Comprehensive Income (Loss), Fair Value Hedge, Gain (Loss), Reclassification, before Tax Amortization of intangible assets Amortization of intangible assets Amortization of intangible assets Amortization of Intangible Assets Entity Shell Company Entity Shell Company Investments Total Long-term Investment Securities: Long-Term Investments Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Recent Accounting Standards Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Cash and Cash Equivalents, Beginning of Year Cash and Cash Equivalents, End of Period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Accumulated amortization of intangible assets Finite-Lived Intangible Assets, Accumulated Amortization Prepaid expenses and other receivables Prepaid Expense and Other Receivables Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other receivables that are expected to be realized within one year or the normal operating cycle, if longer. Interest (income) Investment Income, Interest Common shares, issued (in shares) Common Stock, Shares, Issued Acquisition purchase price Business Combination, Consideration Transferred Employee related severance and other charges Severance Costs Common shares held in treasury, at cost — Shares: 2024: 250,155,515; 2023: 253,807,494 Treasury Stock, Common, Value Security Exchange Name Security Exchange Name Total Assets Assets, Fair Value Disclosure Outstanding borrowings Total Long-term Debt Long-Term Debt Number of developed technology intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Number of Finite-Lived Intangibles Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Number of Finite-Lived Intangibles Selling, general and administrative Selling, General and Administrative Expense Accumulated Other Comprehensive Income (Loss) Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Other comprehensive income (loss) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Stock Options Employee Stock Option [Member] Cumulative Foreign Currency Translation (Loss) Adjustments Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Financial Instruments, Derivatives and Fair Value Measures Derivative Instruments and Hedging Activities Disclosure [Text Block] Interest rate swap derivative financial instruments Interest Rate Derivative Liabilities, at Fair Value Total unrecognized compensation cost, expected period for recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Total operating cost and expenses Costs and Expenses Maximum Maximum [Member] Comprehensive Income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Total unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Document Type Document Type Entity Address, Address Line One Entity Address, Address Line One Purchased Treasury Stock, Value, Acquired, Cost Method Incentive Stock Programs Share-Based Payment Arrangement [Text Block] Business Acquisition [Axis] Business Acquisition [Axis] Trade receivables, allowances Accounts Receivable, Allowance for Credit Loss, Current Derivative [Table] Derivative [Table] NEW YORK STOCK EXCHANGE, INC. NEW YORK STOCK EXCHANGE, INC. [Member] Income Statement [Abstract] Income Statement [Abstract] Materials Inventory, Raw Materials, Net of Reserves Issued under incentive stock programs (in shares) Stock Issued During Period, Shares, Incentive Stock Programs Stock Issued During Period, Shares, Incentive Stock Programs Title of 12(b) Security Title of 12(b) Security Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Point of Care Point of Care [Member] It represents the point of care, segment of the entity. Summary of Restructuring Activity Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Business Acquisitions Business Combination Disclosure [Text Block] Indefinite-lived intangible assets related to in-process R&D acquired in a business combination Indefinite-Lived Intangible Assets (Excluding Goodwill) Operating Segments Operating Segments [Member] Share-based compensation Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Dividends payable Dividends Payable, Current Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Entity Listings, Exchange [Axis] Entity Listings, Exchange [Axis] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Decrease in goodwill due to foreign currency translation adjustments Goodwill, Foreign Currency Translation Gain (Loss) Equity method investments carrying value Equity Method Investments Total inventories Inventory, Net Statistical Measurement [Axis] Statistical Measurement [Axis] Other Other Investments [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Entity Interactive Data Current Entity Interactive Data Current Purchases of common shares Payments for Repurchase of Common Stock Corporate functions and benefit plan costs Corporate and Benefit Plan Costs The reconciling item from aggregate segment operating income or loss to consolidated earnings or loss before income tax expense or benefit, related to corporate functions and benefit plan costs. Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax (benefit) Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax Restricted Stock Awards Restricted stock awards [Member] Restricted stock awards. Segments [Domain] Segments [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Consolidation Items [Domain] Consolidation Items [Domain] Earnings employed in the business Retained Earnings (Accumulated Deficit) Payment of cash taxes Payments for Other Taxes Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current Assets: Assets, Current [Abstract] Entity Address, State or Province Entity Address, State or Province Cash Flow From (Used in) Operating Activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Diagnostics Diagnostic Products Diagnostic Products [Member] The diagnostics products segment of the entity. Estimated annual amortization expense, intangible assets, year one Finite-Lived Intangible Asset, Expected Amortization, Year One Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Foreign currency forward exchange contracts Foreign Currency Cash Flow Hedge Liability at Fair Value Interest cost on projected benefit obligations Defined Benefit Plan, Interest Cost Estimation of possible loss Loss Contingency, Estimate of Possible Loss Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Fair Value - Assets Receivable position Derivative Asset, Subject to Master Netting Arrangement, before Offset Foreign currency translation gain (loss) adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Various investment impairments Impairment Of Various Investments Impairment Of Various Investments Net Cash From (Used in) Investing Activities Net Cash Provided by (Used in) Investing Activities Equity securities Equity Securities, FV-NI, Current Income (expense) and gain (loss) reclassified into income, foreign currency forward exchange contracts designated as cash flow hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Net earnings allocated to common shares Net Income (Loss) Available to Common Stockholders, Basic Interest Rate Hedge Contracts Interest Rate Swaps Interest Rate Swap [Member] Debt Instrument [Axis] Debt Instrument [Axis] Credit Facility [Axis] Credit Facility [Axis] Other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax (benefit) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Minimum length of time over which accumulated gains and losses will be recognized in Cost of products sold Minimum Length Of Time Hedged In Cash Flow Hedge Minimum length of time over which the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Net Actuarial (Losses) and Prior Service (Costs) and Credits Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] CHICAGO STOCK EXCHANGE, INC NYSE CHICAGO, INC. [Member] Number of reportable segments Number of Reportable Segments Decrease reasonably possible in gross unrecognized tax benefits Decrease in Unrecognized Tax Benefits is Reasonably Possible Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2024: 1,989,789,999; 2023: 1,987,883,852 Common Stock, Value, Issued Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Total Current Assets Assets, Current Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Medical Devices Medical Devices [Member] The medical devices segment of the entity. Net cost (credit) Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Asset impairment charges Asset Impairment Charges Contingent consideration related to business combinations Business Combination, Contingent Consideration, Liability Equity securities Equity Securities [Member] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Other (income) expense, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Statement [Table] Statement [Table] Other, net Other Cost and Expense, Operating and Nonoperating The reconciling item from segment operating income or loss to consolidated earnings or loss before income tax expense or benefit, related to net other income or expenses. Subsegments [Domain] Subsegments [Domain] Current Fiscal Year End Date Current Fiscal Year End Date Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] New Accounting Standards Accounting Standards Update and Change in Accounting Principle [Text Block] Trade accounts payable Accounts Payable, Trade, Current Gross unrecognized tax benefits Unrecognized Tax Benefits Schedule of Accumulated Other Comprehensive Income (Loss), Net of Taxes Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Preferred shares, authorized (in shares) Preferred Stock, Shares Authorized Medical and Dental Plans Other Postretirement Benefits Plan [Member] Net Cash From Operating Activities Net Cash Provided by (Used in) Operating Activities Exercisable, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Other accrued liabilities Other Accrued Liabilities, Current Prior service cost (credit) Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Other Corporate, Non-Segment [Member] Deferred income taxes and other assets Deferred Income Taxes and Other Assets, Noncurrent Other, net Increase (Decrease) in Other Operating Assets and Liabilities, Net Unearned revenue from cash received during the period Contract With Customer Liability, Change In Unearned Revenue From Cash Received Recognized Amount of revenue recognized arising from contract liability from change in cash received to be satisfied. Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Net deferred tax assets Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets Postemployment Benefits [Abstract] Postemployment Benefits [Abstract] Business Combination and Asset Acquisition [Abstract] Total Abbott Shareholders’ Investment Beginning of the period End of the period Equity, Attributable to Parent Consolidation Items [Axis] Consolidation Items [Axis] Amount of reductions of goodwill relating to impairments Goodwill, Impairment Loss Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Revenue recognized related to contract liability balance Contract with Customer, Liability, Revenue Recognized Subsegments [Axis] Subsegments [Axis] Goodwill and Intangible Assets [Table] Goodwill and Intangible Assets [Table] Goodwill and Intangible Assets Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges and Other Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Earnings before taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Equity investments without readily determinable fair value Equity Securities without Readily Determinable Fair Value, Amount Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Restructuring Plans Restructuring and Related Activities Disclosure [Text Block] Preferred shares, issued (in shares) Preferred Stock, Shares Issued Hedging Designation [Domain] Hedging Designation [Domain] Post-Employment Benefits Postemployment Benefits Disclosure [Text Block] Accounting Standards Update and Change in Accounting Principle [Abstract] Accounting Standards Update and Change in Accounting Principle [Abstract] Significant Other Observable Inputs Fair Value, Inputs, Level 2 [Member] Other Other Security Investments [Member] Net Investment Hedging Net Investment Hedging [Member] Entity Emerging Growth Company Entity Emerging Growth Company Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Intangible assets, net of amortization Intangible Assets, Net (Excluding Goodwill) Schedule of Derivatives Gain (Loss) in OCI and Income (Expense) Derivative Instruments, Gain (Loss) [Table Text Block] Increase (Decrease) in Shareholders' Investment Increase (Decrease) in Stockholders' Equity [Roll Forward] Developed technology intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Document Fiscal Period Focus Document Fiscal Period Focus Restricted stock units granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted Outstanding, weighted-average exercise price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based compensation Share-Based Payment Arrangement, Noncash Expense Common Shares Common Stock [Member] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Product and Service [Axis] Product and Service [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Total Shareholders’ Investment Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Minimum Minimum [Member] Net property and equipment Property, Plant and Equipment, Net Summary of Options Outstanding and Exercisable Share-Based Payment Arrangement, Option, Activity [Table Text Block] Maximum amount of contingent consideration Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Cash dividends declared on common shares Dividends, Common Stock, Cash Assets Assets [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Total Liabilities Liabilities, Fair Value Disclosure Summary of Amounts and Location of Derivative Financial Instruments Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Net foreign exchange (gain) loss Gain (Loss), Foreign Currency Transaction, before Tax Net Cash From (Used in) Financing Activities Net Cash Provided by (Used in) Financing Activities Retirement Plan Type [Axis] Retirement Plan Type [Axis] Litigation and Environmental Matters Commitments and Contingencies Disclosure [Text Block] Other Payments for (Proceeds from) Other Investing Activities Earnings Employed in the Business Retained Earnings [Member] Current portion of long-term debt Long-Term Debt, Current Maturities Total Liabilities and Shareholders' Investment Liabilities and Equity Other net assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Basic Earnings Per Common Share (in dollars per share) Earnings Per Share, Basic Core Laboratory Core Laboratory [Member] It represents the core laboratory, segment of the entity. Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Percentage of remaining performance obligation expected to be recognized in period Revenue Remaining Performance Obligation Expected Timing Percentage Represents the percentage of revenue recognized for remaining performance obligations. Schedule of Long-Term Investments Schedule of Long Term Investments [Table Text Block] Tabular disclosure of the investments which are intended to be held for an extended period of time (longer than one operating cycle). Entity Address, City or Town Entity Address, City or Town Established Pharmaceutical Products Established Pharmaceutical Products [Member] Represents Established Pharmaceutical Products, segment of the entity. Schedule of Segment Information Schedule of Segment Reporting Information, by Segment [Table Text Block] Disclosure Text Block Supplement [Abstract] Disclosure Text Block Supplement [Abstract] Document Transition Report Document Transition Report Interest expense Interest Expense [Member] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Cumulative foreign currency translation (loss) adjustments Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Common shares, authorized (in shares) Common Stock, Shares Authorized Fair value of hedged long-term debt Hedged Liability, Fair Value Hedge Document Information [Table] Document Information [Table] Summary of Investment Holdings [Line Items] Summary of Investment Holdings [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Derivative Instrument [Axis] Derivative Instrument [Axis] Adjustments to reconcile net earnings to net cash from operating activities — Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Nutritionals Nutritional Products Nutritional Products [Member] The nutritional products segment of the entity. Derivative [Line Items] Derivative [Line Items] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Excess tax benefits associated with share-based compensation Excess Tax Expense (Benefit) from Share-based Compensation Amount of tax benefits related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes. Rapid Diagnostics Rapid Diagnostics [Member] It represents the rapid diagnostics, segment of the entity. Provisions/charges to income Accounts Receivable, Credit Loss Expense (Reversal) Document and Entity Information Document Information [Line Items] Restructuring Plan [Axis] Restructuring Plan [Axis] Proceeds from stock options exercised Proceeds from Stock Options Exercised Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Decrease in intangible assets due to foreign currency translation adjustments Finite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss) Estimated annual amortization expense, intangible assets, year three Finite-Lived Intangible Asset, Expected Amortization, Year Three Changes in accumulated other comprehensive income (loss), net of income taxes AOCI Attributable to Parent, Net of Tax [Roll Forward] Beginning balance Ending balance Accounts Receivable, Allowance for Credit Loss Vascular Vascular [Member] It represents the vascular products, segment of the entity. Outstanding, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Entity Registrant Name Entity Registrant Name Contract Liabilities: Contract Liabilities [Roll Forward] Contract Liabilities Dilutive Common Stock Options (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Estimated annual amortization expense, intangible assets, year two Finite-Lived Intangible Asset, Expected Amortization, Year Two Condensed Cash Flow Statements, Captions [Line Items] Condensed Cash Flow Statements, Captions [Line Items] Electrophysiology Electrophysiology [Member] It represents the electrophysiology, segment of the entity. Change in fair value of remaining contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Exchange [Domain] Exchange [Domain] Noncontrolling Interests in Subsidiaries Equity, Attributable to Noncontrolling Interest Payments for restructuring Payments and other adjustments Payments for Restructuring Net borrowings (repayments) of short-term debt and other Proceeds from (Repayments of) Short-Term Debt Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax: Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Document Period End Date Document Period End Date Issuance of restricted stock awards Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Summary of Bases Used to Measure Assets and Liabilities at Fair Value on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Exercisable, weighted-average exercise price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Net amortization of: Defined Benefit Plan Net Amortization Costs [Abstract] No definition available. Summary of Allowance for Doubtful Accounts Activity Accounts Receivable, Allowance for Credit Loss [Table Text Block] Common Shares Held in Treasury Treasury Stock, Common [Member] Entity Central Index Key Entity Central Index Key Recorded accrual balance for legal proceedings and exposures Loss Contingency Accrual Liabilities, at Fair Value Liabilities, Fair Value Disclosure [Abstract] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Annual share-based awards recognized in first quarter (as a percent) Annual Share Based Awards Recognized in First Quarter Percent Percentage of the annual cost of share-based awards which will typically be recognized in the first quarter. Share-based compensation Share-Based Payment Arrangement, Expense Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Gross amount of amortizable intangible assets Finite-Lived Intangible Assets, Gross Taxes on earnings Income Tax Expense (Benefit) Int’l Non-US [Member] Finished products Inventory, Finished Goods, Net of Reserves Designated as Hedging Instrument Designated as Hedging Instrument [Member] Amounts charged off and other adjustments Accounts Receivable, Allowance for Credit Loss, Writeoff Salaries, wages and commissions Employee-related Liabilities, Current Maximum expected cleanup exposure in aggregate Loss Contingency Range of Possible Loss, Maximum Aggregate Sites The estimated maximum loss, for all sites, from the contingency related to the environmental clean up in the United States and Puerto Rico. Other accrued liabilities Other Accrued Liabilities, Current [Member] Other Accrued Liabilities, Current Amounts reclassified from accumulated other comprehensive income Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Other comprehensive income (loss) Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Summary of Revenue by Sales Category Disaggregation of Revenue [Table Text Block] Net sales Sales Net Sales to External Customers Revenue from Contract with Customer, Excluding Assessed Tax Current portion of long-term debt Long-Term Debt, Current Maturities [Member] Long-Term Debt, Current Maturities CSI Cardiovascular Systems, Inc. [Member] Cardiovascular Systems, Inc. Amendment Flag Amendment Flag In-process research and development Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Fair Value Hedging Fair Value Hedging [Member] Actuarial loss, net Defined Benefit Plan, Amortization of Gain (Loss) Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Net interest expense Interest Income (Expense), Net Allowance for Doubtful Accounts: SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Legal proceedings and environmental exposures Legal proceedings and environmental exposures [Member] Loss contingencies related to legal proceedings and environmental exposures. Assets, at Fair Value Assets, Fair Value Disclosure [Abstract] Credit Facility [Domain] Credit Facility [Domain] Purchased (in shares) Treasury Stock, Shares, Acquired Long-term debt Long-Term Debt, Excluding Current Maturities Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares) Weighted Average Number of Shares Outstanding, Diluted Post-employment obligations, deferred income taxes and other long-term liabilities Post-employment Obligations, Deferred Income Taxes and Other Long-term Liabilities [Member] Post-employment Obligations, Deferred Income Taxes and Other Long-term Liabilities Schedule of Changes in Contract Liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Revenue Revenue from Contract with Customer [Text Block] Acquisitions of property and equipment Payments to Acquire Property, Plant, and Equipment Balance Sheet Location [Axis] Balance Sheet Location [Axis] Total Assets Assets Loss Contingencies [Line Items] Loss Contingencies [Line Items] Adult Nutritionals Adult Nutritionals [Member] It represents the adult nutritionals, segment of the entity. Cover [Abstract] Cover [Abstract] Cumulative gains (losses) on derivative instruments designated as cash flow hedges AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax U.S. UNITED STATES Maximum expected cleanup exposure for individual site Loss Contingency Range of Possible Loss, Maximum Individual Site The estimated maximum loss, per individual site, from the contingency related to the environmental clean up in the United States and Puerto Rico. Outstanding Balances Fair Value, Recurring [Member] Segment Reconciling Items Segment Reconciling Items [Member] Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Remaining performance obligations Revenue, Remaining Performance Obligation, Amount Short-term investments Short-Term Investments Foreign currency forward exchange contracts Foreign Currency Cash Flow Hedge Asset at Fair Value Cash Flow Hedging Cash Flow Hedging [Member] Defined Benefit Plans Pension Plan [Member] Segment Information Segment Reporting Disclosure [Text Block] Goodwill and Intangible Assets [Line Items] Goodwill and Intangible Assets [Line Items] Goodwill and Intangible Assets Net Increase (Decrease) in Cash and Cash Equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash Flow From (Used in) Financing Activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Equity Component [Domain] Equity Component [Domain] Post-employment obligations, deferred income taxes and other long-term liabilities Post-employment Obligations, Deferred Income Taxes and Other Long-term Liabilities Amount of Post-employment obligations and amount of deferred tax liability attributable to taxable temporary differences, after deferred tax asset, and other liabilities expected to be paid after one year or operating cycle, if longer. Work in process Inventory, Work in Process, Net of Reserves Income tax claim related to statutory notice of deficiency IRS Statutory Notice of Deficiency, Claim Amount IRS Statutory Notice of Deficiency, Claim Amount Other Other Emerging Markets [Member] Other Emerging Markets Debt Instrument [Line Items] Debt Instrument [Line Items] Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Operating earnings Operating Earnings Operating Income (Loss) Segments [Axis] Segments [Axis] Statement [Line Items] Statement [Line Items] Fair Value Estimate of Fair Value Measurement [Member] Summary of Investment Holdings [Table] Summary of Investment Holdings [Table] Shareholders’ Investment: Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Noncontrolling Interests in Subsidiaries Noncontrolling Interest [Member] EX-101.PRE 10 abt-20240331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover
 3 Months Ended
Mar. 31, 2024
shares
Document and Entity Information  
Document Type 10-Q
Document Quarterly Report true
Document Period End Date Mar. 31, 2024
Document Transition Report false
Entity File Number 1-2189
Entity Registrant Name ABBOTT LABORATORIES
Entity Incorporation, State or Country Code IL
Entity Tax Identification Number 36-0698440
Entity Address, Address Line One 100 Abbott Park Road
Entity Address, City or Town Abbott Park
Entity Address, State or Province IL
Entity Address, Postal Zip Code 60064-6400
City Area Code 224
Local Phone Number 667-6100
Entity Current Reporting Status Yes
Entity Interactive Data Current Yes
Entity Filer Category Large Accelerated Filer
Entity Small Business false
Entity Emerging Growth Company false
Entity Shell Company false
Entity Common Stock, Shares Outstanding 1,739,633,759
Entity Central Index Key 0000001800
Current Fiscal Year End Date --12-31
Document Fiscal Year Focus 2024
Document Fiscal Period Focus Q1
Amendment Flag false
NEW YORK STOCK EXCHANGE, INC.  
Document and Entity Information  
Title of 12(b) Security Common Shares, Without Par Value
Trading Symbol ABT
Security Exchange Name NYSE
CHICAGO STOCK EXCHANGE, INC  
Document and Entity Information  
Title of 12(b) Security Common Shares, Without Par Value
Trading Symbol ABT
Security Exchange Name CHX
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statement of Earnings (Unaudited) - USD ($)
shares in Thousands, $ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Net sales $ 9,964 $ 9,747
Cost of products sold, excluding amortization of intangible assets 4,463 4,331
Amortization of intangible assets 472 491
Research and development 684 654
Selling, general and administrative 2,959 2,762
Total operating cost and expenses 8,578 8,238
Operating earnings 1,386 1,509
Interest expense 141 153
Interest (income) (80) (101)
Net foreign exchange (gain) loss 0 6
Other (income) expense, net (111) (111)
Earnings before taxes 1,436 1,562
Taxes on earnings 211 244
Net Earnings $ 1,225 $ 1,318
Basic Earnings Per Common Share (in dollars per share) $ 0.70 $ 0.75
Diluted Earnings Per Common Share (in dollars per share) $ 0.70 $ 0.75
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) 1,740,203 1,741,738
Dilutive Common Stock Options (in shares) 9,449 9,977
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares) 1,749,652 1,751,715
Outstanding Common Stock Options Having No Dilutive Effect (in shares) 6,892 7,332
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statement of Comprehensive Income (Unaudited) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Statement of Comprehensive Income [Abstract]      
Net Earnings $ 1,225 $ 1,318  
Foreign currency translation gain (loss) adjustments (386) 139  
Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $1 in 2024 and $— in 2023 4 2  
Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $30 in 2024 and $(58) in 2023 55 (129)  
Other comprehensive income (loss) (327) 12  
Comprehensive Income 898 $ 1,330  
Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:      
Cumulative foreign currency translation (loss) adjustments (6,890)   $ (6,504)
Net actuarial (losses) and prior service (costs) and credits (1,372)   (1,376)
Cumulative gains (losses) on derivative instruments designated as cash flow hedges 96   41
Accumulated Other Comprehensive Income (Loss) $ (8,166)   $ (7,839)
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Statement of Comprehensive Income [Abstract]    
Other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax (benefit) $ 1 $ 0
Other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax (benefit) $ 30 $ (58)
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Balance Sheet (Unaudited) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Current Assets:    
Cash and cash equivalents $ 6,284 $ 6,896
Short-term investments 367 383
Trade receivables, less allowances of $439 in 2024 and $444 in 2023 6,605 6,565
Inventories:    
Finished products 4,063 3,946
Work in process 881 807
Materials 1,883 1,817
Total inventories 6,827 6,570
Prepaid expenses and other receivables 2,293 2,256
Total Current Assets 22,376 22,670
Investments 818 799
Property and equipment, at cost 22,055 21,933
Less: accumulated depreciation and amortization 11,948 11,779
Net property and equipment 10,107 10,154
Intangible assets, net of amortization 8,296 8,815
Goodwill 23,383 23,679
Deferred income taxes and other assets 7,487 7,097
Total Assets 72,467 73,214
Current Liabilities:    
Trade accounts payable 4,178 4,295
Salaries, wages and commissions 1,092 1,597
Other accrued liabilities 5,220 5,422
Dividends payable 959 955
Income taxes payable 562 492
Current portion of long-term debt 2,010 1,080
Total Current Liabilities 14,021 13,841
Long-term debt 12,576 13,599
Post-employment obligations, deferred income taxes and other long-term liabilities 6,827 6,947
Commitments and Contingencies
Shareholders’ Investment:    
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued 0 0
Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2024: 1,989,789,999; 2023: 1,987,883,852 24,726 24,869
Common shares held in treasury, at cost — Shares: 2024: 250,155,515; 2023: 253,807,494 (15,761) (15,981)
Earnings employed in the business 38,011 37,554
Accumulated other comprehensive income (loss) (8,166) (7,839)
Total Abbott Shareholders’ Investment 38,810 38,603
Noncontrolling Interests in Subsidiaries 233 224
Total Shareholders’ Investment 39,043 38,827
Total Liabilities and Shareholders' Investment $ 72,467 $ 73,214
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Trade receivables, allowances $ 439 $ 444
Preferred shares, par value (in dollars per share) $ 1 $ 1
Preferred shares, authorized (in shares) 1,000,000 1,000,000
Preferred shares, issued (in shares) 0 0
Common shares, authorized (in shares) 2,400,000,000 2,400,000,000
Common shares, issued (in shares) 1,989,789,999 1,987,883,852
Common shares held in treasury (in shares) 250,155,515 253,807,494
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statement of Shareholders' Investment (Unaudited) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Increase (Decrease) in Shareholders' Investment    
Beginning balance $ 38,827  
Net earnings 1,225 $ 1,318
Other comprehensive income (loss) (327) 12
Ending balance 39,043  
Common Shares    
Increase (Decrease) in Shareholders' Investment    
Beginning balance 24,869 24,709
Issued under incentive stock programs 87 16
Share-based compensation 322 296
Issuance of restricted stock awards (552) (533)
Ending balance 24,726 24,488
Common Shares Held in Treasury    
Increase (Decrease) in Shareholders' Investment    
Beginning balance (15,981) (15,229)
Issued under incentive stock programs 242 242
Purchased (22) (320)
Ending balance (15,761) (15,307)
Earnings Employed in the Business    
Increase (Decrease) in Shareholders' Investment    
Beginning balance 37,554 35,257
Net earnings 1,225 1,318
Cash dividends declared on common shares (960) (890)
Effect of common and treasury share transactions 192 183
Ending balance 38,011 35,868
Accumulated Other Comprehensive Income (Loss)    
Increase (Decrease) in Shareholders' Investment    
Beginning balance (7,839) (8,051)
Other comprehensive income (loss) (327) 12
Ending balance (8,166) (8,039)
Noncontrolling Interests in Subsidiaries    
Increase (Decrease) in Shareholders' Investment    
Beginning balance 224 219
Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases 9 3
Ending balance $ 233 $ 222
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statement of Shareholders' Investment (Unaudited) (Parenthetical) - $ / shares
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Increase (Decrease) in Shareholders' Investment    
Beginning balance, treasury stock, common (in shares) 253,807,494  
Ending balance, treasury stock, common (in shares) 250,155,515  
Common Shares    
Increase (Decrease) in Shareholders' Investment    
Beginning balance (in shares) 1,987,883,852 1,986,519,278
Issued under incentive stock programs (in shares) 1,906,147 384,892
Ending balance (in shares) 1,989,789,999 1,986,904,170
Common Shares Held in Treasury    
Increase (Decrease) in Shareholders' Investment    
Beginning balance, treasury stock, common (in shares) 253,807,494 248,724,257
Issued under incentive stock programs (in shares) 3,838,255 3,933,165
Purchased (in shares) 186,276 3,166,279
Ending balance, treasury stock, common (in shares) 250,155,515 247,957,371
Earnings Employed in the Business    
Increase (Decrease) in Shareholders' Investment    
Cash dividends declared on common shares (in dollars per share) $ 0.55 $ 0.51
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash Flow From (Used in) Operating Activities:    
Net earnings $ 1,225 $ 1,318
Adjustments to reconcile net earnings to net cash from operating activities —    
Depreciation 333 315
Amortization of intangible assets 472 491
Share-based compensation 304 281
Trade receivables (151) 233
Inventories (410) (419)
Other, net (748) (1,076)
Net Cash From Operating Activities 1,025 1,143
Cash Flow From (Used in) Investing Activities:    
Acquisitions of property and equipment (398) (380)
Sales (purchases) of other investment securities, net (28) (86)
Other 1 4
Net Cash From (Used in) Investing Activities (425) (462)
Cash Flow From (Used in) Financing Activities:    
Net borrowings (repayments) of short-term debt and other (127) (42)
Purchases of common shares (226) (540)
Proceeds from stock options exercised 134 62
Dividends paid (957) (890)
Net Cash From (Used in) Financing Activities (1,176) (1,410)
Effect of exchange rate changes on cash and cash equivalents (36) 8
Net Increase (Decrease) in Cash and Cash Equivalents (612) (721)
Cash and Cash Equivalents, Beginning of Year 6,896 9,882
Cash and Cash Equivalents, End of Period $ 6,284 $ 9,161
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Basis of Presentation
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
Note 1 — Basis of Presentation

The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s Annual Report on Form 10-K for the year ended December 31, 2023. The condensed consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.1.u1
New Accounting Standards
 3 Months Ended
Mar. 31, 2024
Accounting Standards Update and Change in Accounting Principle [Abstract]  
New Accounting Standards
Note 2 — New Accounting Standards

Recent Accounting Standards Not Yet Adopted

In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which expands the breadth and frequency of required segment disclosures. The guidance is required to be applied retrospectively to all periods presented in the financial statements. The standard becomes effective for Abbott for full year 2024 reporting and for interim periods beginning in the first quarter of 2025. Abbott is currently evaluating the impact of this new standard on its consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires an entity to disclose annually additional information related to the company's income tax rate reconciliation and income taxes paid during the period. The guidance should be applied prospectively with the option to apply the standard retrospectively. The standard becomes effective for Abbott for full year 2025 reporting. Abbott is currently evaluating the impact of this new standard on its consolidated financial statements.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue
 3 Months Ended
Mar. 31, 2024
Revenue from Contract with Customer [Abstract]  
Revenue
Note 3 — Revenue

Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

The following tables provide detail by sales category:

Three Months Ended March 31, 2024Three Months Ended March 31, 2023
(in millions)U.S.Int’lTotalU.S.Int’lTotal
Established Pharmaceutical Products —
Key Emerging Markets$— $928 $928 $— $912 $912 
Other— 298 298 — 277 277 
Total— 1,226 1,226 — 1,189 1,189 
Nutritionals —    
Pediatric Nutritionals514 495 1,009 459 465 924 
Adult Nutritionals364 695 1,059 353 690 1,043 
Total878 1,190 2,068 812 1,155 1,967 
Diagnostics —     
Core Laboratory310 895 1,205 289 893 1,182 
Molecular42 87 129 47 100 147 
Point of Care98 41 139 93 41 134 
Rapid Diagnostics481 260 741 906 319 1,225 
Total931 1,283 2,214 1,335 1,353 2,688 
Medical Devices —    
Rhythm Management271 291 562 260 267 527 
Electrophysiology269 318 587 238 267 505 
Heart Failure237 68 305 218 63 281 
Vascular254 435 689 218 399 617 
Structural Heart233 282 515 210 251 461 
Neuromodulation181 45 226 155 41 196 
Diabetes Care 589 980 1,569 479 834 1,313 
Total2,034 2,419 4,453 1,778 2,122 3,900 
Other3 — 3 3 — 3 
Total$3,846 $6,118 $9,964 $3,928 $5,819 $9,747 
Products sold by the Diagnostics segment include various types of diagnostic tests to detect the COVID-19 coronavirus. In the first three months of 2024 and 2023, Abbott’s COVID-19 testing-related sales totaled $204 million and $730 million, respectively.
Remaining Performance Obligations

As of March 31, 2024, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was approximately $4.5 billion in the Diagnostics segment and approximately $495 million in the Medical Devices segment. Abbott expects to recognize revenue on approximately 59 percent of these remaining performance obligations over the next 24 months, approximately 16 percent over the subsequent 12 months and the remainder thereafter.

These performance obligations primarily reflect the future sale of reagents/consumables in contracts with minimum purchase obligations, extended warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has applied the practical expedient described in FASB Accounting Standards Codification (ASC) 606-10-50-14 and has not included remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.

Other Contract Assets and Liabilities

Abbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at the net amount expected to be collected. Contract assets primarily relate to Abbott’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were not significant.

Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott’s contract liabilities arise primarily in the Medical Devices reportable segment when payment is received upfront for various multi-period extended service arrangements.

Changes in the contract liabilities during the period are as follows:
(in millions)
Contract Liabilities:
Balance at December 31, 2023$545 
Unearned revenue from cash received during the period120 
Revenue recognized related to contract liability balance(116)
Balance at March 31, 2024$549 
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Supplemental Financial Information
 3 Months Ended
Mar. 31, 2024
Disclosure Text Block Supplement [Abstract]  
Supplemental Financial Information
Note 4 — Supplemental Financial Information

Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Net earnings allocated to common shares for the three months ended March 31, 2024 and 2023 were $1.220 billion and $1.313 billion, respectively.

Other, net in Net cash from operating activities in the Condensed Consolidated Statement of Cash Flows for the first three months of 2024 includes $280 million of pension contributions and the payment of cash taxes of approximately $225 million. The first three months of 2023 includes $282 million of pension contributions and the payment of cash taxes of approximately $122 million.
The following summarizes the activity for the first three months of 2024 related to the allowance for doubtful accounts as of March 31, 2024:

(in millions)
Allowance for Doubtful Accounts:
Balance at December 31, 2023$241 
Provisions/charges to income14 
Amounts charged off and other adjustments(8)
Balance at March 31, 2024$247 

The allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivable. Abbott considers various factors in establishing, monitoring, and adjusting its allowance for doubtful accounts, including the aging of the accounts and aging trends, the historical level of charge-offs, and specific exposures related to particular customers. Abbott also monitors other risk factors and forward-looking information, such as country risk, when determining credit limits for customers and establishing adequate allowances.

The components of long-term investments as of March 31, 2024 and December 31, 2023 are as follows:

(in millions)March 31,
2024		December 31,
2023
Long-term Investments:
Equity securities$547 $555 
Other271 244 
Total$818 $799 

The increase in Abbott’s long-term investments as of March 31, 2024 versus the balance as of December 31, 2023 primarily relates to additional investments and earnings from equity method investments, partially offset by the impairment of certain securities.

Abbott’s equity securities as of March 31, 2024, include $317 million of investments in mutual funds that are held in a rabbi trust. These investments, which are specifically designated as available for the purpose of paying benefits under a deferred compensation plan, are not available for general corporate purposes and are subject to creditor claims in the event of insolvency.

Abbott also holds certain investments as of March 31, 2024 with a carrying value of $154 million that are accounted for under the equity method of accounting and other equity investments with a carrying value of approximately $66 million that do not have a readily determinable fair value.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Changes In Accumulated Other Comprehensive Income (Loss)
 3 Months Ended
Mar. 31, 2024
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Changes In Accumulated Other Comprehensive Income (Loss)
Note 5 — Changes In Accumulated Other Comprehensive Income (Loss)

The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:

Three Months Ended March 31
Cumulative Foreign
Currency Translation
(Loss) Adjustments		Net Actuarial (Losses) and
Prior Service (Costs) and
Credits		Cumulative Gains (Losses)
on Derivative Instruments
Designated as Cash Flow
Hedges and Other
(in millions)202420232024202320242023
Balance at January 1$(6,504)$(6,733)$(1,376)$(1,493)$41 $175 
Other comprehensive income (loss) before reclassifications(386)139 2 2 68 (42)
Amounts reclassified from accumulated other comprehensive income— — 2 — (13)(87)
Net current period comprehensive income (loss)(386)139 4 2 55 (129)
Balance at March 31$(6,890)$(6,594)$(1,372)$(1,491)$96 $46 

Reclassified amounts for cash flow hedges are recorded as Cost of products sold. Net actuarial losses and prior service cost are included as a component of net periodic benefit costs; see Note 13 for additional details.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Business Acquisitions
 3 Months Ended
Mar. 31, 2024
Business Combination and Asset Acquisition [Abstract]  
Business Acquisitions
Note 6 — Business Acquisitions

On September 22, 2023, Abbott completed the acquisition of Bigfoot Biomedical, Inc. (Bigfoot), which will further Abbott's efforts to develop connected solutions for making diabetes management more personal and precise. The purchase price, the preliminary allocation of acquired assets and liabilities, and the revenue and net income contributed by Bigfoot since the date of acquisition are not material to Abbott's condensed consolidated financial statements.

On April 27, 2023, Abbott completed the acquisition of Cardiovascular Systems, Inc. (CSI) for $20 per common share, which equated to a purchase price of $851 million. The transaction was funded with cash on hand and accounted for as a business combination. CSI's atherectomy system, which is used in treating peripheral and coronary artery disease, adds complementary technologies to Abbott's portfolio of vascular device offerings.
The final allocation of the purchase price of the CSI acquisition resulted in the recording of two non-deductible developed technology intangible assets totaling $305 million; non-deductible in-process research and development asset of $15 million, which will be accounted for as an indefinite-lived intangible asset until regulatory approval or discontinuation; non-deductible goodwill of $369 million; net deferred tax assets of $46 million and other net assets of $116 million. The goodwill is identifiable to the Medical Devices reportable segment and is attributable to expected synergies from combining operations, as well as intangible assets that do not qualify for separate recognition. Revenues and earnings of CSI included in Abbott's condensed consolidated financial statements since the acquisition date are not material to Abbott's consolidated revenue and earnings.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Goodwill and Intangible Assets
 3 Months Ended
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets
Note 7 — Goodwill and Intangible Assets

The total amount of goodwill reported was $23.4 billion at March 31, 2024 and $23.7 billion at December 31, 2023. Foreign currency translation adjustments decreased goodwill by approximately $294 million in the first three months of 2024. The amount of goodwill related to reportable segments at March 31, 2024 was $2.7 billion for the Established Pharmaceutical Products segment, $285 million for the Nutritional Products segment, $3.5 billion for the Diagnostic Products segment, and $16.9 billion for the Medical Devices segment. There was no reduction of goodwill relating to impairments in the first three months of 2024.
The gross amount of amortizable intangible assets, primarily product rights and technology, was $27.5 billion and $27.7 billion as of March 31, 2024 and December 31, 2023, respectively. Accumulated amortization was $20.0 billion and $19.7 billion as of March 31, 2024 and December 31, 2023, respectively. In the first three months of 2024, intangible assets decreased $38 million due to foreign currency translation and $8 million due to an impairment charge. Abbott’s estimated annual amortization expense for intangible assets is approximately $1.9 billion in 2024, $1.7 billion in 2025, $1.6 billion in 2026, $1.3 billion in 2027 and $0.7 billion in 2028.
Indefinite-lived intangible assets, which relate to in-process R&D (IPR&D) acquired in a business combination, were approximately $787 million as of March 31, 2024 and as of December 31, 2023.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Restructuring Plans
 3 Months Ended
Mar. 31, 2024
Restructuring and Related Activities [Abstract]  
Restructuring Plans
Note 8 — Restructuring Plans

In 2024, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in its nutritional business, including the discontinuation of its ZonePerfect® product line, and in its medical devices segment. In the first three months of 2024, Abbott recorded employee related severance and other charges of approximately $17 million, of which approximately $11 million was recorded in Cost of products sold, approximately $1 million was recorded in Research and development and approximately $5 million was recorded in Selling, general and administrative expenses. Payments related to these actions totaled $3 million in the first three months of 2024 and the remaining liabilities totaled $14 million at March 31, 2024. In addition, Abbott recognized asset impairment charges of approximately $30 million related to these restructuring plans.

In 2023 and 2022, Abbott management approved plans to restructure or streamline various operations in order to reduce costs in its medical devices, diagnostic, nutritional and established pharmaceutical businesses. The following summarizes the 2024 activity related to these restructuring actions and the status of the related accruals as of March 31, 2024:

(in millions)
Accrued balance at December 31, 2023$137 
Payments and other adjustments(41)
Accrued balance at March 31, 2024$96 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Incentive Stock Programs
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Incentive Stock Programs
Note 9 — Incentive Stock Programs

In the first three months of 2024, Abbott granted 1,666,566 stock options, 404,597 restricted stock awards and 5,189,560 restricted stock units under its incentive stock program. At March 31, 2024, approximately 60 million shares were reserved for future grants. Information regarding the number of options outstanding and exercisable at March 31, 2024 is as follows:

OutstandingExercisable
Number of shares 28,281,501 24,296,425 
Weighted average remaining life (years)
5.14.4
Weighted average exercise price $78.71 $73.05 
Aggregate intrinsic value (in millions)
$1,031 $1,020 

The total unrecognized share-based compensation cost at March 31, 2024 amounted to approximately $787 million, which is expected to be recognized over the next three years.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Debt and Lines of Credit
 3 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
Debt and Lines of Credit
Note 10 — Debt and Lines of Credit

Abbott has readily available financial resources, including unused lines of credit that support commercial paper borrowing arrangements and provide Abbott with the ability to borrow up to $5 billion on an unsecured basis. On January 29, 2024, Abbott terminated its 2020 Five Year Credit Agreement (2020 Agreement) and entered into a new Five Year Credit Agreement (Revolving Credit Agreement). There were no outstanding borrowings under the 2020 Agreement at the time of its termination. Any borrowings under the Revolving Credit Agreement will mature and be payable on January 29, 2029 and will bear interest, at Abbott’s option, based on either a base rate or Secured Overnight Financing Rate (SOFR), plus an applicable margin based on Abbott’s credit ratings.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Financial Instruments, Derivatives and Fair Value Measures
 3 Months Ended
Mar. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Financial Instruments, Derivatives and Fair Value Measures
Note 11 — Financial Instruments, Derivatives and Fair Value Measures

Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates, primarily for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross notional amounts totaling $7.3 billion at March 31, 2024 and at December 31, 2023, are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of March 31, 2024 will be included in Cost of products sold at the time the products are sold, generally through the next twelve to eighteen months.

Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar and European currencies. At March 31, 2024 and December 31, 2023, Abbott held gross notional amounts of $14.5 billion and $13.8 billion, respectively, of such foreign currency forward exchange contracts.

Abbott has designated a yen-denominated, 5-year term loan, scheduled to mature in November 2024, of approximately $395 million and $419 million as of March 31, 2024 and December 31, 2023, respectively, as a hedge of the net investment in certain foreign subsidiaries. The change in the value of the debt, which is due to changes in foreign exchange rates, is recorded in Accumulated other comprehensive income (loss), net of tax.

Abbott is a party to interest rate hedge contracts totaling approximately $2.2 billion at March 31, 2024 and December 31, 2023 to manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.
The following table summarizes the amounts and location of certain derivative financial instruments as of March 31, 2024 and December 31, 2023:

Fair Value - AssetsFair Value - Liabilities
(in millions)March 31,
2024		December 31,
2023		Balance Sheet CaptionMarch 31,
2024		December 31,
2023		Balance Sheet Caption
Interest rate swaps designated as fair value hedges:
Non-current $— $— Deferred income taxes and other assets$88 $95 Post-employment obligations, deferred income taxes and other long-term liabilities
Current— — Prepaid expenses and other receivables31 — Other accrued liabilities
Foreign currency forward exchange contracts:
Hedging instruments118 88 Prepaid expenses and other receivables61 134 Other accrued liabilities
Others not designated as hedges52 81 Prepaid expenses and other receivables39 97 Other accrued liabilities
Debt designated as a hedge of net investment in a foreign subsidiary— — n/a395 419 Current portion of long-term debt
$170 $169 $614 $745 

The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three months ended March 31, 2024 and 2023.

Gain (loss) Recognized in Other Comprehensive Income (loss)Income (expense) and
 Gain (loss) Reclassified into Income
Three Months
Ended March 31		Three Months
Ended March 31
(in millions)2024202320242023Income Statement Caption
Foreign currency forward exchange contracts designated as cash flow hedges$127 $(63)$18 $126 Cost of products sold
Debt designated as a hedge of net investment in a foreign subsidiary24 (5)— — n/a
Interest rate swaps designated as fair value hedgesn/an/a(24)9 Interest expense
Gains of $92 million and losses of $103 million were recognized in the three months ended March 31, 2024 and 2023, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net foreign exchange (gain) loss line.

The carrying values and fair values of certain financial instruments as of March 31, 2024 and December 31, 2023 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.

March 31, 2024December 31, 2023
(in millions)Carrying
Value		Fair
Value		Carrying
Value		Fair
Value
Long-term Investment Securities:
Equity securities$547 $547 $555 $555 
Other271 271 244 244 
Total Long-term Debt(14,586)(14,299)(14,679)(14,769)
Foreign Currency Forward Exchange Contracts:   
Receivable position170 170 169 169 
(Payable) position(100)(100)(231)(231)
Interest Rate Hedge Contracts:    
(Payable) position(119)(119)(95)(95)

The fair value of the debt was determined based on significant other observable inputs, including current interest rates.
The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:

Basis of Fair Value Measurement
(in millions)Outstanding
Balances		Quoted
Prices in
Active
Markets		Significant
Other
Observable
Inputs		Significant
Unobservable
Inputs
March 31, 2024:
Equity securities$327 $327 $— $— 
Foreign currency forward exchange contracts170 — 170 — 
Total Assets$497 $327 $170 $— 
Fair value of hedged long-term debt$2,046 $— $2,046 $— 
Interest rate swap derivative financial instruments119 — 119 — 
Foreign currency forward exchange contracts100 — 100 — 
Contingent consideration related to business combinations59 — — 59 
Total Liabilities$2,324 $— $2,265 $59 
December 31, 2023:
Equity securities$326 $326 $— $— 
Foreign currency forward exchange contracts169 — 169 — 
Total Assets$495 $326 $169 $— 
Fair value of hedged long-term debt$2,052 $— $2,052 $— 
Interest rate swap derivative financial instruments95 — 95 — 
Foreign currency forward exchange contracts231 — 231 — 
Contingent consideration related to business combinations112 — — 112 
Total Liabilities$2,490 $— $2,378 $112 

The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis using significant other observable inputs. The fair value of the contingent consideration was determined based on independent appraisals at the time of acquisition, adjusted for the time value of money and other changes in fair value. The decrease in the amount of contingent consideration from December 31, 2023 reflects a payment of $40 million and a $13 million change in the fair value of the remaining contingent consideration.

The maximum amount for certain contingent consideration is not determinable as it is based on a percent of certain sales. Excluding such contingent consideration, the maximum amount that may be due under the other contingent consideration arrangements was estimated at March 31, 2024 to be approximately $135 million, which is dependent upon attaining certain sales thresholds or upon the occurrence of certain events, such as regulatory approvals.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Litigation and Environmental Matters
 3 Months Ended
Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Litigation and Environmental Matters
Note 12 — Litigation and Environmental Matters

Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million.

Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately $45 million to $60 million. The recorded accrual balance at March 31, 2024 for these proceedings and exposures was approximately $55 million. This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.” Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Post-Employment Benefits
 3 Months Ended
Mar. 31, 2024
Postemployment Benefits [Abstract]  
Post-Employment Benefits
Note 13 — Post-Employment Benefits

Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net periodic benefit costs, other than service costs, are recognized in the Other (income) expense, net line of the Condensed Consolidated Statement of Earnings. Net cost recognized for the three months ended March 31 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:

Defined Benefit PlansMedical and Dental Plans
Three Months
Ended March 31		Three Months
Ended March 31
(in millions)2024202320242023
Service cost - benefits earned during the period$61 $60 $10 $9 
Interest cost on projected benefit obligations118 114 15 14 
Expected return on plan assets(262)(242)(6)(6)
Net amortization of:
Actuarial loss, net6 3 — — 
Prior service cost (credit)— — (3)(3)
Net cost (credit)$(77)$(65)$16 $14 
Abbott funds its domestic defined benefit plans according to Internal Revenue Service funding limitations. International pension plans are funded according to similar regulations. In the first three months of 2024 and 2023, $280 million and $282 million, respectively, were contributed to defined benefit plans. In the first three months of 2024 and 2023, $28 million was contributed in each year to the post-employment medical and dental plans.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Taxes on Earnings
 3 Months Ended
Mar. 31, 2024
Income Tax Disclosure [Abstract]  
Taxes on Earnings
Note 14 — Taxes on Earnings

Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first three months of 2024 and 2023, taxes on earnings include approximately $25 million and $3 million, respectively, in excess tax benefits associated with share-based compensation. In the first three months of 2024 and 2023, taxes on earnings also include approximately $10 million and $22 million, respectively, of tax expense as the result of the resolution of various tax positions related to prior years.

Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease approximately $82 million to $1.34 billion, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters.

In September 2023, Abbott received a Statutory Notice of Deficiency (SNOD) from the U.S. Internal Revenue Service (IRS) for the 2019 Federal tax year in the amount of $417 million. The primary adjustments proposed in the SNOD relate to the reallocation of income between Abbott’s U.S. entities and its foreign affiliates. Abbott believes that the income reallocation adjustments proposed in the SNOD are without merit, in part because certain adjustments contradict methods that were agreed to with the IRS in prior audit periods. The SNOD also contains other proposed adjustments that Abbott believes are erroneous and unsupported. Abbott filed a petition with the U.S. Tax Court contesting the SNOD in December 2023.

Abbott’s 2017 and 2018 Federal tax years are also currently under examination by the IRS with respect to income reallocation issues similar to those included in the 2019 Federal tax year. Abbott intends to vigorously defend its filing positions through ongoing discussions with the IRS, the IRS independent appeals process and/or through litigation as necessary.

Abbott reserves for uncertain tax positions related to unresolved matters with the IRS and other taxing authorities. Abbott continues to believe that its reserves for uncertain tax positions are appropriate.

The Organization for Economic Cooperation & Development (OECD) has proposed a two-pillared plan for a revised international tax system. Pillar 1 proposes to reallocate taxing rights among the jurisdictions in which in-scope multinational corporations operate. Abbott is continuing to analyze the Pillar 1 proposal. Pillar 2 proposes to assess a 15 percent minimum tax on the earnings of in-scope multinational corporations on a country-by-country basis. Numerous countries have enacted legislation to adopt the Pillar 2 model rules. A subset of the rules became effective January 1, 2024, and the remaining rules become effective January 1, 2025 or later. Abbott continues to analyze the Pillar 2 model rules. The full implementation of the model rules may have a material impact on Abbott’s condensed consolidated financial statements in the future.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment Information
 3 Months Ended
Mar. 31, 2024
Segment Reporting [Abstract]  
Segment Information
Note 15 — Segment Information

Abbott’s principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices and government agencies throughout the world.

Abbott’s reportable segments are as follows:

Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical products.

Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products.

Diagnostic Products — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. For segment reporting purposes, the Core Laboratory Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care Diagnostics businesses are aggregated and reported as the Diagnostic Products segment.

Medical Devices — Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. For segment reporting purposes, the Cardiac Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, Neuromodulation and Diabetes Care divisions are aggregated and reported as the Medical Devices segment.

Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. Intersegment transfers of inventory are recorded at standard cost and are not a measure of segment operating earnings. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.
The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the condensed consolidated financial statements.

 Net Sales to External CustomersOperating Earnings
Three Months
Ended March 31		Three Months
Ended March 31
(in millions)202420232024 2023
Established Pharmaceutical Products$1,226 $1,189 $267 $300 
Nutritional Products2,068 1,967 377 380 
Diagnostic Products2,214 2,688 474 651 
Medical Devices4,453 3,900 1,360 1,078 
Total Reportable Segments9,961 9,744 2,478 2,409 
Other 3 3 
Net sales$9,964 $9,747 
Corporate functions and benefit plan costs(66)(77)
Net interest expense (61)(52)
Share-based compensation (a) (304)(281)
Amortization of intangible assets(472)(491)
Other, net (b)(139)54 
Earnings before taxes$1,436 $1,562 
______________________________________
(a)
Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.
(b)
Other, net for the three months ended March 31, 2024 and March 31, 2023 includes charges related to restructuring actions. Other, net for the three months ended March 31, 2024 also includes integration costs associated with the acquisition of CSI and $38 million related to various investment impairments.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
New Accounting Standards (Policies)
 3 Months Ended
Mar. 31, 2024
Accounting Standards Update and Change in Accounting Principle [Abstract]  
Recent Accounting Standards Not Yet Adopted
Recent Accounting Standards Not Yet Adopted

In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which expands the breadth and frequency of required segment disclosures. The guidance is required to be applied retrospectively to all periods presented in the financial statements. The standard becomes effective for Abbott for full year 2024 reporting and for interim periods beginning in the first quarter of 2025. Abbott is currently evaluating the impact of this new standard on its consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires an entity to disclose annually additional information related to the company's income tax rate reconciliation and income taxes paid during the period. The guidance should be applied prospectively with the option to apply the standard retrospectively. The standard becomes effective for Abbott for full year 2025 reporting. Abbott is currently evaluating the impact of this new standard on its consolidated financial statements.
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue (Tables)
 3 Months Ended
Mar. 31, 2024
Revenue from Contract with Customer [Abstract]  
Summary of Revenue by Sales Category
The following tables provide detail by sales category:

Three Months Ended March 31, 2024Three Months Ended March 31, 2023
(in millions)U.S.Int’lTotalU.S.Int’lTotal
Established Pharmaceutical Products —
Key Emerging Markets$— $928 $928 $— $912 $912 
Other— 298 298 — 277 277 
Total— 1,226 1,226 — 1,189 1,189 
Nutritionals —    
Pediatric Nutritionals514 495 1,009 459 465 924 
Adult Nutritionals364 695 1,059 353 690 1,043 
Total878 1,190 2,068 812 1,155 1,967 
Diagnostics —     
Core Laboratory310 895 1,205 289 893 1,182 
Molecular42 87 129 47 100 147 
Point of Care98 41 139 93 41 134 
Rapid Diagnostics481 260 741 906 319 1,225 
Total931 1,283 2,214 1,335 1,353 2,688 
Medical Devices —    
Rhythm Management271 291 562 260 267 527 
Electrophysiology269 318 587 238 267 505 
Heart Failure237 68 305 218 63 281 
Vascular254 435 689 218 399 617 
Structural Heart233 282 515 210 251 461 
Neuromodulation181 45 226 155 41 196 
Diabetes Care 589 980 1,569 479 834 1,313 
Total2,034 2,419 4,453 1,778 2,122 3,900 
Other3 — 3 3 — 3 
Total$3,846 $6,118 $9,964 $3,928 $5,819 $9,747 
Schedule of Changes in Contract Liabilities
Changes in the contract liabilities during the period are as follows:
(in millions)
Contract Liabilities:
Balance at December 31, 2023$545 
Unearned revenue from cash received during the period120 
Revenue recognized related to contract liability balance(116)
Balance at March 31, 2024$549 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Supplemental Financial Information (Tables)
 3 Months Ended
Mar. 31, 2024
Disclosure Text Block Supplement [Abstract]  
Summary of Allowance for Doubtful Accounts Activity
The following summarizes the activity for the first three months of 2024 related to the allowance for doubtful accounts as of March 31, 2024:

(in millions)
Allowance for Doubtful Accounts:
Balance at December 31, 2023$241 
Provisions/charges to income14 
Amounts charged off and other adjustments(8)
Balance at March 31, 2024$247 
Schedule of Long-Term Investments
The components of long-term investments as of March 31, 2024 and December 31, 2023 are as follows:

(in millions)March 31,
2024		December 31,
2023
Long-term Investments:
Equity securities$547 $555 
Other271 244 
Total$818 $799 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Changes In Accumulated Other Comprehensive Income (Loss) (Tables)
 3 Months Ended
Mar. 31, 2024
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Schedule of Accumulated Other Comprehensive Income (Loss), Net of Taxes
The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:

Three Months Ended March 31
Cumulative Foreign
Currency Translation
(Loss) Adjustments		Net Actuarial (Losses) and
Prior Service (Costs) and
Credits		Cumulative Gains (Losses)
on Derivative Instruments
Designated as Cash Flow
Hedges and Other
(in millions)202420232024202320242023
Balance at January 1$(6,504)$(6,733)$(1,376)$(1,493)$41 $175 
Other comprehensive income (loss) before reclassifications(386)139 2 2 68 (42)
Amounts reclassified from accumulated other comprehensive income— — 2 — (13)(87)
Net current period comprehensive income (loss)(386)139 4 2 55 (129)
Balance at March 31$(6,890)$(6,594)$(1,372)$(1,491)$96 $46 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Restructuring Plans (Tables)
 3 Months Ended
Mar. 31, 2024
Restructuring and Related Activities [Abstract]  
Summary of Restructuring Activity The following summarizes the 2024 activity related to these restructuring actions and the status of the related accruals as of March 31, 2024:
(in millions)
Accrued balance at December 31, 2023$137 
Payments and other adjustments(41)
Accrued balance at March 31, 2024$96 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Incentive Stock Programs (Tables)
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Summary of Options Outstanding and Exercisable Information regarding the number of options outstanding and exercisable at March 31, 2024 is as follows:
OutstandingExercisable
Number of shares 28,281,501 24,296,425 
Weighted average remaining life (years)
5.14.4
Weighted average exercise price $78.71 $73.05 
Aggregate intrinsic value (in millions)
$1,031 $1,020 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Financial Instruments, Derivatives and Fair Value Measures (Tables)
 3 Months Ended
Mar. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Summary of Amounts and Location of Derivative Financial Instruments
The following table summarizes the amounts and location of certain derivative financial instruments as of March 31, 2024 and December 31, 2023:

Fair Value - AssetsFair Value - Liabilities
(in millions)March 31,
2024		December 31,
2023		Balance Sheet CaptionMarch 31,
2024		December 31,
2023		Balance Sheet Caption
Interest rate swaps designated as fair value hedges:
Non-current $— $— Deferred income taxes and other assets$88 $95 Post-employment obligations, deferred income taxes and other long-term liabilities
Current— — Prepaid expenses and other receivables31 — Other accrued liabilities
Foreign currency forward exchange contracts:
Hedging instruments118 88 Prepaid expenses and other receivables61 134 Other accrued liabilities
Others not designated as hedges52 81 Prepaid expenses and other receivables39 97 Other accrued liabilities
Debt designated as a hedge of net investment in a foreign subsidiary— — n/a395 419 Current portion of long-term debt
$170 $169 $614 $745 
Schedule of Derivatives Gain (Loss) in OCI and Income (Expense)
The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three months ended March 31, 2024 and 2023.

Gain (loss) Recognized in Other Comprehensive Income (loss)Income (expense) and
 Gain (loss) Reclassified into Income
Three Months
Ended March 31		Three Months
Ended March 31
(in millions)2024202320242023Income Statement Caption
Foreign currency forward exchange contracts designated as cash flow hedges$127 $(63)$18 $126 Cost of products sold
Debt designated as a hedge of net investment in a foreign subsidiary24 (5)— — n/a
Interest rate swaps designated as fair value hedgesn/an/a(24)9 Interest expense
Schedule of Carrying Values and Fair Values of Financial Instruments
The carrying values and fair values of certain financial instruments as of March 31, 2024 and December 31, 2023 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.

March 31, 2024December 31, 2023
(in millions)Carrying
Value		Fair
Value		Carrying
Value		Fair
Value
Long-term Investment Securities:
Equity securities$547 $547 $555 $555 
Other271 271 244 244 
Total Long-term Debt(14,586)(14,299)(14,679)(14,769)
Foreign Currency Forward Exchange Contracts:   
Receivable position170 170 169 169 
(Payable) position(100)(100)(231)(231)
Interest Rate Hedge Contracts:    
(Payable) position(119)(119)(95)(95)
Summary of Bases Used to Measure Assets and Liabilities at Fair Value on a Recurring Basis
The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:

Basis of Fair Value Measurement
(in millions)Outstanding
Balances		Quoted
Prices in
Active
Markets		Significant
Other
Observable
Inputs		Significant
Unobservable
Inputs
March 31, 2024:
Equity securities$327 $327 $— $— 
Foreign currency forward exchange contracts170 — 170 — 
Total Assets$497 $327 $170 $— 
Fair value of hedged long-term debt$2,046 $— $2,046 $— 
Interest rate swap derivative financial instruments119 — 119 — 
Foreign currency forward exchange contracts100 — 100 — 
Contingent consideration related to business combinations59 — — 59 
Total Liabilities$2,324 $— $2,265 $59 
December 31, 2023:
Equity securities$326 $326 $— $— 
Foreign currency forward exchange contracts169 — 169 — 
Total Assets$495 $326 $169 $— 
Fair value of hedged long-term debt$2,052 $— $2,052 $— 
Interest rate swap derivative financial instruments95 — 95 — 
Foreign currency forward exchange contracts231 — 231 — 
Contingent consideration related to business combinations112 — — 112 
Total Liabilities$2,490 $— $2,378 $112 
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Post-Employment Benefits (Tables)
 3 Months Ended
Mar. 31, 2024
Postemployment Benefits [Abstract]  
Schedule of Net Periodic Cost Net cost recognized for the three months ended March 31 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:
Defined Benefit PlansMedical and Dental Plans
Three Months
Ended March 31		Three Months
Ended March 31
(in millions)2024202320242023
Service cost - benefits earned during the period$61 $60 $10 $9 
Interest cost on projected benefit obligations118 114 15 14 
Expected return on plan assets(262)(242)(6)(6)
Net amortization of:
Actuarial loss, net6 3 — — 
Prior service cost (credit)— — (3)(3)
Net cost (credit)$(77)$(65)$16 $14 
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment Information (Tables)
 3 Months Ended
Mar. 31, 2024
Segment Reporting [Abstract]  
Schedule of Segment Information
The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the condensed consolidated financial statements.

 Net Sales to External CustomersOperating Earnings
Three Months
Ended March 31		Three Months
Ended March 31
(in millions)202420232024 2023
Established Pharmaceutical Products$1,226 $1,189 $267 $300 
Nutritional Products2,068 1,967 377 380 
Diagnostic Products2,214 2,688 474 651 
Medical Devices4,453 3,900 1,360 1,078 
Total Reportable Segments9,961 9,744 2,478 2,409 
Other 3 3 
Net sales$9,964 $9,747 
Corporate functions and benefit plan costs(66)(77)
Net interest expense (61)(52)
Share-based compensation (a) (304)(281)
Amortization of intangible assets(472)(491)
Other, net (b)(139)54 
Earnings before taxes$1,436 $1,562 
______________________________________
(a)
Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.
(b)
Other, net for the three months ended March 31, 2024 and March 31, 2023 includes charges related to restructuring actions. Other, net for the three months ended March 31, 2024 also includes integration costs associated with the acquisition of CSI and $38 million related to various investment impairments.
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue - Narrative (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2024
USD ($)
segment
Mar. 31, 2023
USD ($)
segment
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]    
Number of reportable segments | segment 4 4
Sales $ 9,964 $ 9,747
Diagnostics    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]    
Remaining performance obligations 4,500  
Diagnostics | COVID-19 Testing    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]    
Sales 204 $ 730
Medical Devices    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]    
Remaining performance obligations $ 495  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-04-01    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]    
Percentage of remaining performance obligation expected to be recognized in period 59.00%  
Expected timing of satisfaction period (in months) 24 months  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-04-01    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]    
Percentage of remaining performance obligation expected to be recognized in period 16.00%  
Expected timing of satisfaction period (in months) 12 months  
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue - Summary of Revenue by Sales Category (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Segment Reporting Information [Line Items]    
Net sales $ 9,964 $ 9,747
Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 9,961 9,744
Other    
Segment Reporting Information [Line Items]    
Net sales 3 3
U.S.    
Segment Reporting Information [Line Items]    
Net sales 3,846 3,928
U.S. | Other    
Segment Reporting Information [Line Items]    
Net sales 3 3
Int’l    
Segment Reporting Information [Line Items]    
Net sales 6,118 5,819
Int’l | Other    
Segment Reporting Information [Line Items]    
Net sales 0 0
Established Pharmaceutical Products | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 1,226 1,189
Established Pharmaceutical Products | U.S. | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 0 0
Established Pharmaceutical Products | Int’l | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 1,226 1,189
Nutritionals | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 2,068 1,967
Nutritionals | U.S. | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 878 812
Nutritionals | Int’l | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 1,190 1,155
Diagnostics | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 2,214 2,688
Diagnostics | U.S. | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 931 1,335
Diagnostics | Int’l | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 1,283 1,353
Medical Devices | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 4,453 3,900
Medical Devices | U.S. | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 2,034 1,778
Medical Devices | Int’l | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 2,419 2,122
Key Emerging Markets | Established Pharmaceutical Products | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 928 912
Key Emerging Markets | Established Pharmaceutical Products | U.S. | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 0 0
Key Emerging Markets | Established Pharmaceutical Products | Int’l | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 928 912
Other | Established Pharmaceutical Products | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 298 277
Other | Established Pharmaceutical Products | U.S. | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 0 0
Other | Established Pharmaceutical Products | Int’l | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 298 277
Pediatric Nutritionals | Nutritionals | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 1,009 924
Pediatric Nutritionals | Nutritionals | U.S. | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 514 459
Pediatric Nutritionals | Nutritionals | Int’l | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 495 465
Adult Nutritionals | Nutritionals | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 1,059 1,043
Adult Nutritionals | Nutritionals | U.S. | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 364 353
Adult Nutritionals | Nutritionals | Int’l | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 695 690
Core Laboratory | Diagnostics | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 1,205 1,182
Core Laboratory | Diagnostics | U.S. | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 310 289
Core Laboratory | Diagnostics | Int’l | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 895 893
Molecular | Diagnostics | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 129 147
Molecular | Diagnostics | U.S. | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 42 47
Molecular | Diagnostics | Int’l | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 87 100
Point of Care | Diagnostics | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 139 134
Point of Care | Diagnostics | U.S. | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 98 93
Point of Care | Diagnostics | Int’l | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 41 41
Rapid Diagnostics | Diagnostics | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 741 1,225
Rapid Diagnostics | Diagnostics | U.S. | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 481 906
Rapid Diagnostics | Diagnostics | Int’l | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 260 319
Rhythm Management | Medical Devices | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 562 527
Rhythm Management | Medical Devices | U.S. | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 271 260
Rhythm Management | Medical Devices | Int’l | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 291 267
Electrophysiology | Medical Devices | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 587 505
Electrophysiology | Medical Devices | U.S. | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 269 238
Electrophysiology | Medical Devices | Int’l | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 318 267
Heart Failure | Medical Devices | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 305 281
Heart Failure | Medical Devices | U.S. | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 237 218
Heart Failure | Medical Devices | Int’l | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 68 63
Vascular | Medical Devices | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 689 617
Vascular | Medical Devices | U.S. | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 254 218
Vascular | Medical Devices | Int’l | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 435 399
Structural Heart | Medical Devices | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 515 461
Structural Heart | Medical Devices | U.S. | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 233 210
Structural Heart | Medical Devices | Int’l | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 282 251
Neuromodulation | Medical Devices | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 226 196
Neuromodulation | Medical Devices | U.S. | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 181 155
Neuromodulation | Medical Devices | Int’l | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 45 41
Diabetes Care | Medical Devices | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 1,569 1,313
Diabetes Care | Medical Devices | U.S. | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 589 479
Diabetes Care | Medical Devices | Int’l | Operating Segments    
Segment Reporting Information [Line Items]    
Net sales $ 980 $ 834
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue - Schedule of Changes in Contract Liabilities (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2024
USD ($)
Contract Liabilities:  
Beginning balance $ 545
Unearned revenue from cash received during the period 120
Revenue recognized related to contract liability balance (116)
Ending balance $ 549
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Supplemental Financial Information - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Condensed Cash Flow Statements, Captions [Line Items]    
Net earnings allocated to common shares $ 1,220 $ 1,313
Payment of cash taxes 225 122
Equity method investments carrying value 154  
Equity investments without readily determinable fair value 66  
St. Jude Medical    
Condensed Cash Flow Statements, Captions [Line Items]    
Investments in mutual funds held in a rabbi trust 317  
Defined Benefit Plans    
Condensed Cash Flow Statements, Captions [Line Items]    
Pension contributions $ 280 $ 282
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Supplemental Financial Information - Allowance for Doubtful Accounts (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2024
USD ($)
Allowance for Doubtful Accounts:  
Beginning balance $ 241
Provisions/charges to income 14
Amounts charged off and other adjustments (8)
Ending balance $ 247
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Supplemental Financial Information - Long-Term Investments (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Summary of Investment Holdings [Line Items]    
Total $ 818 $ 799
Equity securities    
Summary of Investment Holdings [Line Items]    
Total 547 555
Other    
Summary of Investment Holdings [Line Items]    
Total $ 271 $ 244
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Changes In Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Changes in accumulated other comprehensive income (loss), net of income taxes    
Beginning of the period $ 38,603  
Other comprehensive income (loss) (327) $ 12
End of the period 38,810  
Cumulative Foreign Currency Translation (Loss) Adjustments    
Changes in accumulated other comprehensive income (loss), net of income taxes    
Beginning of the period (6,504) (6,733)
Other comprehensive income (loss) before reclassifications (386) 139
Amounts reclassified from accumulated other comprehensive income 0 0
Other comprehensive income (loss) (386) 139
End of the period (6,890) (6,594)
Net Actuarial (Losses) and Prior Service (Costs) and Credits    
Changes in accumulated other comprehensive income (loss), net of income taxes    
Beginning of the period (1,376) (1,493)
Other comprehensive income (loss) before reclassifications 2 2
Amounts reclassified from accumulated other comprehensive income 2 0
Other comprehensive income (loss) 4 2
End of the period (1,372) (1,491)
Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges and Other    
Changes in accumulated other comprehensive income (loss), net of income taxes    
Beginning of the period 41 175
Other comprehensive income (loss) before reclassifications 68 (42)
Amounts reclassified from accumulated other comprehensive income (13) (87)
Other comprehensive income (loss) 55 (129)
End of the period $ 96 $ 46
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Business Acquisitions (Details)
$ / shares in Units, $ in Millions
Apr. 27, 2023
USD ($)
intangibleAsset
$ / shares
Mar. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Business Acquisition [Line Items]      
Goodwill   $ 23,383 $ 23,679
CSI      
Business Acquisition [Line Items]      
Acquisition share price (in dollars per share) | $ / shares $ 20    
Acquisition purchase price $ 851    
Number of developed technology intangible assets | intangibleAsset 2    
Developed technology intangible assets $ 305    
In-process research and development 15    
Goodwill 369    
Net deferred tax assets 46    
Other net assets $ 116    
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Goodwill and Intangible Assets (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Goodwill and Intangible Assets [Line Items]    
Goodwill $ 23,383 $ 23,679
Decrease in goodwill due to foreign currency translation adjustments 294  
Amount of reductions of goodwill relating to impairments 0  
Gross amount of amortizable intangible assets 27,500 27,700
Accumulated amortization of intangible assets 20,000 19,700
Decrease in intangible assets due to foreign currency translation adjustments 38  
Impairment charge 8  
Estimated annual amortization expense, intangible assets, remainder of year 1,900  
Estimated annual amortization expense, intangible assets, year one 1,700  
Estimated annual amortization expense, intangible assets, year two 1,600  
Estimated annual amortization expense, intangible assets, year three 1,300  
Estimated annual amortization expense, intangible assets, year four 700  
Indefinite-lived intangible assets related to in-process R&D acquired in a business combination 787 $ 787
Established Pharmaceutical Products    
Goodwill and Intangible Assets [Line Items]    
Goodwill 2,700  
Nutritionals    
Goodwill and Intangible Assets [Line Items]    
Goodwill 285  
Diagnostics    
Goodwill and Intangible Assets [Line Items]    
Goodwill 3,500  
Medical Devices    
Goodwill and Intangible Assets [Line Items]    
Goodwill $ 16,900  
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Restructuring Plans - Narrative (Details) - 2024 Restructuring Plan
$ in Millions
 3 Months Ended
Mar. 31, 2024
USD ($)
Restructuring Cost and Reserve [Line Items]  
Employee related severance and other charges $ 17
Payments for restructuring 3
Remaining liabilities 14
Asset impairment charges 30
Cost of products sold  
Restructuring Cost and Reserve [Line Items]  
Employee related severance and other charges 11
Research and development  
Restructuring Cost and Reserve [Line Items]  
Employee related severance and other charges 1
Selling, general and administrative expenses  
Restructuring Cost and Reserve [Line Items]  
Employee related severance and other charges $ 5
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Restructuring Plans - Restructuring Activity (Details) - 2022 and 2023 Restructuring Plan
$ in Millions
 3 Months Ended
Mar. 31, 2024
USD ($)
Restructuring Reserve [Roll Forward]  
Accrued balance at beginning of the period $ 137
Payments and other adjustments (41)
Accrued balance at end of the period $ 96
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Incentive Stock Programs - Narrative (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2024
USD ($)
shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Incentive stock program, shares reserved for future grants (in shares) 60,000,000
Total unrecognized compensation cost | $ $ 787
Total unrecognized compensation cost, expected period for recognition 3 years
Stock Options  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Stock options granted (in shares) 1,666,566
Restricted Stock Awards  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Restricted stock awards granted (in shares) 404,597
Restricted Stock Units (RSUs)  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Restricted stock units granted (in shares) 5,189,560
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Incentive Stock Programs - Options (Details) - Stock Options
$ / shares in Units, $ in Millions
 3 Months Ended
Mar. 31, 2024
USD ($)
$ / shares
shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Outstanding, number of shares (in shares) | shares 28,281,501
Exercisable, number of shares (in shares) | shares 24,296,425
Outstanding, weighted-average remaining life 5 years 1 month 6 days
Exercisable, weighted-average remaining life 4 years 4 months 24 days
Outstanding, weighted-average exercise price (in dollars per share) | $ / shares $ 78.71
Exercisable, weighted-average exercise price (in dollars per share) | $ / shares $ 73.05
Outstanding, aggregate intrinsic value | $ $ 1,031
Exercisable, aggregate intrinsic value | $ $ 1,020
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Debt and Lines of Credit (Details) - USD ($)
$ in Millions
Jan. 29, 2024
Nov. 12, 2020
Mar. 31, 2024
Line of Credit | 2020 Five Year Credit Agreement      
Debt Instrument [Line Items]      
Debt instrument, term   5 years  
Outstanding borrowings $ 0    
Revolving Credit Facility | 2024 Five Year Credit Agreement      
Debt Instrument [Line Items]      
Maximum borrowing capacity     $ 5,000
Debt instrument, term 5 years    
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Financial Instruments, Derivatives and Fair Value Measures - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Derivative [Line Items]      
Yen-denominated term loan $ 614   $ 745
Gain (loss) from foreign currency forward exchange contracts not designated as hedges 92 $ (103)  
Payment for contingent consideration 40    
Change in fair value of remaining contingent consideration 13    
Various Business Acquisitions      
Derivative [Line Items]      
Maximum amount of contingent consideration $ 135    
Net Investment Hedging | Designated as Hedging Instrument | Five Year Term Loan due 2024      
Derivative [Line Items]      
Debt instrument, term 5 years   5 years
Yen-denominated term loan $ 395   $ 419
Foreign Currency Forward Exchange Contracts | Not Designated as Hedging Instrument      
Derivative [Line Items]      
Derivative, notional amount 14,500   13,800
Foreign Currency Forward Exchange Contracts | Cash Flow Hedging | Designated as Hedging Instrument      
Derivative [Line Items]      
Derivative, notional amount $ 7,300   7,300
Minimum length of time over which accumulated gains and losses will be recognized in Cost of products sold 12 months    
Maximum length of time over which accumulated gains and losses will be recognized in Cost of products sold 18 months    
Interest Rate Hedge Contracts | Fair Value Hedging | Designated as Hedging Instrument      
Derivative [Line Items]      
Derivative, notional amount $ 2,200   $ 2,200
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Financial Instruments, Derivatives and Fair Value Measures - Amounts and Location of Derivative Instruments (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Derivatives, Fair Value [Line Items]    
Fair Value - Assets $ 170 $ 169
Fair Value - Liabilities 614 745
Designated as Hedging Instrument | Interest Rate Swaps | Deferred income taxes and other assets | Fair Value Hedging    
Derivatives, Fair Value [Line Items]    
Fair Value - Assets 0 0
Designated as Hedging Instrument | Interest Rate Swaps | Prepaid expenses and other receivables, current | Fair Value Hedging    
Derivatives, Fair Value [Line Items]    
Fair Value - Assets 0 0
Designated as Hedging Instrument | Interest Rate Swaps | Post-employment obligations, deferred income taxes and other long-term liabilities | Fair Value Hedging    
Derivatives, Fair Value [Line Items]    
Fair Value - Liabilities 88 95
Designated as Hedging Instrument | Interest Rate Swaps | Other accrued liabilities | Fair Value Hedging    
Derivatives, Fair Value [Line Items]    
Fair Value - Liabilities 31 0
Designated as Hedging Instrument | Foreign Currency Forward Exchange Contracts | Prepaid expenses and other receivables    
Derivatives, Fair Value [Line Items]    
Fair Value - Assets 118 88
Designated as Hedging Instrument | Foreign Currency Forward Exchange Contracts | Other accrued liabilities    
Derivatives, Fair Value [Line Items]    
Fair Value - Liabilities 61 134
Designated as Hedging Instrument | Debt | Current portion of long-term debt | Net Investment Hedging    
Derivatives, Fair Value [Line Items]    
Fair Value - Liabilities 395 419
Not Designated as Hedging Instrument | Foreign Currency Forward Exchange Contracts | Prepaid expenses and other receivables    
Derivatives, Fair Value [Line Items]    
Fair Value - Assets 52 81
Not Designated as Hedging Instrument | Foreign Currency Forward Exchange Contracts | Other accrued liabilities    
Derivatives, Fair Value [Line Items]    
Fair Value - Liabilities $ 39 $ 97
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Financial Instruments, Derivatives and Fair Value Measures - Schedule of Derivatives Gain (Loss) in OCI and Income (Expense) (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Foreign Currency Forward Exchange Contracts | Cost of products sold    
Derivative Instruments, Gain (Loss) [Line Items]    
Gain (loss) recognized in other comprehensive income (loss), foreign currency forward exchange contracts designated as cash flow hedges $ 127 $ (63)
Income (expense) and gain (loss) reclassified into income, foreign currency forward exchange contracts designated as cash flow hedges 18 126
Debt    
Derivative Instruments, Gain (Loss) [Line Items]    
Gain (loss) recognized in other comprehensive income (loss), debt designated as a hedge of net investment in a foreign subsidiary 24 (5)
Interest Rate Swaps | Interest expense    
Derivative Instruments, Gain (Loss) [Line Items]    
Income (expense) and gain (loss) reclassified into income, interest rate swaps designated as fair value hedges $ (24) $ 9
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Derivative [Line Items]    
Long-term Investment Securities: $ 818 $ 799
Receivable position 170 169
(Payable) position (614) (745)
Equity securities    
Derivative [Line Items]    
Long-term Investment Securities: 547 555
Carrying Value    
Derivative [Line Items]    
Total Long-term Debt (14,586) (14,679)
Carrying Value | Foreign Currency Forward Exchange Contracts    
Derivative [Line Items]    
Receivable position 170 169
(Payable) position (100) (231)
Carrying Value | Interest Rate Hedge Contracts    
Derivative [Line Items]    
(Payable) position (119) (95)
Carrying Value | Equity securities    
Derivative [Line Items]    
Long-term Investment Securities: 547 555
Carrying Value | Other    
Derivative [Line Items]    
Long-term Investment Securities: 271 244
Fair Value    
Derivative [Line Items]    
Total Long-term Debt (14,299) (14,769)
Fair Value | Foreign Currency Forward Exchange Contracts    
Derivative [Line Items]    
Receivable position 170 169
(Payable) position (100) (231)
Fair Value | Interest Rate Hedge Contracts    
Derivative [Line Items]    
(Payable) position (119) (95)
Fair Value | Equity securities    
Derivative [Line Items]    
Long-term Investment Securities: 547 555
Fair Value | Other    
Derivative [Line Items]    
Long-term Investment Securities: $ 271 $ 244
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Quoted Prices in Active Markets    
Assets, at Fair Value    
Equity securities $ 327 $ 326
Foreign currency forward exchange contracts 0 0
Total Assets 327 326
Liabilities, at Fair Value    
Fair value of hedged long-term debt 0 0
Interest rate swap derivative financial instruments 0 0
Foreign currency forward exchange contracts 0 0
Contingent consideration related to business combinations 0 0
Total Liabilities 0 0
Significant Other Observable Inputs    
Assets, at Fair Value    
Equity securities 0 0
Foreign currency forward exchange contracts 170 169
Total Assets 170 169
Liabilities, at Fair Value    
Fair value of hedged long-term debt 2,046 2,052
Interest rate swap derivative financial instruments 119 95
Foreign currency forward exchange contracts 100 231
Contingent consideration related to business combinations 0 0
Total Liabilities 2,265 2,378
Significant Unobservable Inputs    
Assets, at Fair Value    
Equity securities 0 0
Foreign currency forward exchange contracts 0 0
Total Assets 0 0
Liabilities, at Fair Value    
Fair value of hedged long-term debt 0 0
Interest rate swap derivative financial instruments 0 0
Foreign currency forward exchange contracts 0 0
Contingent consideration related to business combinations 59 112
Total Liabilities 59 112
Outstanding Balances    
Assets, at Fair Value    
Equity securities 327 326
Foreign currency forward exchange contracts 170 169
Total Assets 497 495
Liabilities, at Fair Value    
Fair value of hedged long-term debt 2,046 2,052
Interest rate swap derivative financial instruments 119 95
Foreign currency forward exchange contracts 100 231
Contingent consideration related to business combinations 59 112
Total Liabilities $ 2,324 $ 2,490
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Litigation and Environmental Matters (Details)
$ in Millions
Mar. 31, 2024
USD ($)
Loss Contingencies [Line Items]  
Maximum expected cleanup exposure for individual site $ 4
Maximum expected cleanup exposure in aggregate 10
Legal proceedings and environmental exposures  
Loss Contingencies [Line Items]  
Recorded accrual balance for legal proceedings and exposures 55
Legal proceedings and environmental exposures | Minimum  
Loss Contingencies [Line Items]  
Estimation of possible loss 45
Legal proceedings and environmental exposures | Maximum  
Loss Contingencies [Line Items]  
Estimation of possible loss $ 60
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Post-Employment Benefits - Schedule of Net Periodic Cost (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Defined Benefit Plans    
Defined Benefit Plan Disclosure [Line Items]    
Service cost - benefits earned during the period $ 61 $ 60
Interest cost on projected benefit obligations 118 114
Expected return on plan assets (262) (242)
Net amortization of:    
Actuarial loss, net 6 3
Prior service cost (credit) 0 0
Net cost (credit) (77) (65)
Medical and Dental Plans    
Defined Benefit Plan Disclosure [Line Items]    
Service cost - benefits earned during the period 10 9
Interest cost on projected benefit obligations 15 14
Expected return on plan assets (6) (6)
Net amortization of:    
Actuarial loss, net 0 0
Prior service cost (credit) (3) (3)
Net cost (credit) $ 16 $ 14
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Post-Employment Benefits - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Defined Benefit Plans    
Defined Benefit Plan Disclosure [Line Items]    
Company contributions $ 280 $ 282
Medical and Dental Plans    
Defined Benefit Plan Disclosure [Line Items]    
Company contributions $ 28 $ 28
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Taxes on Earnings (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Sep. 30, 2023
Income Tax Disclosure [Abstract]      
Excess tax benefits associated with share-based compensation $ 25 $ 3  
Tax expense from prior year tax positions 10 $ 22  
Decrease reasonably possible in gross unrecognized tax benefits 82    
Gross unrecognized tax benefits $ 1,340    
Income tax claim related to statutory notice of deficiency     $ 417
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment Information (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Segment Reporting Information [Line Items]    
Net Sales to External Customers $ 9,964 $ 9,747
Operating Earnings 1,386 1,509
Amortization of intangible assets (472) (491)
Earnings before taxes $ 1,436 $ 1,562
Annual share-based awards recognized in first quarter (as a percent) 45.00% 45.00%
Operating Segments    
Segment Reporting Information [Line Items]    
Net Sales to External Customers $ 9,961 $ 9,744
Operating Earnings 2,478 2,409
Operating Segments | Established Pharmaceutical Products    
Segment Reporting Information [Line Items]    
Net Sales to External Customers 1,226 1,189
Operating Earnings 267 300
Operating Segments | Nutritional Products    
Segment Reporting Information [Line Items]    
Net Sales to External Customers 2,068 1,967
Operating Earnings 377 380
Operating Segments | Diagnostic Products    
Segment Reporting Information [Line Items]    
Net Sales to External Customers 2,214 2,688
Operating Earnings 474 651
Operating Segments | Medical Devices    
Segment Reporting Information [Line Items]    
Net Sales to External Customers 4,453 3,900
Operating Earnings 1,360 1,078
Other    
Segment Reporting Information [Line Items]    
Net Sales to External Customers 3 3
Segment Reconciling Items    
Segment Reporting Information [Line Items]    
Corporate functions and benefit plan costs (66) (77)
Net interest expense (61) (52)
Share-based compensation (304) (281)
Amortization of intangible assets (472) (491)
Other, net (139) $ 54
Various investment impairments $ 38  
EXCEL 69 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 70 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 71 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 73 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 289 260 1 false 81 0 false 6 false false R1.htm 0000001 - Document - Cover Sheet http://www.abbott.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Statement of Earnings (Unaudited) Sheet http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited Condensed Consolidated Statement of Earnings (Unaudited) Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Statement of Comprehensive Income (Unaudited) Sheet http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited Condensed Consolidated Statement of Comprehensive Income (Unaudited) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical) Sheet http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnauditedParenthetical Condensed Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical) Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Balance Sheet (Unaudited) Sheet http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited Condensed Consolidated Balance Sheet (Unaudited) Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical) Sheet http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical) Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statement of Shareholders' Investment (Unaudited) Sheet http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited Condensed Consolidated Statement of Shareholders' Investment (Unaudited) Statements 7 false false R8.htm 0000008 - Statement - Condensed Consolidated Statement of Shareholders' Investment (Unaudited) (Parenthetical) Sheet http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical Condensed Consolidated Statement of Shareholders' Investment (Unaudited) (Parenthetical) Statements 8 false false R9.htm 0000009 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited) Sheet http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited Condensed Consolidated Statement of Cash Flows (Unaudited) Statements 9 false false R10.htm 0000010 - Disclosure - Basis of Presentation Sheet http://www.abbott.com/role/BasisofPresentation Basis of Presentation Notes 10 false false R11.htm 0000011 - Disclosure - New Accounting Standards Sheet http://www.abbott.com/role/NewAccountingStandards New Accounting Standards Notes 11 false false R12.htm 0000012 - Disclosure - Revenue Sheet http://www.abbott.com/role/Revenue Revenue Notes 12 false false R13.htm 0000013 - Disclosure - Supplemental Financial Information Sheet http://www.abbott.com/role/SupplementalFinancialInformation Supplemental Financial Information Notes 13 false false R14.htm 0000014 - Disclosure - Changes In Accumulated Other Comprehensive Income (Loss) Sheet http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLoss Changes In Accumulated Other Comprehensive Income (Loss) Notes 14 false false R15.htm 0000015 - Disclosure - Business Acquisitions Sheet http://www.abbott.com/role/BusinessAcquisitions Business Acquisitions Notes 15 false false R16.htm 0000016 - Disclosure - Goodwill and Intangible Assets Sheet http://www.abbott.com/role/GoodwillandIntangibleAssets Goodwill and Intangible Assets Notes 16 false false R17.htm 0000017 - Disclosure - Restructuring Plans Sheet http://www.abbott.com/role/RestructuringPlans Restructuring Plans Notes 17 false false R18.htm 0000018 - Disclosure - Incentive Stock Programs Sheet http://www.abbott.com/role/IncentiveStockPrograms Incentive Stock Programs Notes 18 false false R19.htm 0000019 - Disclosure - Debt and Lines of Credit Sheet http://www.abbott.com/role/DebtandLinesofCredit Debt and Lines of Credit Notes 19 false false R20.htm 0000020 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures Sheet http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasures Financial Instruments, Derivatives and Fair Value Measures Notes 20 false false R21.htm 0000021 - Disclosure - Litigation and Environmental Matters Sheet http://www.abbott.com/role/LitigationandEnvironmentalMatters Litigation and Environmental Matters Notes 21 false false R22.htm 0000022 - Disclosure - Post-Employment Benefits Sheet http://www.abbott.com/role/PostEmploymentBenefits Post-Employment Benefits Notes 22 false false R23.htm 0000023 - Disclosure - Taxes on Earnings Sheet http://www.abbott.com/role/TaxesonEarnings Taxes on Earnings Notes 23 false false R24.htm 0000024 - Disclosure - Segment Information Sheet http://www.abbott.com/role/SegmentInformation Segment Information Notes 24 false false R25.htm 9954471 - Disclosure - New Accounting Standards (Policies) Sheet http://www.abbott.com/role/NewAccountingStandardsPolicies New Accounting Standards (Policies) Policies http://www.abbott.com/role/NewAccountingStandards 25 false false R26.htm 9954472 - Disclosure - Revenue (Tables) Sheet http://www.abbott.com/role/RevenueTables Revenue (Tables) Tables http://www.abbott.com/role/Revenue 26 false false R27.htm 9954473 - Disclosure - Supplemental Financial Information (Tables) Sheet http://www.abbott.com/role/SupplementalFinancialInformationTables Supplemental Financial Information (Tables) Tables http://www.abbott.com/role/SupplementalFinancialInformation 27 false false R28.htm 9954474 - Disclosure - Changes In Accumulated Other Comprehensive Income (Loss) (Tables) Sheet http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossTables Changes In Accumulated Other Comprehensive Income (Loss) (Tables) Tables http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLoss 28 false false R29.htm 9954475 - Disclosure - Restructuring Plans (Tables) Sheet http://www.abbott.com/role/RestructuringPlansTables Restructuring Plans (Tables) Tables http://www.abbott.com/role/RestructuringPlans 29 false false R30.htm 9954476 - Disclosure - Incentive Stock Programs (Tables) Sheet http://www.abbott.com/role/IncentiveStockProgramsTables Incentive Stock Programs (Tables) Tables http://www.abbott.com/role/IncentiveStockPrograms 30 false false R31.htm 9954477 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Tables) Sheet http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables Financial Instruments, Derivatives and Fair Value Measures (Tables) Tables http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasures 31 false false R32.htm 9954478 - Disclosure - Post-Employment Benefits (Tables) Sheet http://www.abbott.com/role/PostEmploymentBenefitsTables Post-Employment Benefits (Tables) Tables http://www.abbott.com/role/PostEmploymentBenefits 32 false false R33.htm 9954479 - Disclosure - Segment Information (Tables) Sheet http://www.abbott.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.abbott.com/role/SegmentInformation 33 false false R34.htm 9954480 - Disclosure - Revenue - Narrative (Details) Sheet http://www.abbott.com/role/RevenueNarrativeDetails Revenue - Narrative (Details) Details 34 false false R35.htm 9954481 - Disclosure - Revenue - Summary of Revenue by Sales Category (Details) Sheet http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails Revenue - Summary of Revenue by Sales Category (Details) Details 35 false false R36.htm 9954482 - Disclosure - Revenue - Schedule of Changes in Contract Liabilities (Details) Sheet http://www.abbott.com/role/RevenueScheduleofChangesinContractLiabilitiesDetails Revenue - Schedule of Changes in Contract Liabilities (Details) Details 36 false false R37.htm 9954483 - Disclosure - Supplemental Financial Information - Narrative (Details) Sheet http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails Supplemental Financial Information - Narrative (Details) Details 37 false false R38.htm 9954484 - Disclosure - Supplemental Financial Information - Allowance for Doubtful Accounts (Details) Sheet http://www.abbott.com/role/SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails Supplemental Financial Information - Allowance for Doubtful Accounts (Details) Details 38 false false R39.htm 9954485 - Disclosure - Supplemental Financial Information - Long-Term Investments (Details) Sheet http://www.abbott.com/role/SupplementalFinancialInformationLongTermInvestmentsDetails Supplemental Financial Information - Long-Term Investments (Details) Details 39 false false R40.htm 9954486 - Disclosure - Changes In Accumulated Other Comprehensive Income (Loss) (Details) Sheet http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails Changes In Accumulated Other Comprehensive Income (Loss) (Details) Details http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossTables 40 false false R41.htm 9954487 - Disclosure - Business Acquisitions (Details) Sheet http://www.abbott.com/role/BusinessAcquisitionsDetails Business Acquisitions (Details) Details http://www.abbott.com/role/BusinessAcquisitions 41 false false R42.htm 9954488 - Disclosure - Goodwill and Intangible Assets (Details) Sheet http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails Goodwill and Intangible Assets (Details) Details http://www.abbott.com/role/GoodwillandIntangibleAssets 42 false false R43.htm 9954489 - Disclosure - Restructuring Plans - Narrative (Details) Sheet http://www.abbott.com/role/RestructuringPlansNarrativeDetails Restructuring Plans - Narrative (Details) Details 43 false false R44.htm 9954490 - Disclosure - Restructuring Plans - Restructuring Activity (Details) Sheet http://www.abbott.com/role/RestructuringPlansRestructuringActivityDetails Restructuring Plans - Restructuring Activity (Details) Details 44 false false R45.htm 9954491 - Disclosure - Incentive Stock Programs - Narrative (Details) Sheet http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails Incentive Stock Programs - Narrative (Details) Details 45 false false R46.htm 9954492 - Disclosure - Incentive Stock Programs - Options (Details) Sheet http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails Incentive Stock Programs - Options (Details) Details 46 false false R47.htm 9954493 - Disclosure - Debt and Lines of Credit (Details) Sheet http://www.abbott.com/role/DebtandLinesofCreditDetails Debt and Lines of Credit (Details) Details http://www.abbott.com/role/DebtandLinesofCredit 47 false false R48.htm 9954494 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Narrative (Details) Sheet http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails Financial Instruments, Derivatives and Fair Value Measures - Narrative (Details) Details http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables 48 false false R49.htm 9954495 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Amounts and Location of Derivative Instruments (Details) Sheet http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails Financial Instruments, Derivatives and Fair Value Measures - Amounts and Location of Derivative Instruments (Details) Details 49 false false R50.htm 9954496 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Schedule of Derivatives Gain (Loss) in OCI and Income (Expense) (Details) Sheet http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails Financial Instruments, Derivatives and Fair Value Measures - Schedule of Derivatives Gain (Loss) in OCI and Income (Expense) (Details) Details 50 false false R51.htm 9954497 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details) Sheet http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details) Details 51 false false R52.htm 9954498 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details) Sheet http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details) Details 52 false false R53.htm 9954499 - Disclosure - Litigation and Environmental Matters (Details) Sheet http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails Litigation and Environmental Matters (Details) Details http://www.abbott.com/role/LitigationandEnvironmentalMatters 53 false false R54.htm 9954500 - Disclosure - Post-Employment Benefits - Schedule of Net Periodic Cost (Details) Sheet http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicCostDetails Post-Employment Benefits - Schedule of Net Periodic Cost (Details) Details 54 false false R55.htm 9954501 - Disclosure - Post-Employment Benefits - Narrative (Details) Sheet http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails Post-Employment Benefits - Narrative (Details) Details 55 false false R56.htm 9954502 - Disclosure - Taxes on Earnings (Details) Sheet http://www.abbott.com/role/TaxesonEarningsDetails Taxes on Earnings (Details) Details http://www.abbott.com/role/TaxesonEarnings 56 false false R57.htm 9954503 - Disclosure - Segment Information (Details) Sheet http://www.abbott.com/role/SegmentInformationDetails Segment Information (Details) Details http://www.abbott.com/role/SegmentInformationTables 57 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: abt:MinimumLengthOfTimeHedgedInCashFlowHedge - abt-20240331.htm 4 abt-20240331.htm abt-20240331.xsd abt-20240331_cal.xml abt-20240331_def.xml abt-20240331_lab.xml abt-20240331_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 76 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "abt-20240331.htm": { "nsprefix": "abt", "nsuri": "http://www.abbott.com/20240331", "dts": { "inline": { "local": [ "abt-20240331.htm" ] }, "schema": { "local": [ "abt-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd" ] }, "calculationLink": { "local": [ "abt-20240331_cal.xml" ] }, "definitionLink": { "local": [ "abt-20240331_def.xml" ] }, "labelLink": { "local": [ "abt-20240331_lab.xml" ] }, "presentationLink": { "local": [ "abt-20240331_pre.xml" ] } }, "keyStandard": 240, "keyCustom": 20, "axisStandard": 25, "axisCustom": 0, "memberStandard": 44, "memberCustom": 37, "hidden": { "total": 6, "http://xbrl.sec.gov/dei/2023": 5, "http://www.abbott.com/20240331": 1 }, "contextCount": 289, "entityCount": 1, "segmentCount": 81, "elementCount": 464, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 701, "http://xbrl.sec.gov/dei/2023": 32 }, "report": { "R1": { "role": "http://www.abbott.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited", "longName": "0000002 - Statement - Condensed Consolidated Statement of Earnings (Unaudited)", "shortName": "Condensed Consolidated Statement of Earnings (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "unique": true } }, "R3": { "role": "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited", "longName": "0000003 - Statement - Condensed Consolidated Statement of Comprehensive Income (Unaudited)", "shortName": "Condensed Consolidated Statement of Comprehensive Income (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "unique": true } }, "R4": { "role": "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnauditedParenthetical", "longName": "0000004 - Statement - Condensed Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited", "longName": "0000005 - Statement - Condensed Consolidated Balance Sheet (Unaudited)", "shortName": "Condensed Consolidated Balance Sheet (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical", "longName": "0000006 - Statement - Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "longName": "0000007 - Statement - Condensed Consolidated Statement of Shareholders' Investment (Unaudited)", "shortName": "Condensed Consolidated Statement of Shareholders' Investment (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "unique": true } }, "R8": { "role": "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical", "longName": "0000008 - Statement - Condensed Consolidated Statement of Shareholders' Investment (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Statement of Shareholders' Investment (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:TreasuryStockCommonShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "unique": true } }, "R9": { "role": "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited", "longName": "0000009 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statement of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "unique": true } }, "R10": { "role": "http://www.abbott.com/role/BasisofPresentation", "longName": "0000010 - Disclosure - Basis of Presentation", "shortName": "Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.abbott.com/role/NewAccountingStandards", "longName": "0000011 - Disclosure - New Accounting Standards", "shortName": "New Accounting Standards", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.abbott.com/role/Revenue", "longName": "0000012 - Disclosure - Revenue", "shortName": "Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.abbott.com/role/SupplementalFinancialInformation", "longName": "0000013 - Disclosure - Supplemental Financial Information", "shortName": "Supplemental Financial Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLoss", "longName": "0000014 - Disclosure - Changes In Accumulated Other Comprehensive Income (Loss)", "shortName": "Changes In Accumulated Other Comprehensive Income (Loss)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.abbott.com/role/BusinessAcquisitions", "longName": "0000015 - Disclosure - Business Acquisitions", "shortName": "Business Acquisitions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.abbott.com/role/GoodwillandIntangibleAssets", "longName": "0000016 - Disclosure - Goodwill and Intangible Assets", "shortName": "Goodwill and Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.abbott.com/role/RestructuringPlans", "longName": "0000017 - Disclosure - Restructuring Plans", "shortName": "Restructuring Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.abbott.com/role/IncentiveStockPrograms", "longName": "0000018 - Disclosure - Incentive Stock Programs", "shortName": "Incentive Stock Programs", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.abbott.com/role/DebtandLinesofCredit", "longName": "0000019 - Disclosure - Debt and Lines of Credit", "shortName": "Debt and Lines of Credit", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasures", "longName": "0000020 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures", "shortName": "Financial Instruments, Derivatives and Fair Value Measures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.abbott.com/role/LitigationandEnvironmentalMatters", "longName": "0000021 - Disclosure - Litigation and Environmental Matters", "shortName": "Litigation and Environmental Matters", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.abbott.com/role/PostEmploymentBenefits", "longName": "0000022 - Disclosure - Post-Employment Benefits", "shortName": "Post-Employment Benefits", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.abbott.com/role/TaxesonEarnings", "longName": "0000023 - Disclosure - Taxes on Earnings", "shortName": "Taxes on Earnings", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.abbott.com/role/SegmentInformation", "longName": "0000024 - Disclosure - Segment Information", "shortName": "Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.abbott.com/role/NewAccountingStandardsPolicies", "longName": "9954471 - Disclosure - New Accounting Standards (Policies)", "shortName": "New Accounting Standards (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.abbott.com/role/RevenueTables", "longName": "9954472 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.abbott.com/role/SupplementalFinancialInformationTables", "longName": "9954473 - Disclosure - Supplemental Financial Information (Tables)", "shortName": "Supplemental Financial Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossTables", "longName": "9954474 - Disclosure - Changes In Accumulated Other Comprehensive Income (Loss) (Tables)", "shortName": "Changes In Accumulated Other Comprehensive Income (Loss) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.abbott.com/role/RestructuringPlansTables", "longName": "9954475 - Disclosure - Restructuring Plans (Tables)", "shortName": "Restructuring Plans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.abbott.com/role/IncentiveStockProgramsTables", "longName": "9954476 - Disclosure - Incentive Stock Programs (Tables)", "shortName": "Incentive Stock Programs (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables", "longName": "9954477 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Tables)", "shortName": "Financial Instruments, Derivatives and Fair Value Measures (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.abbott.com/role/PostEmploymentBenefitsTables", "longName": "9954478 - Disclosure - Post-Employment Benefits (Tables)", "shortName": "Post-Employment Benefits (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.abbott.com/role/SegmentInformationTables", "longName": "9954479 - Disclosure - Segment Information (Tables)", "shortName": "Segment Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.abbott.com/role/RevenueNarrativeDetails", "longName": "9954480 - Disclosure - Revenue - Narrative (Details)", "shortName": "Revenue - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:NumberOfReportableSegments", "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:NumberOfReportableSegments", "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "longName": "9954481 - Disclosure - Revenue - Summary of Revenue by Sales Category (Details)", "shortName": "Revenue - Summary of Revenue by Sales Category (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-159", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "unique": true } }, "R36": { "role": "http://www.abbott.com/role/RevenueScheduleofChangesinContractLiabilitiesDetails", "longName": "9954482 - Disclosure - Revenue - Schedule of Changes in Contract Liabilities (Details)", "shortName": "Revenue - Schedule of Changes in Contract Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails", "longName": "9954483 - Disclosure - Supplemental Financial Information - Narrative (Details)", "shortName": "Supplemental Financial Information - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.abbott.com/role/SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails", "longName": "9954484 - Disclosure - Supplemental Financial Information - Allowance for Doubtful Accounts (Details)", "shortName": "Supplemental Financial Information - Allowance for Doubtful Accounts (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.abbott.com/role/SupplementalFinancialInformationLongTermInvestmentsDetails", "longName": "9954485 - Disclosure - Supplemental Financial Information - Long-Term Investments (Details)", "shortName": "Supplemental Financial Information - Long-Term Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LongTermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-175", "name": "us-gaap:LongTermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "abt:ScheduleOfLongTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "unique": true } }, "R40": { "role": "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails", "longName": "9954486 - Disclosure - Changes In Accumulated Other Comprehensive Income (Loss) (Details)", "shortName": "Changes In Accumulated Other Comprehensive Income (Loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-178", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "unique": true } }, "R41": { "role": "http://www.abbott.com/role/BusinessAcquisitionsDetails", "longName": "9954487 - Disclosure - Business Acquisitions (Details)", "shortName": "Business Acquisitions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-196", "name": "us-gaap:BusinessAcquisitionSharePrice", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "unique": true } }, "R42": { "role": "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails", "longName": "9954488 - Disclosure - Goodwill and Intangible Assets (Details)", "shortName": "Goodwill and Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "unique": true } }, "R43": { "role": "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "longName": "9954489 - Disclosure - Restructuring Plans - Narrative (Details)", "shortName": "Restructuring Plans - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-200", "name": "us-gaap:SeveranceCosts1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-200", "name": "us-gaap:SeveranceCosts1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.abbott.com/role/RestructuringPlansRestructuringActivityDetails", "longName": "9954490 - Disclosure - Restructuring Plans - Restructuring Activity (Details)", "shortName": "Restructuring Plans - Restructuring Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-205", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-205", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails", "longName": "9954491 - Disclosure - Incentive Stock Programs - Narrative (Details)", "shortName": "Incentive Stock Programs - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails", "longName": "9954492 - Disclosure - Incentive Stock Programs - Options (Details)", "shortName": "Incentive Stock Programs - Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-211", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-211", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.abbott.com/role/DebtandLinesofCreditDetails", "longName": "9954493 - Disclosure - Debt and Lines of Credit (Details)", "shortName": "Debt and Lines of Credit (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-213", "name": "us-gaap:DebtInstrumentTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-213", "name": "us-gaap:DebtInstrumentTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails", "longName": "9954494 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Narrative (Details)", "shortName": "Financial Instruments, Derivatives and Fair Value Measures - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "unique": true } }, "R49": { "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "longName": "9954495 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Amounts and Location of Derivative Instruments (Details)", "shortName": "Financial Instruments, Derivatives and Fair Value Measures - Amounts and Location of Derivative Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-227", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "unique": true } }, "R50": { "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails", "longName": "9954496 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Schedule of Derivatives Gain (Loss) in OCI and Income (Expense) (Details)", "shortName": "Financial Instruments, Derivatives and Fair Value Measures - Schedule of Derivatives Gain (Loss) in OCI and Income (Expense) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-245", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-245", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "longName": "9954497 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details)", "shortName": "Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LongTermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-259", "name": "us-gaap:LongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "unique": true } }, "R52": { "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails", "longName": "9954498 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details)", "shortName": "Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-272", "name": "us-gaap:EquitySecuritiesFvNi", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-272", "name": "us-gaap:EquitySecuritiesFvNi", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails", "longName": "9954499 - Disclosure - Litigation and Environmental Matters (Details)", "shortName": "Litigation and Environmental Matters (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-4", "name": "abt:LossContingencyRangeOfPossibleLossMaximumIndividualSite", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "abt:LossContingencyRangeOfPossibleLossMaximumIndividualSite", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicCostDetails", "longName": "9954500 - Disclosure - Post-Employment Benefits - Schedule of Net Periodic Cost (Details)", "shortName": "Post-Employment Benefits - Schedule of Net Periodic Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-171", "name": "us-gaap:DefinedBenefitPlanServiceCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-171", "name": "us-gaap:DefinedBenefitPlanServiceCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails", "longName": "9954501 - Disclosure - Post-Employment Benefits - Narrative (Details)", "shortName": "Post-Employment Benefits - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-171", "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-283", "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "unique": true } }, "R56": { "role": "http://www.abbott.com/role/TaxesonEarningsDetails", "longName": "9954502 - Disclosure - Taxes on Earnings (Details)", "shortName": "Taxes on Earnings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-1", "name": "abt:ExcessTaxExpenseBenefitFromShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "abt:ExcessTaxExpenseBenefitFromShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.abbott.com/role/SegmentInformationDetails", "longName": "9954503 - Disclosure - Segment Information (Details)", "shortName": "Segment Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "abt:AnnualShareBasedAwardsRecognizedInFirstQuarterPercent", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240331.htm", "unique": true } } }, "tag": { "abt_A2020FiveYearCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "A2020FiveYearCreditAgreementMember", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2020 Five Year Credit Agreement", "label": "2020 Five Year Credit Agreement [Member]", "documentation": "This member stands for 2020 Five Year Credit Agreement." } } }, "auth_ref": [] }, "abt_A2022And2023RestructuringPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "A2022And2023RestructuringPlanMember", "presentation": [ "http://www.abbott.com/role/RestructuringPlansRestructuringActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022 and 2023 Restructuring Plan", "label": "2022 and 2023 Restructuring Plan [Member]", "documentation": "The entity's 2022 and 2023 restructuring plans to streamline various commercial operations in order to reduce costs and improve efficiencies in the entity's core diagnostics, established pharmaceuticals and nutritionals businesses." } } }, "auth_ref": [] }, "abt_A2024FiveYearCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "A2024FiveYearCreditAgreementMember", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024 Five Year Credit Agreement", "label": "2024 Five Year Credit Agreement [Member]", "documentation": "2024 Five Year Credit Agreement" } } }, "auth_ref": [] }, "abt_A2024RestructuringPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "A2024RestructuringPlanMember", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024 Restructuring Plan", "label": "2024 Restructuring Plan [Member]", "documentation": "2024 Restructuring Plan" } } }, "auth_ref": [] }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AOCIAttributableToParentNetOfTaxRollForward", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in accumulated other comprehensive income (loss), net of income taxes", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableTradeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableTradeCurrent", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Trade accounts payable", "label": "Accounts Payable, Trade, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r35", "r36" ] }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Allowance for Doubtful Accounts Activity", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r846" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Trade receivables, less allowances of $439 in 2024 and $444 in 2023", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r297", "r298" ] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Income taxes payable", "label": "Accrued Income Taxes, Current", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": [ "r118", "r161" ] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Actuarial (Losses) and Prior Service (Costs) and Credits", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": [ "r7", "r21", "r46", "r831", "r832", "r833" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Less: accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r62", "r190", "r617" ] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges and Other", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r207", "r215", "r216", "r537", "r775", "r831" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Net actuarial (losses) and prior service (costs) and credits", "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax", "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit)." } } }, "auth_ref": [ "r8", "r46", "r860" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative foreign currency translation (loss) adjustments", "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax", "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses." } } }, "auth_ref": [ "r202", "r204", "r206", "r207", "r571" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r214", "r215", "r581", "r582", "r583", "r584", "r585", "r586" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 }, "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Accumulated Other Comprehensive Income (Loss)", "terseLabel": "Accumulated other comprehensive income (loss)", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r45", "r46", "r127", "r197", "r613", "r647", "r650" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r214", "r215", "r581", "r582", "r583", "r584", "r585", "r586" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r5", "r21", "r46", "r548", "r551", "r591", "r643", "r644", "r831", "r832", "r833", "r839", "r840", "r841" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative Foreign Currency Translation (Loss) Adjustments", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r6", "r21", "r46", "r215", "r216", "r582", "r583", "r584", "r585", "r586", "r831" ] }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalFinancialInformationDisclosureTextBlock", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Financial Information", "label": "Additional Financial Information Disclosure [Text Block]", "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net earnings to net cash from operating activities \u2014", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "abt_AdultNutritionalsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "AdultNutritionalsMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adult Nutritionals", "label": "Adult Nutritionals [Member]", "documentation": "It represents the adult nutritionals, segment of the entity." } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "calculation": { "http://www.abbott.com/role/SegmentInformationDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Share-based compensation", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r504", "r512" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r198", "r299", "r307", "r308", "r311", "r878" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables, allowances", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r198", "r299", "r307" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Amounts charged off and other adjustments", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance." } } }, "auth_ref": [ "r310" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 }, "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 }, "http://www.abbott.com/role/SegmentInformationDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited", "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets", "verboseLabel": "Amortization of intangible assets", "negatedLabel": "Amortization of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r15", "r57", "r59" ] }, "abt_AnnualShareBasedAwardsRecognizedInFirstQuarterPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "AnnualShareBasedAwardsRecognizedInFirstQuarterPercent", "presentation": [ "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual share-based awards recognized in first quarter (as a percent)", "label": "Annual Share Based Awards Recognized in First Quarter Percent", "documentation": "Percentage of the annual cost of share-based awards which will typically be recognized in the first quarter." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Common Stock Options Having No Dilutive Effect (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r260" ] }, "us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AociLossCashFlowHedgeCumulativeGainLossAfterTax", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Cumulative gains (losses) on derivative instruments designated as cash flow hedges", "label": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax", "documentation": "Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r204" ] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetImpairmentCharges", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset impairment charges", "label": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r15", "r60" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total Assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r159", "r193", "r226", "r267", "r282", "r288", "r302", "r348", "r349", "r351", "r352", "r353", "r355", "r357", "r359", "r360", "r535", "r538", "r573", "r609", "r695", "r800", "r818", "r855", "r856", "r868" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current Assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r185", "r200", "r226", "r302", "r348", "r349", "r351", "r352", "r353", "r355", "r357", "r359", "r360", "r535", "r538", "r573", "r800", "r855", "r856", "r868" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current Assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total Assets", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r106" ] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets, at Fair Value", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails", "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r93", "r98" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails", "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r531", "r792", "r795" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails", "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r77", "r78", "r531", "r792", "r795" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r531" ] }, "us-gaap_BusinessAcquisitionSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionSharePrice", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition share price (in dollars per share)", "label": "Business Acquisition, Share Price", "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition purchase price", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r1", "r2", "r18" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of remaining contingent consideration", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r534", "r836" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum amount of contingent consideration", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid." } } }, "auth_ref": [ "r82" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "calculation": { "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Contingent consideration related to business combinations", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r3", "r81", "r533" ] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitions" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisitions", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r155", "r532" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other net assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other", "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r80" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net deferred tax assets", "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets", "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date." } } }, "auth_ref": [ "r80" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "In-process research and development", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets", "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date." } } }, "auth_ref": [ "r80" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Developed technology intangible assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": [ "r79", "r80" ] }, "abt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNumberOfFiniteLivedIntangibles": { "xbrltype": "integerItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNumberOfFiniteLivedIntangibles", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of developed technology intangible assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Number of Finite-Lived Intangibles", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Number of Finite-Lived Intangibles" } } }, "auth_ref": [] }, "abt_COVID19TestingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "COVID19TestingMember", "presentation": [ "http://www.abbott.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "COVID-19 Testing", "label": "COVID-19 Testing [Member]", "documentation": "COVID-19 Testing" } } }, "auth_ref": [] }, "abt_CardiovascularSystemsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "CardiovascularSystemsIncMember", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CSI", "label": "Cardiovascular Systems, Inc. [Member]", "documentation": "Cardiovascular Systems, Inc." } } }, "auth_ref": [] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying Value", "label": "Reported Value Measurement [Member]", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": [ "r107", "r108" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r49", "r187", "r768" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and Cash Equivalents, Beginning of Year", "periodEndLabel": "Cash and Cash Equivalents, End of Period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r49", "r136", "r224" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net Increase (Decrease) in Cash and Cash Equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r4", "r136" ] }, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowHedgingMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow Hedging", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": [ "r90" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r41", "r113", "r610", "r682" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMatters" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation and Environmental Matters", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r146", "r339", "r340", "r753", "r850" ] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Cash dividends declared on common shares (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r150" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common Shares", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r803", "r804", "r805", "r807", "r808", "r809", "r812", "r839", "r840", "r863", "r880", "r882" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares, authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r120", "r683" ] }, "us-gaap_CommonStockSharesHeldInEmployeeTrust": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesHeldInEmployeeTrust", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments in mutual funds held in a rabbi trust", "label": "Common Stock, Shares Held in Employee Trust", "documentation": "Value of common stock issued to a trust (for example, but not limited to, rabbi trust) set up specifically to accumulate stock for the sole purpose of distribution to participating employees." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares, issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r120" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r22", "r120", "r683", "r701", "r882", "r883" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Common shares, without par value Authorized \u2014 2,400,000,000 shares Issued at stated capital amount \u2014 Shares: 2024: 1,989,789,999; 2023: 1,987,883,852", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r120", "r612", "r800" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive Income", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r47", "r211", "r213", "r219", "r605", "r622" ] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Changes In Accumulated Other Comprehensive Income (Loss)", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": [ "r126", "r218", "r604", "r621" ] }, "srt_CondensedCashFlowStatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CondensedCashFlowStatementTable", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Condensed Cash Flow Statement [Table]", "label": "Condensed Cash Flow Statement [Table]" } } }, "auth_ref": [ "r228", "r826" ] }, "srt_CondensedCashFlowStatementsCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CondensedCashFlowStatementsCaptionsLineItems", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Condensed Cash Flow Statements, Captions [Line Items]", "label": "Condensed Cash Flow Statements, Captions [Line Items]" } } }, "auth_ref": [ "r228", "r826" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r228", "r269", "r280", "r281", "r282", "r283", "r284", "r286", "r290", "r348", "r349", "r350", "r351", "r353", "r354", "r356", "r358", "r359", "r855", "r856" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]" } } }, "auth_ref": [ "r228", "r269", "r280", "r281", "r282", "r283", "r284", "r286", "r290", "r348", "r349", "r350", "r351", "r353", "r354", "r356", "r358", "r359", "r855", "r856" ] }, "abt_ContractLiabilitiesRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "ContractLiabilitiesRollForward", "presentation": [ "http://www.abbott.com/role/RevenueScheduleofChangesinContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract Liabilities:", "label": "Contract Liabilities [Roll Forward]", "documentation": "Contract Liabilities" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [ "http://www.abbott.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Contract Liabilities", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [ "r858" ] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/RevenueScheduleofChangesinContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r391", "r392", "r403" ] }, "abt_ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/RevenueScheduleofChangesinContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unearned revenue from cash received during the period", "label": "Contract With Customer Liability, Change In Unearned Revenue From Cash Received Recognized", "documentation": "Amount of revenue recognized arising from contract liability from change in cash received to be satisfied." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/RevenueScheduleofChangesinContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Revenue recognized related to contract liability balance", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r404" ] }, "abt_CoreLaboratoryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "CoreLaboratoryMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Core Laboratory", "label": "Core Laboratory [Member]", "documentation": "It represents the core laboratory, segment of the entity." } } }, "auth_ref": [] }, "abt_CorporateAndBenefitPlanCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "CorporateAndBenefitPlanCosts", "crdr": "debit", "calculation": { "http://www.abbott.com/role/SegmentInformationDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Corporate functions and benefit plan costs", "label": "Corporate and Benefit Plan Costs", "documentation": "The reconciling item from aggregate segment operating income or loss to consolidated earnings or loss before income tax expense or benefit, related to corporate functions and benefit plan costs." } } }, "auth_ref": [] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateNonSegmentMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Corporate, Non-Segment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": [ "r29", "r281", "r282", "r283", "r284", "r290", "r843" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of products sold, excluding amortization of intangible assets", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r131", "r598" ] }, "abt_CostOfGoodsAndServicesSoldMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "CostOfGoodsAndServicesSoldMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails", "http://www.abbott.com/role/RestructuringPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of products sold", "label": "Cost of Goods and Services Sold [Member]", "documentation": "Cost of Goods and Services Sold" } } }, "auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating cost and expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r130" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCredit" ], "lang": { "en-us": { "role": { "terseLabel": "Debt and Lines of Credit", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r147", "r225", "r361", "r367", "r368", "r369", "r370", "r371", "r372", "r377", "r384", "r385", "r387" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r34", "r117", "r118", "r160", "r162", "r228", "r362", "r363", "r364", "r365", "r366", "r368", "r373", "r374", "r375", "r376", "r378", "r379", "r380", "r381", "r382", "r383", "r588", "r780", "r781", "r782", "r783", "r784", "r837" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r228", "r362", "r363", "r364", "r365", "r366", "r368", "r373", "r374", "r375", "r376", "r378", "r379", "r380", "r381", "r382", "r383", "r386", "r588", "r780", "r781", "r782", "r783", "r784", "r837" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r40", "r228", "r362", "r363", "r364", "r365", "r366", "r368", "r373", "r374", "r375", "r376", "r378", "r379", "r380", "r381", "r382", "r383", "r588", "r780", "r781", "r782", "r783", "r784", "r837" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r40", "r65", "r66", "r109", "r110", "r112", "r114", "r148", "r149", "r228", "r362", "r363", "r364", "r365", "r366", "r368", "r373", "r374", "r375", "r376", "r378", "r379", "r380", "r381", "r382", "r383", "r386", "r588", "r780", "r781", "r782", "r783", "r784", "r837" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, term", "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt", "label": "Debt [Member]", "documentation": "Contractual obligation to pay money on demand or on fixed or determinable dates." } } }, "auth_ref": [] }, "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/TaxesonEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease reasonably possible in gross unrecognized tax benefits", "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible", "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit." } } }, "auth_ref": [ "r76" ] }, "us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxesAndOtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes and other assets", "label": "Deferred Income Taxes and Other Assets, Noncurrent", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer." } } }, "auth_ref": [] }, "abt_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "DeferredIncomeTaxesAndOtherAssetsNoncurrentMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes and other assets", "label": "Deferred Income Taxes and Other Assets, Noncurrent [Member]", "documentation": "The Deferred Income Taxes and Other Assets line item in the statement of financial position in which the amounts are included." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "crdr": "credit", "calculation": { "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicCostDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Actuarial loss, net", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan." } } }, "auth_ref": [ "r409", "r446", "r462", "r790", "r791" ] }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "crdr": "debit", "calculation": { "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicCostDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Prior service cost (credit)", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan." } } }, "auth_ref": [ "r409", "r447", "r463", "r790", "r791" ] }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanContributionsByEmployer", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails", "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Pension contributions", "terseLabel": "Company contributions", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets." } } }, "auth_ref": [ "r424", "r433", "r466", "r788", "r789", "r790", "r791" ] }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanDisclosureLineItems", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails", "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan Disclosure [Line Items]", "label": "Defined Benefit Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "crdr": "credit", "calculation": { "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicCostDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Expected return on plan assets", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan." } } }, "auth_ref": [ "r409", "r445", "r461", "r790", "r791" ] }, "us-gaap_DefinedBenefitPlanInterestCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanInterestCost", "crdr": "debit", "calculation": { "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest cost on projected benefit obligations", "label": "Defined Benefit Plan, Interest Cost", "documentation": "Amount of cost recognized for passage of time related to defined benefit plan." } } }, "auth_ref": [ "r409", "r413", "r444", "r460", "r790", "r791" ] }, "abt_DefinedBenefitPlanNetAmortizationCostsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "DefinedBenefitPlanNetAmortizationCostsAbstract", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net amortization of:", "label": "Defined Benefit Plan Net Amortization Costs [Abstract]", "documentation": "No definition available." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "crdr": "debit", "calculation": { "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicCostDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicCostDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net cost (credit)", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan." } } }, "auth_ref": [ "r442", "r458", "r790", "r791" ] }, "us-gaap_DefinedBenefitPlanServiceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanServiceCost", "crdr": "debit", "calculation": { "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service cost - benefits earned during the period", "label": "Defined Benefit Plan, Service Cost", "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": [ "r411", "r443", "r459", "r790", "r791" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r15", "r61" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r670", "r673", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r696", "r697", "r698", "r699", "r711", "r712", "r713", "r714", "r717", "r718", "r719", "r720", "r737", "r738", "r741", "r742", "r803", "r805" ] }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeAsset", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value - Assets", "verboseLabel": "Receivable position", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement." } } }, "auth_ref": [ "r31", "r96", "r125", "r201", "r774" ] }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Yen-denominated term loan", "terseLabel": "Fair Value - Liabilities", "negatedTerseLabel": "(Payable) position", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": [ "r31", "r96", "r125", "r201", "r774" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r94", "r97", "r99", "r101", "r670", "r673", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r696", "r697", "r698", "r699", "r711", "r712", "r713", "r714", "r717", "r718", "r719", "r720", "r737", "r738", "r741", "r742", "r774", "r803", "r805" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasures" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments, Derivatives and Fair Value Measures", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r158", "r545", "r554" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r23", "r94", "r99" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Table]", "label": "Derivative Instruments, Gain (Loss) [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r23", "r94", "r99", "r101", "r104", "r105", "r543" ] }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r543" ] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLineItems", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r554" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, notional amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r861", "r862" ] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeTable", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": [ "r23", "r86", "r87", "r88", "r92", "r95", "r99", "r102", "r103", "r105", "r554" ] }, "us-gaap_DerivativesFairValueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesFairValueLineItems", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives, Fair Value [Line Items]", "label": "Derivatives, Fair Value [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Designated as Hedging Instrument", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r23" ] }, "abt_DiabetesCareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "DiabetesCareMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diabetes Care", "label": "Diabetes Care [Member]", "documentation": "It represents the Diabetes Care, segment of the entity." } } }, "auth_ref": [] }, "abt_DiagnosticProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "DiagnosticProductsMember", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails", "http://www.abbott.com/role/RevenueNarrativeDetails", "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diagnostics", "verboseLabel": "Diagnostic Products", "label": "Diagnostic Products [Member]", "documentation": "The diagnostics products segment of the entity." } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.abbott.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Revenue by Sales Category", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r859" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.abbott.com/role/IncentiveStockPrograms" ], "lang": { "en-us": { "role": { "terseLabel": "Incentive Stock Programs", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r473", "r477", "r505", "r506", "r508", "r799" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisclosureTextBlockSupplementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureTextBlockSupplementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure Text Block Supplement [Abstract]", "label": "Disclosure Text Block Supplement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DividendsCommonStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsCommonStockCash", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash dividends declared on common shares", "label": "Dividends, Common Stock, Cash", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash." } } }, "auth_ref": [ "r150" ] }, "us-gaap_DividendsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsPayableCurrent", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends payable", "label": "Dividends Payable, Current", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r38" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document and Entity Information", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r822" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r823" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Basic Earnings Per Common Share (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r220", "r238", "r239", "r240", "r241", "r242", "r248", "r251", "r257", "r258", "r259", "r261", "r557", "r558", "r606", "r623", "r776" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted Earnings Per Common Share (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r220", "r238", "r239", "r240", "r241", "r242", "r251", "r257", "r258", "r259", "r261", "r557", "r558", "r606", "r623", "r776" ] }, "abt_EffectOfCommonAndTreasuryShareTransactions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "EffectOfCommonAndTreasuryShareTransactions", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Effect of common and treasury share transactions", "label": "Effect of Common and Treasury Share Transactions", "documentation": "This element represents the effect on retained earning due to common and treasury stock transactions." } } }, "auth_ref": [] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash and cash equivalents", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r865" ] }, "abt_ElectrophysiologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "ElectrophysiologyMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Electrophysiology", "label": "Electrophysiology [Member]", "documentation": "It represents the electrophysiology, segment of the entity." } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Salaries, wages and commissions", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r38" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total unrecognized compensation cost", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r507" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total unrecognized compensation cost, expected period for recognition", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r507" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails", "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r820" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r820" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r820" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r824" ] }, "dei_EntityListingsExchangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityListingsExchangeAxis", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Listings, Exchange [Axis]", "label": "Entity Listings, Exchange [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r820" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r820" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r820" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r820" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r22", "r180", "r214", "r215", "r216", "r229", "r230", "r231", "r235", "r243", "r245", "r262", "r303", "r306", "r390", "r509", "r510", "r511", "r521", "r522", "r547", "r548", "r549", "r550", "r551", "r553", "r556", "r581", "r582", "r583", "r584", "r585", "r586", "r591", "r643", "r644", "r645", "r658", "r724" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestments", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method investments carrying value", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r277", "r301", "r829", "r844" ] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "calculation": { "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity securities", "label": "Equity Securities, FV-NI, Current", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": [ "r194", "r569", "r770" ] }, "us-gaap_EquitySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/SupplementalFinancialInformationLongTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity securities", "label": "Equity Securities [Member]", "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants." } } }, "auth_ref": [ "r54", "r813", "r814", "r815", "r885" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity investments without readily determinable fair value", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "documentation": "Amount of investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r300" ] }, "abt_EstablishedPharmaceuticalProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "EstablishedPharmaceuticalProductsMember", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails", "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Established Pharmaceutical Products", "label": "Established Pharmaceutical Products [Member]", "documentation": "Represents Established Pharmaceutical Products, segment of the entity." } } }, "auth_ref": [] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": [ "r375", "r572", "r781", "r782" ] }, "abt_ExcessTaxExpenseBenefitFromShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "ExcessTaxExpenseBenefitFromShareBasedCompensation", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/TaxesonEarningsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Excess tax benefits associated with share-based compensation", "label": "Excess Tax Expense (Benefit) from Share-based Compensation", "documentation": "Amount of tax benefits related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes." } } }, "auth_ref": [] }, "dei_ExchangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ExchangeDomain", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange [Domain]", "label": "Exchange [Domain]", "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r563", "r564", "r567" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r563", "r564", "r567" ] }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByBalanceSheetGroupingTextBlock", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Carrying Values and Fair Values of Financial Instruments", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r106", "r107" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r375", "r433", "r434", "r435", "r436", "r437", "r438", "r564", "r593", "r594", "r595", "r781", "r782", "r788", "r789", "r790" ] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementBasisAxis", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Basis [Axis]", "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": [ "r32", "r106", "r375", "r781", "r782" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r563", "r564", "r565", "r566", "r568" ] }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosureItemAmountsDomain", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement [Domain]", "label": "Fair Value Measurement [Domain]", "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value." } } }, "auth_ref": [ "r375", "r781", "r782" ] }, "us-gaap_FairValueHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueHedgingMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hedging", "label": "Fair Value Hedging [Member]", "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk." } } }, "auth_ref": [ "r89" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quoted Prices in Active Markets", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r375", "r433", "r438", "r564", "r593", "r788", "r789", "r790" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Other Observable Inputs", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r375", "r433", "r438", "r564", "r594", "r781", "r782", "r788", "r789", "r790" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Unobservable Inputs", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r375", "r433", "r434", "r435", "r436", "r437", "r438", "r564", "r595", "r781", "r782", "r788", "r789", "r790" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r375", "r433", "r434", "r435", "r436", "r437", "r438", "r593", "r594", "r595", "r781", "r782", "r788", "r789", "r790" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Balances", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r562", "r568" ] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated amortization of intangible assets", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r192", "r324" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated annual amortization expense, intangible assets, year one", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r143" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated annual amortization expense, intangible assets, remainder of year", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated annual amortization expense, intangible assets, year four", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r143" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated annual amortization expense, intangible assets, year three", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r143" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated annual amortization expense, intangible assets, year two", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r143" ] }, "us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease in intangible assets due to foreign currency translation adjustments", "label": "Finite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross amount of amortizable intangible assets", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r142", "r602" ] }, "abt_FiveYearTermLoanDue2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "FiveYearTermLoanDue2024Member", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Five Year Term Loan due 2024", "label": "Five Year Term Loan due 2024 [Member]", "documentation": "Represents the term loan." } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyCashFlowHedgeAssetAtFairValue", "crdr": "debit", "calculation": { "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Foreign currency forward exchange contracts", "label": "Foreign Currency Cash Flow Hedge Asset at Fair Value", "documentation": "Fair value as of the balance sheet date of all foreign currency derivative assets designated as cash flow hedging instruments." } } }, "auth_ref": [ "r97" ] }, "us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyCashFlowHedgeLiabilityAtFairValue", "crdr": "credit", "calculation": { "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Foreign currency forward exchange contracts", "label": "Foreign Currency Cash Flow Hedge Liability at Fair Value", "documentation": "Fair value as of the balance sheet date of all foreign currency derivative liabilities designated as cash flow hedging instruments." } } }, "auth_ref": [ "r97" ] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Net foreign exchange (gain) loss", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r577", "r578", "r579", "r580", "r721" ] }, "us-gaap_ForeignExchangeForwardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignExchangeForwardMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Forward Exchange Contracts", "label": "Foreign Exchange Forward [Member]", "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate." } } }, "auth_ref": [ "r689", "r693", "r698", "r713", "r719", "r739", "r740", "r741", "r805" ] }, "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) from foreign currency forward exchange contracts not designated as hedges", "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments", "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments." } } }, "auth_ref": [ "r94", "r100" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionsDetails", "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r191", "r312", "r603", "r779", "r800", "r847", "r848" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r141" ] }, "abt_GoodwillAndIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "GoodwillAndIntangibleAssetsLineItems", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets [Line Items]", "label": "Goodwill and Intangible Assets [Line Items]", "documentation": "Goodwill and Intangible Assets" } } }, "auth_ref": [] }, "abt_GoodwillAndIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "GoodwillAndIntangibleAssetsTable", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets [Table]", "label": "Goodwill and Intangible Assets [Table]", "documentation": "Goodwill and Intangible Assets" } } }, "auth_ref": [] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease in goodwill due to foreign currency translation adjustments", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r320" ] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of reductions of goodwill relating to impairments", "label": "Goodwill, Impairment Loss", "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r15", "r313", "r319", "r323", "r779" ] }, "abt_HeartFailureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "HeartFailureMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Heart Failure", "label": "Heart Failure [Member]", "documentation": "It represents the Heart Failure, segment of the entity." } } }, "auth_ref": [] }, "us-gaap_HedgedLiabilityFairValueHedge": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgedLiabilityFairValueHedge", "crdr": "credit", "calculation": { "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of hedged long-term debt", "label": "Hedged Liability, Fair Value Hedge", "documentation": "Amount of liability hedged in fair value hedging relationship." } } }, "auth_ref": [ "r544" ] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationAxis", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r23", "r543" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationDomain", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r23" ] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingRelationshipDomain", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": [ "r23" ] }, "abt_IRSStatutoryNoticeOfDeficiencyClaimAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "IRSStatutoryNoticeOfDeficiencyClaimAmount", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/TaxesonEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax claim related to statutory notice of deficiency", "label": "IRS Statutory Notice of Deficiency, Claim Amount", "documentation": "IRS Statutory Notice of Deficiency, Claim Amount" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment charge", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value." } } }, "auth_ref": [ "r15", "r28" ] }, "abt_ImpairmentOfVariousInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "ImpairmentOfVariousInvestments", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Various investment impairments", "label": "Impairment Of Various Investments", "documentation": "Impairment Of Various Investments" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.abbott.com/role/SegmentInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited", "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Earnings before taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r128", "r167", "r267", "r281", "r287", "r290", "r607", "r619", "r777" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails", "http://www.abbott.com/role/RestructuringPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r325", "r331", "r707" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails", "http://www.abbott.com/role/RestructuringPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r331", "r707" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.abbott.com/role/TaxesonEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Taxes on Earnings", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r227", "r514", "r517", "r519", "r520", "r526", "r528", "r529", "r530", "r655" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Taxes on earnings", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r171", "r177", "r244", "r245", "r275", "r516", "r527", "r624" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Trade receivables", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r14" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r14" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Other, net", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other." } } }, "auth_ref": [ "r14" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Shareholders' Investment", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Dilutive Common Stock Options (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r252", "r253", "r254", "r259", "r476" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived intangible assets related to in-process R&D acquired in a business combination", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r144" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net of amortization", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r56", "r58" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r111", "r170", "r217", "r271", "r587", "r708", "r816", "r881" ] }, "us-gaap_InterestExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense [Member]", "documentation": "Primary financial statement caption encompassing interest expense." } } }, "auth_ref": [ "r30" ] }, "us-gaap_InterestIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.abbott.com/role/SegmentInformationDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net interest expense", "label": "Interest Income (Expense), Net", "documentation": "The net amount of operating interest income (expense)." } } }, "auth_ref": [ "r169" ] }, "us-gaap_InterestRateDerivativeLiabilitiesAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateDerivativeLiabilitiesAtFairValue", "crdr": "credit", "calculation": { "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate swap derivative financial instruments", "label": "Interest Rate Derivative Liabilities, at Fair Value", "documentation": "Fair value as of the balance sheet date of interest rate derivative liabilities, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as liabilities." } } }, "auth_ref": [] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateSwapMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest Rate Hedge Contracts", "terseLabel": "Interest Rate Swaps", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": [ "r765", "r810", "r811" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Finished products", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r140", "r771" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r199", "r769", "r800" ] }, "us-gaap_InventoryNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNetAbstract", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories:", "label": "Inventory, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r140", "r773" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Work in process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r140", "r772" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest (income)", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r133", "r270" ] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeAxis", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/SupplementalFinancialInformationLongTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Type [Axis]", "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": [ "r661", "r663", "r664", "r667", "r671", "r727", "r729", "r731", "r735", "r736", "r743", "r744", "r746", "r747", "r748", "r749", "r750", "r805" ] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeCategorizationMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/SupplementalFinancialInformationLongTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments [Domain]", "label": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": [ "r661", "r663", "r664", "r667", "r671", "r727", "r729", "r731", "r735", "r736", "r743", "r744", "r746", "r747", "r748", "r749", "r750", "r805" ] }, "abt_KeyEmergingMarketsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "KeyEmergingMarketsMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Key Emerging Markets", "label": "Key Emerging Markets [Member]", "documentation": "It represents the key emerging markets, segment of the entity." } } }, "auth_ref": [] }, "abt_LegalProceedingsAndEnvironmentalExposuresMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "LegalProceedingsAndEnvironmentalExposuresMember", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal proceedings and environmental exposures", "label": "Legal proceedings and environmental exposures [Member]", "documentation": "Loss contingencies related to legal proceedings and environmental exposures." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities and Shareholders' Investment", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r124", "r164", "r616", "r800", "r838", "r845", "r864" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Shareholders\u2019 Investment", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current Liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r39", "r186", "r226", "r302", "r348", "r349", "r351", "r352", "r353", "r355", "r357", "r359", "r360", "r536", "r538", "r539", "r573", "r800", "r855", "r868", "r869" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current Liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r106" ] }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities, at Fair Value", "label": "Liabilities, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r37" ] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditMember", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding borrowings", "negatedTerseLabel": "Total Long-term Debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r34", "r162", "r374", "r388", "r781", "r782", "r877" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of long-term debt", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r195" ] }, "abt_LongTermDebtCurrentMaturitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "LongTermDebtCurrentMaturitiesMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of long-term debt", "label": "Long-Term Debt, Current Maturities [Member]", "documentation": "Long-Term Debt, Current Maturities" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r196" ] }, "us-gaap_LongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermInvestments", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/SupplementalFinancialInformationLongTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments", "netLabel": "Total", "verboseLabel": "Long-term Investment Securities:", "label": "Long-Term Investments", "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)." } } }, "auth_ref": [ "r188" ] }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesByNatureOfContingencyAxis", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency Nature [Axis]", "label": "Loss Contingency Nature [Axis]", "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur." } } }, "auth_ref": [ "r341", "r342", "r343", "r347", "r851", "r852" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r341", "r342", "r343", "r347", "r851", "r852" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesTable", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations." } } }, "auth_ref": [ "r341", "r342", "r343", "r347", "r851", "r852" ] }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recorded accrual balance for legal proceedings and exposures", "label": "Loss Contingency Accrual", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": [ "r341", "r825" ] }, "us-gaap_LossContingencyEstimateOfPossibleLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyEstimateOfPossibleLoss", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimation of possible loss", "label": "Loss Contingency, Estimate of Possible Loss", "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date." } } }, "auth_ref": [ "r342", "r343", "r346", "r347" ] }, "us-gaap_LossContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyNatureDomain", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency, Nature [Domain]", "label": "Loss Contingency, Nature [Domain]", "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability." } } }, "auth_ref": [ "r341", "r342", "r343", "r347", "r851", "r852" ] }, "abt_LossContingencyRangeOfPossibleLossMaximumAggregateSites": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "LossContingencyRangeOfPossibleLossMaximumAggregateSites", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum expected cleanup exposure in aggregate", "label": "Loss Contingency Range of Possible Loss, Maximum Aggregate Sites", "documentation": "The estimated maximum loss, for all sites, from the contingency related to the environmental clean up in the United States and Puerto Rico." } } }, "auth_ref": [] }, "abt_LossContingencyRangeOfPossibleLossMaximumIndividualSite": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "LossContingencyRangeOfPossibleLossMaximumIndividualSite", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum expected cleanup exposure for individual site", "label": "Loss Contingency Range of Possible Loss, Maximum Individual Site", "documentation": "The estimated maximum loss, per individual site, from the contingency related to the environmental clean up in the United States and Puerto Rico." } } }, "auth_ref": [] }, "us-gaap_MaterialReconcilingItemsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MaterialReconcilingItemsMember", "presentation": [ "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reconciling Items", "label": "Segment Reconciling Items [Member]", "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity." } } }, "auth_ref": [ "r53" ] }, "us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MaximumLengthOfTimeHedgedInCashFlowHedge1", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum length of time over which accumulated gains and losses will be recognized in Cost of products sold", "label": "Maximum Length of Time Hedged in Cash Flow Hedge", "documentation": "Maximum length of time over which the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r19" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r342", "r343", "r344", "r345", "r471", "r597", "r642", "r672", "r673", "r728", "r730", "r732", "r733", "r745", "r763", "r764", "r778", "r785", "r798", "r802", "r857", "r870", "r871", "r872", "r873", "r874", "r875" ] }, "abt_MedicalDevicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "MedicalDevicesMember", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails", "http://www.abbott.com/role/RevenueNarrativeDetails", "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medical Devices", "label": "Medical Devices [Member]", "documentation": "The medical devices segment of the entity." } } }, "auth_ref": [] }, "abt_MinimumLengthOfTimeHedgedInCashFlowHedge": { "xbrltype": "durationItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "MinimumLengthOfTimeHedgedInCashFlowHedge", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum length of time over which accumulated gains and losses will be recognized in Cost of products sold", "label": "Minimum Length Of Time Hedged In Cash Flow Hedge", "documentation": "Minimum length of time over which the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r342", "r343", "r344", "r345", "r471", "r597", "r642", "r672", "r673", "r728", "r730", "r732", "r733", "r745", "r763", "r764", "r778", "r785", "r798", "r802", "r857", "r870", "r871", "r872", "r873", "r874", "r875" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Noncontrolling Interests in Subsidiaries", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r44", "r163", "r226", "r302", "r348", "r351", "r352", "r353", "r359", "r360", "r573", "r615", "r685" ] }, "abt_MolecularMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "MolecularMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Molecular", "label": "Molecular [Member]", "documentation": "It represents the molecular, segment of the entity." } } }, "auth_ref": [] }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MovementInValuationAllowancesAndReservesRollForward", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for Doubtful Accounts:", "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash From (Used in) Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r223" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow From (Used in) Financing Activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash From (Used in) Investing Activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r223" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow From (Used in) Investing Activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash From Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r136", "r137", "r138" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow From (Used in) Operating Activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 }, "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net Earnings", "verboseLabel": "Net Earnings", "terseLabel": "Net earnings", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r129", "r138", "r168", "r184", "r209", "r212", "r216", "r226", "r234", "r238", "r239", "r240", "r241", "r244", "r245", "r255", "r267", "r281", "r287", "r290", "r302", "r348", "r349", "r351", "r352", "r353", "r355", "r357", "r359", "r360", "r558", "r573", "r620", "r703", "r722", "r723", "r777", "r816", "r855" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net earnings allocated to common shares", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r222", "r238", "r239", "r240", "r241", "r248", "r249", "r256", "r259", "r267", "r281", "r287", "r290", "r777" ] }, "us-gaap_NetInvestmentHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetInvestmentHedgingMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Investment Hedging", "label": "Net Investment Hedging [Member]", "documentation": "Hedges of a net investment in a foreign operation." } } }, "auth_ref": [ "r91" ] }, "abt_NeuromodulationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "NeuromodulationMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Neuromodulation", "label": "Neuromodulation [Member]", "documentation": "It represents the neuromodulation, segment of the entity." } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Abstract]", "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "presentation": [ "http://www.abbott.com/role/NewAccountingStandards" ], "lang": { "en-us": { "role": { "terseLabel": "New Accounting Standards", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle." } } }, "auth_ref": [ "r175", "r176", "r178", "r182", "r232", "r233", "r236", "r237", "r246", "r247", "r304", "r305", "r523", "r524", "r525", "r552", "r555", "r559", "r560", "r561", "r574", "r575", "r576", "r589", "r590", "r592", "r599", "r600", "r601", "r646", "r647", "r648", "r649", "r650" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.abbott.com/role/NewAccountingStandardsPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Standards Not Yet Adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonUsMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Int\u2019l", "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r884", "r886", "r887", "r888" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interests in Subsidiaries", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r83", "r390", "r839", "r840", "r841", "r882" ] }, "abt_NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interests\u2019 share of income, business combinations, net of distributions and share repurchases", "label": "Noncontrolling Interests Share of Income Net of Distributions and Share Repurchases and Business Combinations", "documentation": "This element represent Noncontrolling Interests' share of income, net of distributions, share repurchases and business combinations." } } }, "auth_ref": [] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NondesignatedMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Not Designated as Hedging Instrument", "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r23" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.abbott.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r842" ] }, "abt_NutritionalProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "NutritionalProductsMember", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails", "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nutritionals", "verboseLabel": "Nutritional Products", "label": "Nutritional Products [Member]", "documentation": "The nutritional products segment of the entity." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://www.abbott.com/role/SegmentInformationDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited", "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Operating earnings", "terseLabel": "Operating Earnings", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r267", "r281", "r287", "r290", "r777" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r280", "r281", "r282", "r283", "r284", "r290" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.abbott.com/role/BasisofPresentation" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r116", "r156", "r651", "r652" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other accrued liabilities", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r38" ] }, "abt_OtherAccruedLiabilitiesCurrentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "OtherAccruedLiabilitiesCurrentMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other accrued liabilities", "label": "Other Accrued Liabilities, Current [Member]", "documentation": "Other Accrued Liabilities, Current" } } }, "auth_ref": [] }, "us-gaap_OtherAggregatedInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAggregatedInvestmentsMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Security Investments [Member]", "documentation": "Other investments in debt and equity securities and other forms of securities that provide ownership interests." } } }, "auth_ref": [ "r663", "r664", "r734" ] }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $1 in 2024 and $\u2014 in 2023", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent." } } }, "auth_ref": [ "r8", "r20", "r127", "r157" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation gain (loss) adjustments", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r12", "r20", "r157" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "crdr": "credit", "calculation": { "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss) before reclassifications", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r33", "r46", "r215", "r581", "r583", "r586", "r831" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $30 in 2024 and $(58) in 2023", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r204" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax (benefit)", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax", "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r205" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) recognized in other comprehensive income (loss), foreign currency forward exchange contracts designated as cash flow hedges", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r203", "r204", "r540", "r541", "r546" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income (expense) and gain (loss) reclassified into income, foreign currency forward exchange contracts designated as cash flow hedges", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r174", "r204", "r208" ] }, "abt_OtherComprehensiveIncomeLossFairValueHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "OtherComprehensiveIncomeLossFairValueHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income (expense) and gain (loss) reclassified into income, interest rate swaps designated as fair value hedges", "label": "Other Comprehensive Income (Loss), Fair Value Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Other Comprehensive Income (Loss), Fair Value Hedge, Gain (Loss), Reclassification, before Tax" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresScheduleofDerivativesGainLossinOCIandIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) recognized in other comprehensive income (loss), debt designated as a hedge of net investment in a foreign subsidiary", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge." } } }, "auth_ref": [ "r542" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss)", "verboseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r12", "r20", "r157", "r210", "r213" ] }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax (benefit)", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax", "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan." } } }, "auth_ref": [ "r8", "r9", "r157" ] }, "abt_OtherCostAndExpenseOperatingAndNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "OtherCostAndExpenseOperatingAndNonoperating", "crdr": "debit", "calculation": { "http://www.abbott.com/role/SegmentInformationDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Other, net", "label": "Other Cost and Expense, Operating and Nonoperating", "documentation": "The reconciling item from segment operating income or loss to consolidated earnings or loss before income tax expense or benefit, related to net other income or expenses." } } }, "auth_ref": [] }, "abt_OtherEmergingMarketsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "OtherEmergingMarketsMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Emerging Markets [Member]", "documentation": "Other Emerging Markets" } } }, "auth_ref": [] }, "us-gaap_OtherInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherInvestmentsMember", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationLongTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other", "label": "Other Investments [Member]", "documentation": "Primary financial statement caption encompassing other investments." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Other (income) expense, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r134" ] }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails", "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medical and Dental Plans", "label": "Other Postretirement Benefits Plan [Member]", "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits." } } }, "auth_ref": [ "r408", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r790", "r791", "r792", "r793", "r794" ] }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment for contingent consideration", "label": "Payment for Contingent Consideration Liability, Financing Activities", "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date." } } }, "auth_ref": [ "r11" ] }, "us-gaap_PaymentsForOtherTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForOtherTaxes", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment of cash taxes", "label": "Payments for Other Taxes", "documentation": "Amount of cash outflow for taxes classified as other." } } }, "auth_ref": [ "r13" ] }, "us-gaap_PaymentsForProceedsFromInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForProceedsFromInvestments", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Sales (purchases) of other investment securities, net", "label": "Payments for (Proceeds from) Investments", "documentation": "The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets." } } }, "auth_ref": [] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Other", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": [ "r827", "r834" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of common shares", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r48" ] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "http://www.abbott.com/role/RestructuringPlansRestructuringActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments for restructuring", "negatedTerseLabel": "Payments and other adjustments", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r330", "r835" ] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Dividends paid", "label": "Payments of Ordinary Dividends, Common Stock", "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": [ "r48" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisitions of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r135" ] }, "abt_PediatricNutritionalsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "PediatricNutritionalsMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pediatric Nutritionals", "label": "Pediatric Nutritionals [Member]", "documentation": "It represents the pediatric nutritionals, segment of the entity." } } }, "auth_ref": [] }, "us-gaap_PensionPlansDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PensionPlansDefinedBenefitMember", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails", "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicCostDetails", "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plans", "label": "Pension Plan [Member]", "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits." } } }, "auth_ref": [ "r408", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r472", "r790", "r791", "r795", "r796", "r797" ] }, "abt_PointOfCareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "PointOfCareMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Point of Care", "label": "Point of Care [Member]", "documentation": "It represents the point of care, segment of the entity." } } }, "auth_ref": [] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Portion at Fair Value Measurement", "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": [ "r570" ] }, "abt_PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Post-employment obligations, deferred income taxes and other long-term liabilities", "label": "Post-employment Obligations, Deferred Income Taxes and Other Long-term Liabilities", "documentation": "Amount of Post-employment obligations and amount of deferred tax liability attributable to taxable temporary differences, after deferred tax asset, and other liabilities expected to be paid after one year or operating cycle, if longer." } } }, "auth_ref": [] }, "abt_PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Post-employment obligations, deferred income taxes and other long-term liabilities", "label": "Post-employment Obligations, Deferred Income Taxes and Other Long-term Liabilities [Member]", "documentation": "Post-employment Obligations, Deferred Income Taxes and Other Long-term Liabilities" } } }, "auth_ref": [] }, "us-gaap_PostemploymentBenefitsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PostemploymentBenefitsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Postemployment Benefits [Abstract]", "label": "Postemployment Benefits [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PostemploymentBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PostemploymentBenefitsDisclosureTextBlock", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefits" ], "lang": { "en-us": { "role": { "terseLabel": "Post-Employment Benefits", "label": "Postemployment Benefits Disclosure [Text Block]", "documentation": "The entire disclosure for postemployment benefits, which may include supplemental unemployment benefits, obligations recognized for all types of benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement. Disclosure may also include discussion that an obligation for postemployment benefits is not accrued in accordance with regulation only because the amount cannot be reasonably estimated." } } }, "auth_ref": [ "r406", "r407" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred shares, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r119", "r389" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred shares, authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r119", "r683" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred shares, issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r119", "r389" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Preferred shares, one dollar par value Authorized \u2014 1,000,000 shares, none issued", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r119", "r611", "r800" ] }, "abt_PrepaidExpenseAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "PrepaidExpenseAndOtherReceivables", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Prepaid expenses and other receivables", "label": "Prepaid Expense and Other Receivables", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other receivables that are expected to be realized within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "abt_PrepaidExpenseAndOtherReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "PrepaidExpenseAndOtherReceivablesMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other receivables", "label": "Prepaid Expense and Other Receivables [Member]", "documentation": "The Other Prepaid Expenses and Receivables line item in the statement of financial position in which the amounts are included." } } }, "auth_ref": [] }, "abt_PrepaidExpensesAndOtherReceivablesCurrentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "PrepaidExpensesAndOtherReceivablesCurrentMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresAmountsandLocationofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other receivables, current", "label": "Prepaid Expenses and Other Receivables, Current [Member]", "documentation": "Prepaid Expenses and Other Receivables, Current" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRepaymentsOfShortTermDebt", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Net borrowings (repayments) of short-term debt and other", "label": "Proceeds from (Repayments of) Short-Term Debt", "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from stock options exercised", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r10", "r27" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.abbott.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r292", "r598", "r636", "r637", "r638", "r639", "r640", "r641", "r766", "r786", "r801", "r828", "r853", "r854", "r859", "r879" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.abbott.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r292", "r598", "r636", "r637", "r638", "r639", "r640", "r641", "r766", "r786", "r801", "r828", "r853", "r854", "r859", "r879" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, at cost", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r145", "r189", "r618" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net property and equipment", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r16", "r608", "r618", "r800" ] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions/charges to income", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r221", "r309" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r342", "r343", "r344", "r345", "r431", "r471", "r500", "r501", "r502", "r596", "r597", "r642", "r672", "r673", "r728", "r730", "r732", "r733", "r745", "r763", "r764", "r778", "r785", "r798", "r802", "r805", "r849", "r857", "r871", "r872", "r873", "r874", "r875" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r342", "r343", "r344", "r345", "r431", "r471", "r500", "r501", "r502", "r596", "r597", "r642", "r672", "r673", "r728", "r730", "r732", "r733", "r745", "r763", "r764", "r778", "r785", "r798", "r802", "r805", "r849", "r857", "r871", "r872", "r873", "r874", "r875" ] }, "abt_RapidDiagnosticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "RapidDiagnosticsMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rapid Diagnostics", "label": "Rapid Diagnostics [Member]", "documentation": "It represents the rapid diagnostics, segment of the entity." } } }, "auth_ref": [] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "crdr": "debit", "calculation": { "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Amounts reclassified from accumulated other comprehensive income", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r33", "r46", "r215", "r581", "r585", "r586", "r831" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r115", "r513", "r876" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "abt_RestrictedStockAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "RestrictedStockAwardsMember", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Awards", "label": "Restricted stock awards [Member]", "documentation": "Restricted stock awards." } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units (RSUs)", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Activities [Abstract]", "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://www.abbott.com/role/RestructuringPlans" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plans", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r327", "r328", "r330", "r333", "r338" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "http://www.abbott.com/role/RestructuringPlansRestructuringActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r329", "r330", "r331", "r332", "r335", "r336", "r337" ] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringPlanAxis", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "http://www.abbott.com/role/RestructuringPlansRestructuringActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Axis]", "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringPlanDomain", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "http://www.abbott.com/role/RestructuringPlansRestructuringActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Domain]", "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "http://www.abbott.com/role/RestructuringPlansRestructuringActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining liabilities", "periodStartLabel": "Accrued balance at beginning of the period", "periodEndLabel": "Accrued balance at end of the period", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r330", "r334" ] }, "us-gaap_RestructuringReserveRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserveRollForward", "presentation": [ "http://www.abbott.com/role/RestructuringPlansRestructuringActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Reserve [Roll Forward]", "label": "Restructuring Reserve [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings employed in the business", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r121", "r150", "r614", "r646", "r650", "r654", "r684", "r800" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Employed in the Business", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r180", "r229", "r230", "r231", "r235", "r243", "r245", "r303", "r306", "r509", "r510", "r511", "r521", "r522", "r547", "r549", "r550", "r553", "r556", "r643", "r645", "r658", "r882" ] }, "us-gaap_RetirementPlanTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanTypeAxis", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails", "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicCostDetails", "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Axis]", "label": "Retirement Plan Type [Axis]", "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r408", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r472", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797" ] }, "us-gaap_RetirementPlanTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanTypeDomain", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails", "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicCostDetails", "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Domain]", "label": "Retirement Plan Type [Domain]", "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r408", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r472", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited", "http://www.abbott.com/role/RevenueNarrativeDetails", "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net sales", "netLabel": "Sales", "verboseLabel": "Net Sales to External Customers", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r268", "r269", "r280", "r285", "r286", "r292", "r294", "r296", "r401", "r402", "r598" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.abbott.com/role/Revenue" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r179", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r405" ] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining performance obligations", "label": "Revenue, Remaining Performance Obligation, Amount", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r172" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "presentation": [ "http://www.abbott.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "presentation": [ "http://www.abbott.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected timing of satisfaction period (in months)", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r173" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "presentation": [ "http://www.abbott.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format." } } }, "auth_ref": [ "r173" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "presentation": [ "http://www.abbott.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation." } } }, "auth_ref": [] }, "abt_RevenueRemainingPerformanceObligationExpectedTimingPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "RevenueRemainingPerformanceObligationExpectedTimingPercentage", "presentation": [ "http://www.abbott.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of remaining performance obligation expected to be recognized in period", "label": "Revenue Remaining Performance Obligation Expected Timing Percentage", "documentation": "Represents the percentage of revenue recognized for remaining performance obligations." } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "abt_RhythmManagementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "RhythmManagementMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rhythm Management", "label": "Rhythm Management [Member]", "documentation": "It represents the rhythm management, segment of the entity." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss), Net of Taxes", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r46", "r866", "r867" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.abbott.com/role/BusinessAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r77", "r78", "r531" ] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails", "http://www.abbott.com/role/PostEmploymentBenefitsScheduleofNetPeriodicCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r17", "r69", "r70", "r71", "r72" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Derivatives Gain (Loss) in OCI and Income (Expense)", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r94", "r99", "r543" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Amounts and Location of Derivative Financial Instruments", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": [ "r95" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Bases Used to Measure Assets and Liabilities at Fair Value on a Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r563", "r564" ] }, "abt_ScheduleOfLongTermInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "ScheduleOfLongTermInvestmentsTableTextBlock", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-Term Investments", "label": "Schedule of Long Term Investments [Table Text Block]", "documentation": "Tabular disclosure of the investments which are intended to be held for an extended period of time (longer than one operating cycle)." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Net Periodic Cost", "label": "Schedule of Net Benefit Costs [Table Text Block]", "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments." } } }, "auth_ref": [ "r151" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "http://www.abbott.com/role/RestructuringPlansRestructuringActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Schedule of Restructuring and Related Costs [Table]", "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring." } } }, "auth_ref": [ "r329", "r330", "r331", "r332", "r335", "r336", "r337" ] }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "presentation": [ "http://www.abbott.com/role/RestructuringPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Restructuring Activity", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period." } } }, "auth_ref": [ "r63", "r64" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r50", "r51", "r52", "r55" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.abbott.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Information", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r50", "r51", "r52", "r55" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails", "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r474", "r475", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Options Outstanding and Exercisable", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r25", "r26", "r74" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r819" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r821" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails", "http://www.abbott.com/role/RevenueNarrativeDetails", "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r264", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r290", "r296", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r332", "r337", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r779", "r828", "r879" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r294", "r295", "r662", "r666", "r668", "r729", "r731", "r736", "r746", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r767", "r787", "r805", "r859", "r879" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.abbott.com/role/SegmentInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Information", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r263", "r264", "r265", "r266", "r267", "r279", "r284", "r288", "r289", "r290", "r291", "r292", "r293", "r296" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r132" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expenses", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeveranceCosts1", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Employee related severance and other charges", "label": "Severance Costs", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r15" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r14" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock awards granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r492" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails", "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r474", "r475", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock units granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted", "documentation": "Net number of non-option equity instruments granted to participants." } } }, "auth_ref": [ "r24" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incentive stock program, shares reserved for future grants (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r73" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable, number of shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r483" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable, weighted-average exercise price (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r483" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r485" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding, aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r73" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding, number of shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r481", "r482" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding, weighted-average exercise price (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r481", "r482" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsNarrativeDetails", "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Exercisable, aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r73" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable, weighted-average remaining life", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r73" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramsOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding, weighted-average remaining life", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r152" ] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Short-Term Investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": [ "r165", "r166", "r830" ] }, "abt_StJudeMedicalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "StJudeMedicalMember", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "St. Jude Medical", "label": "St Jude Medical [Member]", "documentation": "Represents information relating to acquisition of St. Jude Medical, Inc." } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails", "http://www.abbott.com/role/RevenueNarrativeDetails", "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r183", "r264", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r290", "r296", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r326", "r332", "r337", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r779", "r828", "r879" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r22", "r42", "r180", "r214", "r215", "r216", "r229", "r230", "r231", "r235", "r243", "r245", "r262", "r303", "r306", "r390", "r509", "r510", "r511", "r521", "r522", "r547", "r548", "r549", "r550", "r551", "r553", "r556", "r581", "r582", "r583", "r584", "r585", "r586", "r591", "r643", "r644", "r645", "r658", "r724" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r294", "r295", "r662", "r666", "r668", "r729", "r731", "r736", "r746", "r752", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r767", "r787", "r805", "r859", "r879" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r229", "r230", "r231", "r262", "r598", "r653", "r659", "r676", "r677", "r678", "r679", "r680", "r681", "r683", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r696", "r697", "r698", "r699", "r700", "r702", "r705", "r706", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r724", "r806" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r229", "r230", "r231", "r262", "r598", "r653", "r659", "r676", "r677", "r678", "r679", "r680", "r681", "r683", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r696", "r697", "r698", "r699", "r700", "r702", "r705", "r706", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r724", "r806" ] }, "abt_StockIssuedDuringPeriodSharesIncentiveStockPrograms": { "xbrltype": "sharesItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "StockIssuedDuringPeriodSharesIncentiveStockPrograms", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Issued under incentive stock programs (in shares)", "label": "Stock Issued During Period, Shares, Incentive Stock Programs", "documentation": "Stock Issued During Period, Shares, Incentive Stock Programs" } } }, "auth_ref": [] }, "abt_StockIssuedDuringPeriodValueIncentiveStockPrograms": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "StockIssuedDuringPeriodValueIncentiveStockPrograms", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issued under incentive stock programs", "label": "Stock Issued During Period, Value, Incentive Stock Programs", "documentation": "Stock Issued During Period, Value, Incentive Stock Programs" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of restricted stock awards", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r22", "r150" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r75", "r119", "r120", "r150" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/ChangesInAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total Abbott Shareholders\u2019 Investment", "periodStartLabel": "Beginning of the period", "periodEndLabel": "End of the period", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r120", "r122", "r123", "r139", "r685", "r701", "r725", "r726", "r800", "r818", "r838", "r845", "r864", "r882" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total Shareholders\u2019 Investment", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r83", "r84", "r85", "r180", "r181", "r215", "r229", "r230", "r231", "r235", "r243", "r303", "r306", "r390", "r509", "r510", "r511", "r521", "r522", "r547", "r548", "r549", "r550", "r551", "r553", "r556", "r581", "r582", "r586", "r591", "r644", "r645", "r657", "r685", "r701", "r725", "r726", "r751", "r817", "r838", "r845", "r864", "r882" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders\u2019 Investment:", "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "abt_StructuralHeartMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "StructuralHeartMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Structural Heart", "label": "Structural Heart [Member]", "documentation": "It represents the structural heart, segment of the entity." } } }, "auth_ref": [] }, "us-gaap_SubsegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsegmentsAxis", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsegments [Axis]", "label": "Subsegments [Axis]", "documentation": "Information by business subsegments." } } }, "auth_ref": [] }, "us-gaap_SubsegmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsegmentsDomain", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsegments [Domain]", "label": "Subsegments [Domain]", "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [] }, "us-gaap_SummaryOfInvestmentHoldingsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SummaryOfInvestmentHoldingsLineItems", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationLongTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Investment Holdings [Line Items]", "label": "Summary of Investment Holdings [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r656", "r660", "r661", "r662", "r663", "r664", "r665", "r667", "r668", "r669", "r670", "r671", "r674", "r675", "r704", "r805" ] }, "us-gaap_SummaryOfInvestmentHoldingsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SummaryOfInvestmentHoldingsTable", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationLongTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Investment Holdings [Table]", "label": "Summary of Investment Holdings [Table]", "documentation": "The summary of investment holding table is used for any listing of investment in a summary form. Table lists the 50 largest investments and any other investment the value of which exceeded 1 percent of net asset value of the registrant as of the close of the period." } } }, "auth_ref": [ "r656", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r674", "r675", "r704", "r805" ] }, "us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxAdjustmentsSettlementsAndUnusualProvisions", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/TaxesonEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax expense from prior year tax positions", "label": "Tax Adjustments, Settlements, and Unusual Provisions", "documentation": "Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement." } } }, "auth_ref": [ "r153", "r154" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common Shares Held in Treasury", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r67" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares held in treasury (in shares)", "periodStartLabel": "Beginning balance, treasury stock, common (in shares)", "periodEndLabel": "Ending balance, treasury stock, common (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r67" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Common shares held in treasury, at cost \u2014 Shares: 2024: 250,155,515; 2023: 253,807,494", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r43", "r67", "r68" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Purchased (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r22", "r120", "r150" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchased", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r22", "r67", "r150" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S.", "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.abbott.com/role/TaxesonEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross unrecognized tax benefits", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r515", "r518" ] }, "abt_VariousBusinessAcquisitionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "VariousBusinessAcquisitionsMember", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Various Business Acquisitions", "label": "Various Business Acquisitions [Member]", "documentation": "Represents the aggregation and reporting of combined amounts of various business acquisitions." } } }, "auth_ref": [] }, "abt_VascularMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abbott.com/20240331", "localname": "VascularMember", "presentation": [ "http://www.abbott.com/role/RevenueSummaryofRevenuebySalesCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vascular", "label": "Vascular [Member]", "documentation": "It represents the vascular products, segment of the entity." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r250", "r259" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r248", "r259" ] }, "exch_XCHI": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/exch/2023", "localname": "XCHI", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "CHICAGO STOCK EXCHANGE, INC", "label": "NYSE CHICAGO, INC. [Member]" } } }, "auth_ref": [] }, "exch_XNYS": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/exch/2023", "localname": "XNYS", "presentation": [ "http://www.abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "NEW YORK STOCK EXCHANGE, INC.", "label": "NEW YORK STOCK EXCHANGE, INC. [Member]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a),(b),(c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i),(j),(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i-k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(f)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "30", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480870/815-30-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(1)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-4" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "320", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a),(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-7" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//220/tableOfContent" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350/tableOfContent" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(h)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482620/740-10-25-10" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482620/740-10-25-8" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//815/tableOfContent" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "SubTopic": "20", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "SubTopic": "20", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//250/tableOfContent" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-6" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//420/tableOfContent" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "712", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//712/tableOfContent" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "712", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481565/712-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3A" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480606/715-80-35-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-9" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4EE", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4EE" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5C" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480627/815-20-45-3" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-5A" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-9" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-18" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r825": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r826": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-11" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 77 0001628280-24-020011-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-24-020011-xbrl.zip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b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

&UL4$L! A0#% @ M8(&B6//.69Y-W0 HRX( !0 ( !"7,! &%B="TR,#(T,#,S M,5]L86(N>&UL4$L! A0#% @ 8(&B6-;[*UOSA R]X% !0 M ( !B% " &%B="TR,#(T,#,S,5]P&UL4$L! A0#% @ 8(&B M6/U1=?!0!P GR0 !( ( !K=4" '$Q,C R-#$P<65X,S$Q M+FAT;5!+ 0(4 Q0 ( &"!HE@TTJ6H6 < )(D 2 " M 2W= @!Q,3(P,C0Q,'%E>#,Q,BYH=&U02P$"% ,4 " !@@:)8&,@7N9($ M &$P $@ @ &UY ( <3$R,#(T,3!Q97@S,C$N:'1M4$L! M A0#% @ 8(&B6#XNQ XML 79 abt-20240331_htm.xml IDEA: XBRL DOCUMENT 0000001800 2024-01-01 2024-03-31 0000001800 exch:XNYS 2024-01-01 2024-03-31 0000001800 exch:XCHI 2024-01-01 2024-03-31 0000001800 2024-03-31 0000001800 2023-01-01 2023-03-31 0000001800 2023-12-31 0000001800 us-gaap:CommonStockMember 2023-12-31 0000001800 us-gaap:CommonStockMember 2022-12-31 0000001800 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000001800 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000001800 us-gaap:CommonStockMember 2024-03-31 0000001800 us-gaap:CommonStockMember 2023-03-31 0000001800 us-gaap:TreasuryStockCommonMember 2023-12-31 0000001800 us-gaap:TreasuryStockCommonMember 2022-12-31 0000001800 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0000001800 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0000001800 us-gaap:TreasuryStockCommonMember 2024-03-31 0000001800 us-gaap:TreasuryStockCommonMember 2023-03-31 0000001800 us-gaap:RetainedEarningsMember 2023-12-31 0000001800 us-gaap:RetainedEarningsMember 2022-12-31 0000001800 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000001800 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000001800 us-gaap:RetainedEarningsMember 2024-03-31 0000001800 us-gaap:RetainedEarningsMember 2023-03-31 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000001800 us-gaap:NoncontrollingInterestMember 2023-12-31 0000001800 us-gaap:NoncontrollingInterestMember 2022-12-31 0000001800 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0000001800 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0000001800 us-gaap:NoncontrollingInterestMember 2024-03-31 0000001800 us-gaap:NoncontrollingInterestMember 2023-03-31 0000001800 2022-12-31 0000001800 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember abt:AdultNutritionalsMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember abt:AdultNutritionalsMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember abt:AdultNutritionalsMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember abt:AdultNutritionalsMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember abt:AdultNutritionalsMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember abt:AdultNutritionalsMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:MolecularMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:MolecularMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:MolecularMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:MolecularMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:MolecularMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:MolecularMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:PointOfCareMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:PointOfCareMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:PointOfCareMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:PointOfCareMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:PointOfCareMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:PointOfCareMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:RhythmManagementMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:RhythmManagementMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:RhythmManagementMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:RhythmManagementMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:RhythmManagementMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:RhythmManagementMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:ElectrophysiologyMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:ElectrophysiologyMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:ElectrophysiologyMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:ElectrophysiologyMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:ElectrophysiologyMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:ElectrophysiologyMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:HeartFailureMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:HeartFailureMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:HeartFailureMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:HeartFailureMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:HeartFailureMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:HeartFailureMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:VascularMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:VascularMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:VascularMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:VascularMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:VascularMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:VascularMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:StructuralHeartMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:StructuralHeartMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:StructuralHeartMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:StructuralHeartMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:StructuralHeartMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:StructuralHeartMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:NeuromodulationMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:NeuromodulationMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:NeuromodulationMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:NeuromodulationMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:NeuromodulationMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:NeuromodulationMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:DiabetesCareMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:DiabetesCareMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:DiabetesCareMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:DiabetesCareMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:DiabetesCareMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:DiabetesCareMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember 2023-01-01 2023-03-31 0000001800 us-gaap:CorporateNonSegmentMember country:US 2024-01-01 2024-03-31 0000001800 us-gaap:CorporateNonSegmentMember us-gaap:NonUsMember 2024-01-01 2024-03-31 0000001800 us-gaap:CorporateNonSegmentMember 2024-01-01 2024-03-31 0000001800 us-gaap:CorporateNonSegmentMember country:US 2023-01-01 2023-03-31 0000001800 us-gaap:CorporateNonSegmentMember us-gaap:NonUsMember 2023-01-01 2023-03-31 0000001800 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-03-31 0000001800 country:US 2024-01-01 2024-03-31 0000001800 us-gaap:NonUsMember 2024-01-01 2024-03-31 0000001800 country:US 2023-01-01 2023-03-31 0000001800 us-gaap:NonUsMember 2023-01-01 2023-03-31 0000001800 abt:COVID19TestingMember abt:DiagnosticProductsMember 2024-01-01 2024-03-31 0000001800 abt:COVID19TestingMember abt:DiagnosticProductsMember 2023-01-01 2023-03-31 0000001800 abt:DiagnosticProductsMember 2024-03-31 0000001800 abt:MedicalDevicesMember 2024-03-31 0000001800 2024-04-01 2024-01-01 2024-03-31 0000001800 2024-04-01 2024-03-31 0000001800 2026-04-01 2024-01-01 2024-03-31 0000001800 2026-04-01 2024-03-31 0000001800 us-gaap:PensionPlansDefinedBenefitMember 2024-01-01 2024-03-31 0000001800 us-gaap:PensionPlansDefinedBenefitMember 2023-01-01 2023-03-31 0000001800 us-gaap:EquitySecuritiesMember 2024-03-31 0000001800 us-gaap:EquitySecuritiesMember 2023-12-31 0000001800 us-gaap:OtherInvestmentsMember 2024-03-31 0000001800 us-gaap:OtherInvestmentsMember 2023-12-31 0000001800 abt:StJudeMedicalMember 2024-03-31 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-12-31 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-12-31 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-12-31 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-12-31 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-01 2024-03-31 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-03-31 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-01-01 2024-03-31 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 2023-03-31 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-01 2024-03-31 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 2023-03-31 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2024-03-31 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2023-03-31 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-03-31 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-03-31 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-03-31 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-03-31 0000001800 abt:CardiovascularSystemsIncMember 2023-04-27 0000001800 abt:CardiovascularSystemsIncMember 2023-04-27 2023-04-27 0000001800 abt:EstablishedPharmaceuticalProductsMember 2024-03-31 0000001800 abt:NutritionalProductsMember 2024-03-31 0000001800 abt:A2024RestructuringPlanMember 2024-01-01 2024-03-31 0000001800 abt:CostOfGoodsAndServicesSoldMember abt:A2024RestructuringPlanMember 2024-01-01 2024-03-31 0000001800 us-gaap:ResearchAndDevelopmentExpenseMember abt:A2024RestructuringPlanMember 2024-01-01 2024-03-31 0000001800 us-gaap:SellingGeneralAndAdministrativeExpensesMember abt:A2024RestructuringPlanMember 2024-01-01 2024-03-31 0000001800 abt:A2024RestructuringPlanMember 2024-03-31 0000001800 abt:A2022And2023RestructuringPlanMember 2023-12-31 0000001800 abt:A2022And2023RestructuringPlanMember 2024-01-01 2024-03-31 0000001800 abt:A2022And2023RestructuringPlanMember 2024-03-31 0000001800 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0000001800 abt:RestrictedStockAwardsMember 2024-01-01 2024-03-31 0000001800 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0000001800 us-gaap:EmployeeStockOptionMember 2024-03-31 0000001800 us-gaap:RevolvingCreditFacilityMember abt:A2024FiveYearCreditAgreementMember 2024-03-31 0000001800 us-gaap:LineOfCreditMember abt:A2020FiveYearCreditAgreementMember 2020-11-12 2020-11-12 0000001800 us-gaap:RevolvingCreditFacilityMember abt:A2024FiveYearCreditAgreementMember 2024-01-29 2024-01-29 0000001800 us-gaap:LineOfCreditMember abt:A2020FiveYearCreditAgreementMember 2024-01-29 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-01-01 2024-03-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2024-03-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2023-12-31 0000001800 abt:FiveYearTermLoanDue2024Member us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-01-01 2024-03-31 0000001800 abt:FiveYearTermLoanDue2024Member us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-12-31 0000001800 abt:FiveYearTermLoanDue2024Member us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000001800 abt:FiveYearTermLoanDue2024Member us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000001800 abt:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000001800 abt:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000001800 abt:PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000001800 abt:PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000001800 abt:PrepaidExpensesAndOtherReceivablesCurrentMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000001800 abt:PrepaidExpensesAndOtherReceivablesCurrentMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000001800 abt:OtherAccruedLiabilitiesCurrentMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000001800 abt:OtherAccruedLiabilitiesCurrentMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000001800 abt:PrepaidExpenseAndOtherReceivablesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000001800 abt:PrepaidExpenseAndOtherReceivablesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000001800 abt:OtherAccruedLiabilitiesCurrentMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000001800 abt:OtherAccruedLiabilitiesCurrentMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000001800 abt:PrepaidExpenseAndOtherReceivablesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2024-03-31 0000001800 abt:PrepaidExpenseAndOtherReceivablesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2023-12-31 0000001800 abt:OtherAccruedLiabilitiesCurrentMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2024-03-31 0000001800 abt:OtherAccruedLiabilitiesCurrentMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2023-12-31 0000001800 abt:LongTermDebtCurrentMaturitiesMember us-gaap:DebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000001800 abt:LongTermDebtCurrentMaturitiesMember us-gaap:DebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000001800 us-gaap:ForeignExchangeForwardMember abt:CostOfGoodsAndServicesSoldMember 2024-01-01 2024-03-31 0000001800 us-gaap:ForeignExchangeForwardMember abt:CostOfGoodsAndServicesSoldMember 2023-01-01 2023-03-31 0000001800 us-gaap:DebtMember 2024-01-01 2024-03-31 0000001800 us-gaap:DebtMember 2023-01-01 2023-03-31 0000001800 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2024-01-01 2024-03-31 0000001800 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2023-01-01 2023-03-31 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2024-03-31 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2024-03-31 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2023-12-31 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2023-12-31 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:OtherAggregatedInvestmentsMember 2024-03-31 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherAggregatedInvestmentsMember 2024-03-31 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:OtherAggregatedInvestmentsMember 2023-12-31 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherAggregatedInvestmentsMember 2023-12-31 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-03-31 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-03-31 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-12-31 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-03-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-03-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-12-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0000001800 us-gaap:InterestRateSwapMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-03-31 0000001800 us-gaap:InterestRateSwapMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-03-31 0000001800 us-gaap:InterestRateSwapMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-12-31 0000001800 us-gaap:InterestRateSwapMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0000001800 us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000001800 us-gaap:FairValueInputsLevel1Member 2024-03-31 0000001800 us-gaap:FairValueInputsLevel2Member 2024-03-31 0000001800 us-gaap:FairValueInputsLevel3Member 2024-03-31 0000001800 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000001800 us-gaap:FairValueInputsLevel1Member 2023-12-31 0000001800 us-gaap:FairValueInputsLevel2Member 2023-12-31 0000001800 us-gaap:FairValueInputsLevel3Member 2023-12-31 0000001800 abt:VariousBusinessAcquisitionsMember 2024-03-31 0000001800 srt:MinimumMember abt:LegalProceedingsAndEnvironmentalExposuresMember 2024-03-31 0000001800 srt:MaximumMember abt:LegalProceedingsAndEnvironmentalExposuresMember 2024-03-31 0000001800 abt:LegalProceedingsAndEnvironmentalExposuresMember 2024-03-31 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-01-01 2024-03-31 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-01-01 2023-03-31 0000001800 2023-09-30 0000001800 us-gaap:OperatingSegmentsMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember 2023-01-01 2023-03-31 0000001800 us-gaap:MaterialReconcilingItemsMember 2024-01-01 2024-03-31 0000001800 us-gaap:MaterialReconcilingItemsMember 2023-01-01 2023-03-31 shares iso4217:USD iso4217:USD shares abt:segment pure abt:intangibleAsset 0000001800 --12-31 2024 Q1 false P12M 10-Q true 2024-03-31 false 1-2189 ABBOTT LABORATORIES IL 36-0698440 100 Abbott Park Road Abbott Park IL 60064-6400 224 667-6100 Common Shares, Without Par Value Common Shares, Without Par Value ABT ABT NYSE CHX Yes Yes Large Accelerated Filer false false false 1739633759 9964000000 9747000000 4463000000 4331000000 472000000 491000000 684000000 654000000 2959000000 2762000000 8578000000 8238000000 1386000000 1509000000 141000000 153000000 80000000 101000000 0 -6000000 111000000 111000000 1436000000 1562000000 211000000 244000000 1225000000 1318000000 0.70 0.75 0.70 0.75 1740203000 1741738000 9449000 9977000 1749652000 1751715000 6892000 7332000 1225000000 1318000000 -386000000 139000000 1000000 0 -4000000 -2000000 30000000 -58000000 55000000 -129000000 -327000000 12000000 898000000 1330000000 -6890000000 -6504000000 1372000000 1376000000 96000000 41000000 -8166000000 -7839000000 6284000000 6896000000 367000000 383000000 439000000 444000000 6605000000 6565000000 4063000000 3946000000 881000000 807000000 1883000000 1817000000 6827000000 6570000000 2293000000 2256000000 22376000000 22670000000 818000000 799000000 22055000000 21933000000 11948000000 11779000000 10107000000 10154000000 8296000000 8815000000 23383000000 23679000000 7487000000 7097000000 72467000000 73214000000 4178000000 4295000000 1092000000 1597000000 5220000000 5422000000 959000000 955000000 562000000 492000000 2010000000 1080000000 14021000000 13841000000 12576000000 13599000000 6827000000 6947000000 1 1 1000000 1000000 0 0 0 0 2400000000 2400000000 1989789999 1987883852 24726000000 24869000000 250155515 253807494 15761000000 15981000000 38011000000 37554000000 -8166000000 -7839000000 38810000000 38603000000 233000000 224000000 39043000000 38827000000 72467000000 73214000000 1987883852 1986519278 24869000000 24709000000 1906147 384892 87000000 16000000 322000000 296000000 -552000000 -533000000 1989789999 1986904170 24726000000 24488000000 253807494 248724257 -15981000000 -15229000000 3838255 3933165 242000000 242000000 186276 3166279 22000000 320000000 250155515 247957371 -15761000000 -15307000000 37554000000 35257000000 1225000000 1318000000 0.55 0.51 960000000 890000000 -192000000 -183000000 38011000000 35868000000 -7839000000 -8051000000 -327000000 12000000 -8166000000 -8039000000 224000000 219000000 9000000 3000000 233000000 222000000 1225000000 1318000000 333000000 315000000 472000000 491000000 304000000 281000000 151000000 -233000000 410000000 419000000 748000000 1076000000 1025000000 1143000000 398000000 380000000 28000000 86000000 -1000000 -4000000 -425000000 -462000000 -127000000 -42000000 226000000 540000000 134000000 62000000 957000000 890000000 -1176000000 -1410000000 -36000000 8000000 -612000000 -721000000 6896000000 9882000000 6284000000 9161000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 1 — Basis of Presentation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s Annual Report on Form 10-K for the year ended December 31, 2023. The condensed consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Note 2 — New Accounting Standards</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Recent Accounting Standards Not Yet Adopted</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Segment Reporting (Topic 280):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which expands the breadth and frequency of required segment disclosures. The guidance is required to be applied retrospectively to all periods presented in the financial statements. The standard becomes effective for Abbott for full year 2024 reporting and for interim periods beginning in the first quarter of 2025. Abbott is currently evaluating the impact of this new standard on its consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which requires an entity to disclose annually additional information related to the company's income tax rate reconciliation and income taxes paid during the period. The guidance should be applied prospectively with the option to apply the standard retrospectively. The standard becomes effective for Abbott for full year 2025 reporting. Abbott is currently evaluating the impact of this new standard on its consolidated financial statements.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Recent Accounting Standards Not Yet Adopted</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Segment Reporting (Topic 280):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which expands the breadth and frequency of required segment disclosures. The guidance is required to be applied retrospectively to all periods presented in the financial statements. The standard becomes effective for Abbott for full year 2024 reporting and for interim periods beginning in the first quarter of 2025. Abbott is currently evaluating the impact of this new standard on its consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which requires an entity to disclose annually additional information related to the company's income tax rate reconciliation and income taxes paid during the period. The guidance should be applied prospectively with the option to apply the standard retrospectively. The standard becomes effective for Abbott for full year 2025 reporting. Abbott is currently evaluating the impact of this new standard on its consolidated financial statements.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 3 — Revenue</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide detail by sales category: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Established Pharmaceutical Products — </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Key Emerging Markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">928 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">928 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,226 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,226 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,189 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,189 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nutritionals —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pediatric Nutritionals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">514 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,009 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">459 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">465 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">924 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adult Nutritionals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">364 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">695 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,059 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">690 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,043 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">878 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,190 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,068 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">812 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,155 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,967 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostics — </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Core Laboratory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">895 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">893 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,182 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Molecular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Point of Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rapid Diagnostics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">481 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">260 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">741 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">906 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">931 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,283 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,214 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,335 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,353 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,688 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Devices —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rhythm Management</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">260 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">527 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Electrophysiology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">587 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">505 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Heart Failure</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vascular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">435 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">689 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">617 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Structural Heart</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">515 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">461 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diabetes Care </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,569 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">479 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">834 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,034 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,419 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,453 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,778 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,122 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,846 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,118 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,964 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,928 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,819 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,747 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products sold by the Diagnostics segment include various types of diagnostic tests to detect the COVID-19 coronavirus. In the first three months of 2024 and 2023, Abbott’s COVID-19 testing-related sales totaled $204 million and $730 million, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remaining Performance Obligations</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was approximately $4.5 billion in the Diagnostics segment and approximately $495 million in the Medical Devices segment. Abbott expects to recognize revenue on approximately 59 percent of these remaining performance obligations over the next 24 months, approximately 16 percent over the subsequent 12 months and the remainder thereafter.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These performance obligations primarily reflect the future sale of reagents/consumables in contracts with minimum purchase obligations, extended warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has applied the practical expedient described in FASB Accounting Standards Codification (ASC) 606-10-50-14 and has not included remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Contract Assets and Liabilities</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at the net amount expected to be collected. Contract assets primarily relate to Abbott’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were not significant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott’s contract liabilities arise primarily in the Medical Devices reportable segment when payment is received upfront for various multi-period extended service arrangements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the contract liabilities during the period are as follows:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unearned revenue from cash received during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized related to contract liability balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 4 4 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide detail by sales category: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Established Pharmaceutical Products — </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Key Emerging Markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">928 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">928 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,226 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,226 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,189 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,189 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nutritionals —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pediatric Nutritionals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">514 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,009 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">459 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">465 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">924 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adult Nutritionals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">364 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">695 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,059 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">690 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,043 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">878 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,190 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,068 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">812 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,155 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,967 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostics — </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Core Laboratory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">895 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">893 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,182 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Molecular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Point of Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rapid Diagnostics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">481 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">260 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">741 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">906 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">931 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,283 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,214 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,335 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,353 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,688 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Devices —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rhythm Management</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">260 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">527 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Electrophysiology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">587 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">505 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Heart Failure</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vascular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">435 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">689 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">617 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Structural Heart</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">515 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">461 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diabetes Care </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,569 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">479 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">834 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,034 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,419 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,453 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,778 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,122 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,846 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,118 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,964 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,928 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,819 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,747 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 928000000 928000000 0 912000000 912000000 0 298000000 298000000 0 277000000 277000000 0 1226000000 1226000000 0 1189000000 1189000000 514000000 495000000 1009000000 459000000 465000000 924000000 364000000 695000000 1059000000 353000000 690000000 1043000000 878000000 1190000000 2068000000 812000000 1155000000 1967000000 310000000 895000000 1205000000 289000000 893000000 1182000000 42000000 87000000 129000000 47000000 100000000 147000000 98000000 41000000 139000000 93000000 41000000 134000000 481000000 260000000 741000000 906000000 319000000 1225000000 931000000 1283000000 2214000000 1335000000 1353000000 2688000000 271000000 291000000 562000000 260000000 267000000 527000000 269000000 318000000 587000000 238000000 267000000 505000000 237000000 68000000 305000000 218000000 63000000 281000000 254000000 435000000 689000000 218000000 399000000 617000000 233000000 282000000 515000000 210000000 251000000 461000000 181000000 45000000 226000000 155000000 41000000 196000000 589000000 980000000 1569000000 479000000 834000000 1313000000 2034000000 2419000000 4453000000 1778000000 2122000000 3900000000 3000000 0 3000000 3000000 0 3000000 3846000000 6118000000 9964000000 3928000000 5819000000 9747000000 204000000 730000000 4500000000 495000000 0.59 P24M 0.16 P12M <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the contract liabilities during the period are as follows:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unearned revenue from cash received during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized related to contract liability balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 545000000 120000000 116000000 549000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 4 — Supplemental Financial Information</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Net earnings allocated to common shares for the three months ended March 31, 2024 and 2023 were $1.220 billion and $1.313 billion, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other, net in Net cash from operating activities in the Condensed Consolidated Statement of Cash Flows for the first three months of 2024 includes $280 million of pension contributions and the payment of cash taxes of approximately $225 million. The first three months of 2023 includes $282 million of pension contributions and the payment of cash taxes of approximately $122 million.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the activity for the first three months of 2024 related to the allowance for doubtful accounts as of March 31, 2024:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for Doubtful Accounts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions/charges to income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts charged off and other adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivable. Abbott considers various factors in establishing, monitoring, and adjusting its allowance for doubtful accounts, including the aging of the accounts and aging trends, the historical level of charge-offs, and specific exposures related to particular customers. Abbott also monitors other risk factors and forward-looking information, such as country risk, when determining credit limits for customers and establishing adequate allowances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of long-term investments as of March 31, 2024 and December 31, 2023 are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">818 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in Abbott’s long-term investments as of March 31, 2024 versus the balance as of December 31, 2023 primarily relates to additional investments and earnings from equity method investments,</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially offset by the impairment of certain securities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott’s equity securities as of March 31, 2024, include $317 million of investments in mutual funds that are held in a rabbi trust. These investments, which are specifically designated as available for the purpose of paying benefits under a deferred compensation plan, are not available for general corporate purposes and are subject to creditor claims in the event of insolvency.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott also holds certain investments as of March 31, 2024 with a carrying value of $154 million that are accounted for under the equity method of accounting and other equity investments with a carrying value of approximately $66 million that do not have a readily determinable fair value.</span></div> 1220000000 1313000000 280000000 225000000 282000000 122000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the activity for the first three months of 2024 related to the allowance for doubtful accounts as of March 31, 2024:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for Doubtful Accounts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions/charges to income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts charged off and other adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 241000000 14000000 8000000 247000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of long-term investments as of March 31, 2024 and December 31, 2023 are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">818 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 547000000 555000000 271000000 244000000 818000000 799000000 317000000 154000000 66000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 5 — Changes In Accumulated Other Comprehensive Income (Loss)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Foreign<br/>Currency Translation<br/>(Loss) Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Actuarial (Losses) and<br/>Prior Service (Costs) and<br/>Credits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Gains (Losses)<br/>on Derivative Instruments<br/>Designated as Cash Flow<br/>Hedges and Other</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,504)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,733)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,376)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,493)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(386)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(386)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,890)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,594)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,372)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,491)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassified amounts for cash flow hedges are recorded as Cost of products sold. Net actuarial losses and prior service cost are included as a component of net periodic benefit costs; see Note 13 for additional details.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Foreign<br/>Currency Translation<br/>(Loss) Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Actuarial (Losses) and<br/>Prior Service (Costs) and<br/>Credits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Gains (Losses)<br/>on Derivative Instruments<br/>Designated as Cash Flow<br/>Hedges and Other</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,504)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,733)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,376)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,493)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(386)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(386)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,890)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,594)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,372)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,491)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -6504000000 -6733000000 -1376000000 -1493000000 41000000 175000000 -386000000 139000000 2000000 2000000 68000000 -42000000 0 0 -2000000 0 13000000 87000000 -386000000 139000000 4000000 2000000 55000000 -129000000 -6890000000 -6594000000 -1372000000 -1491000000 96000000 46000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 6 — Business Acquisitions</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 22, 2023, Abbott completed the acquisition of Bigfoot Biomedical, Inc. (Bigfoot), which will further Abbott's efforts to develop connected solutions for making diabetes management more personal and precise. The purchase price, the preliminary allocation of acquired assets and liabilities, and the revenue and net income contributed by Bigfoot since the date of acquisition are not material to Abbott's condensed consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 27, 2023, Abbott completed the acquisition of Cardiovascular Systems, Inc. (CSI) for $20 per common share, which equated to a purchase price of $851 million. The transaction was funded with cash on hand and accounted for as a business combination. CSI's atherectomy system, which is used in treating peripheral and coronary artery disease, adds complementary technologies to Abbott's portfolio of vascular device offerings.</span></div>The final allocation of the purchase price of the CSI acquisition resulted in the recording of two non-deductible developed technology intangible assets totaling $305 million; non-deductible in-process research and development asset of $15 million, which will be accounted for as an indefinite-lived intangible asset until regulatory approval or discontinuation; non-deductible goodwill of $369 million; net deferred tax assets of $46 million and other net assets of $116 million. The goodwill is identifiable to the Medical Devices reportable segment and is attributable to expected synergies from combining operations, as well as intangible assets that do not qualify for separate recognition. Revenues and earnings of CSI included in Abbott's condensed consolidated financial statements since the acquisition date are not material to Abbott's consolidated revenue and earnings. 20 851000000 2 305000000 15000000 369000000 46000000 116000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 7 — Goodwill and Intangible Assets</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total amount of goodwill reported was $23.4 billion at March 31, 2024 and $23.7 billion at December 31, 2023. Foreign currency translation adjustments decreased goodwill by approximately $294 million in the first three months of 2024. The amount of goodwill related to reportable segments at March 31, 2024 was $2.7 billion for the Established Pharmaceutical Products segment, $285 million for the Nutritional Products segment, $3.5 billion for the Diagnostic Products segment, and $16.9 billion for the Medical Devices segment. There was no reduction of goodwill relating to impairments in the first three months of 2024.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross amount of amortizable intangible assets, primarily product rights and technology, was $27.5 billion and $27.7 billion as of March 31, 2024 and December 31, 2023, respectively. Accumulated amortization was $20.0 billion and $19.7 billion as of March 31, 2024 and December 31, 2023, respectively. In the first three months of 2024, intangible assets decreased $38 million due to foreign currency translation and $8 million due to an impairment charge. Abbott’s estimated annual amortization expense for intangible assets is approximately $1.9 billion in 2024, $1.7 billion in 2025, $1.6 billion in 2026, $1.3 billion in 2027 and $0.7 billion in 2028.</span></div>Indefinite-lived intangible assets, which relate to in-process R&amp;D (IPR&amp;D) acquired in a business combination, were approximately $787 million as of March 31, 2024 and as of December 31, 2023. 23400000000 23700000000 -294000000 2700000000 285000000 3500000000 16900000000 0 27500000000 27700000000 20000000000 19700000000 -38000000 8000000 1900000000 1700000000 1600000000 1300000000 700000000 787000000 787000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 8 — Restructuring Plans</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in its nutritional business, including the discontinuation of its ZonePerfect</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line, and in its medical devices segment. In the first three months of 2024, Abbott recorded employee related severance and other charges of approximately $17 million, of which approximately $11 million was recorded in Cost of products sold, approximately $1 million was recorded in Research and development and approximately $5 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was recorded in Selling, general and administrative expenses. Payments related to these actions totaled $3 million in the first three months of 2024 and the remaining liabilities totaled $14 million at March 31, 2024. In addition, Abbott recognized asset impairment charges of approximately $30 million related to these restructuring plans.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023 and 2022, Abbott management approved plans to restructure or streamline various operations in order to reduce costs in its medical devices, diagnostic, nutritional and established pharmaceutical businesses. The following summarizes the 2024 activity related to these restructuring actions and the status of the related accruals as of March 31, 2024:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance at March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 17000000 11000000 1000000 5000000 3000000 14000000 30000000 The following summarizes the 2024 activity related to these restructuring actions and the status of the related accruals as of March 31, 2024:<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance at March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 137000000 41000000 96000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 9 — Incentive Stock Programs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first three months of 2024, Abbott granted 1,666,566 stock options, 404,597 restricted stock awards and 5,189,560 restricted stock units under its incentive stock program. At March 31, 2024, approximately 60 million shares were reserved for future grants. Information regarding the number of options outstanding and exercisable at March 31, 2024 is as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,281,501 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,296,425 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining life </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(years)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.05 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate intrinsic value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,031 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total unrecognized share-based compensation cost at March 31, 2024 amounted to approximately $787 million, which is expected to be recognized over the next three years.</span></div> 1666566 404597 5189560 60000000 Information regarding the number of options outstanding and exercisable at March 31, 2024 is as follows:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,281,501 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,296,425 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining life </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(years)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.05 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate intrinsic value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,031 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 28281501 24296425 P5Y1M6D P4Y4M24D 78.71 73.05 1031000000 1020000000 787000000 P3Y <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 10 — Debt and Lines of Credit</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott has readily available financial resources, including unused lines of credit that support commercial paper borrowing arrangements and provide Abbott with the ability to borrow up to $5 billion on an unsecured basis. On January 29, 2024, Abbott terminated its 2020 Five Year Credit Agreement (2020 Agreement) and entered into a new Five Year Credit Agreement (Revolving Credit Agreement). There were no outstanding borrowings under the 2020 Agreement at the time of its termination. Any borrowings under the Revolving Credit Agreement will mature and be payable on January 29, 2029 and will bear interest, at Abbott’s option, based on either a base rate or Secured Overnight Financing Rate (SOFR), plus an applicable margin based on Abbott’s credit ratings.</span></div> 5000000000 P5Y P5Y 0 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 11 — Financial Instruments, Derivatives and Fair Value Measures</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates, primarily for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross notional amounts totaling $7.3 billion at March 31, 2024 and at December 31, 2023, are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of March 31, 2024 will be included in Cost of products sold at the time the products are sold, generally through the next <span style="-sec-ix-hidden:f-548">twelve</span> to eighteen months.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar and European currencies. At March 31, 2024 and December 31, 2023, Abbott held gross notional amounts of $14.5 billion and $13.8 billion, respectively, of such foreign currency forward exchange contracts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott has designated a yen-denominated, 5-year term loan, scheduled to mature in November 2024, of approximately $395 million and $419 million as of March 31, 2024 and December 31, 2023, respectively, as a hedge of the net investment in certain foreign subsidiaries. The change in the value of the debt, which is due to changes in foreign exchange rates, is recorded in Accumulated other comprehensive income (loss), net of tax.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott is a party to interest rate hedge contracts totaling approximately $2.2 billion at March 31, 2024 and December 31, 2023 to manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts and location of certain derivative financial instruments as of March 31, 2024 and December 31, 2023:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps designated as fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Post-employment obligations, deferred income taxes and other long-term liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Others not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt designated as a hedge of net investment in a foreign subsidiary</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">395 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">419 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of long-term debt </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">614 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">745 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three months ended March 31, 2024 and 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.388%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gain (loss) Recognized in Other Comprehensive Income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income (expense) and<br/> Gain (loss) Reclassified into Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended March 31</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended March 31</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt designated as a hedge of net investment in a foreign subsidiary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps designated as fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains of $92 million and losses of $103 million were recognized in the three months ended March 31, 2024 and 2023, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net foreign exchange (gain) loss line.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values and fair values of certain financial instruments as of March 31, 2024 and December 31, 2023 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Investment Securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Long-term Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,586)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,679)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,769)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Forward Exchange Contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivable position</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Payable) position</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Rate Hedge Contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Payable) position</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the debt was determined based on significant other observable inputs, including current interest rates.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis of Fair Value Measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding<br/>Balances</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted<br/>Prices in<br/>Active<br/>Markets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2024:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of hedged long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap derivative financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration related to business combinations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,324 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,265 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of hedged long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,052 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,052 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap derivative financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration related to business combinations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,490 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,378 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis using significant other observable inputs. The fair value of the contingent consideration was determined based on independent appraisals at the time of acquisition, adjusted for the time value of money and other changes in fair value. The decrease in the amount of contingent consideration from December 31, 2023 reflects a payment of $40 million and a $13 million change in the fair value of the remaining contingent consideration. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum amount for certain contingent consideration is not determinable as it is based on a percent of certain sales. Excluding such contingent consideration, the maximum amount that may be due under the other contingent consideration arrangements was estimated at March 31, 2024 to be approximately $135 million, which is dependent upon attaining certain sales thresholds or upon the occurrence of certain events, such as regulatory approvals.</span></div> 7300000000 7300000000 P18M 14500000000 13800000000 P5Y P5Y 395000000 419000000 2200000000 2200000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts and location of certain derivative financial instruments as of March 31, 2024 and December 31, 2023:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps designated as fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Post-employment obligations, deferred income taxes and other long-term liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Others not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt designated as a hedge of net investment in a foreign subsidiary</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">395 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">419 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of long-term debt </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">614 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">745 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div> 0 0 88000000 95000000 0 0 31000000 0 118000000 88000000 61000000 134000000 52000000 81000000 39000000 97000000 395000000 419000000 170000000 169000000 614000000 745000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three months ended March 31, 2024 and 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.388%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gain (loss) Recognized in Other Comprehensive Income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income (expense) and<br/> Gain (loss) Reclassified into Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended March 31</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended March 31</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt designated as a hedge of net investment in a foreign subsidiary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps designated as fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr></table></div> 127000000 -63000000 18000000 126000000 24000000 -5000000 -24000000 9000000 92000000 -103000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values and fair values of certain financial instruments as of March 31, 2024 and December 31, 2023 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Investment Securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Long-term Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,586)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,679)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,769)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Forward Exchange Contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivable position</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Payable) position</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Rate Hedge Contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Payable) position</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 547000000 547000000 555000000 555000000 271000000 271000000 244000000 244000000 14586000000 14299000000 14679000000 14769000000 170000000 170000000 169000000 169000000 100000000 100000000 231000000 231000000 119000000 119000000 95000000 95000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis of Fair Value Measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding<br/>Balances</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted<br/>Prices in<br/>Active<br/>Markets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2024:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of hedged long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap derivative financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration related to business combinations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,324 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,265 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of hedged long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,052 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,052 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap derivative financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration related to business combinations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,490 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,378 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 327000000 327000000 0 0 170000000 0 170000000 0 497000000 327000000 170000000 0 2046000000 0 2046000000 0 119000000 0 119000000 0 100000000 0 100000000 0 59000000 0 0 59000000 2324000000 0 2265000000 59000000 326000000 326000000 0 0 169000000 0 169000000 0 495000000 326000000 169000000 0 2052000000 0 2052000000 0 95000000 0 95000000 0 231000000 0 231000000 0 112000000 0 0 112000000 2490000000 0 2378000000 112000000 40000000 13000000 135000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 12 — Litigation and Environmental Matters</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately $45 million to $60 million. The recorded accrual balance at March 31, 2024 for these proceedings and exposures was approximately $55 million. This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.” Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations.</span></div> 4000000 10000000 45000000 60000000 55000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 13 — Post-Employment Benefits</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net periodic benefit costs, other than service costs, are recognized in the Other (income) expense, net line of the Condensed Consolidated Statement of Earnings. Net cost recognized for the three months ended March 31 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.415%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.266%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical and Dental Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended March 31</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended March 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost - benefits earned during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost on projected benefit obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(262)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(242)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net amortization of:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial loss, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior service cost (credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cost (credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>Abbott funds its domestic defined benefit plans according to Internal Revenue Service funding limitations. International pension plans are funded according to similar regulations. In the first three months of 2024 and 2023, $280 million and $282 million, respectively, were contributed to defined benefit plans. In the first three months of 2024 and 2023, $28 million was contributed in each year to the post-employment medical and dental plans. Net cost recognized for the three months ended March 31 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.415%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.266%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical and Dental Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended March 31</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended March 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost - benefits earned during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost on projected benefit obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(262)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(242)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net amortization of:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial loss, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior service cost (credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cost (credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 61000000 60000000 10000000 9000000 118000000 114000000 15000000 14000000 262000000 242000000 6000000 6000000 -6000000 -3000000 0 0 0 0 -3000000 -3000000 -77000000 -65000000 16000000 14000000 280000000 282000000 28000000 28000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 14 — Taxes on Earnings </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first three months of 2024 and 2023, taxes on earnings include approximately $25 million and $3 million, respectively, in excess tax benefits associated with share-based compensation. In the first three months of 2024 and 2023, taxes on earnings also include approximately $10 million and $22 million, respectively, of tax expense as the result of the resolution of various tax positions related to prior years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease approximately $82 million to $1.34 billion, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, Abbott received a Statutory Notice of Deficiency (SNOD) from the U.S. Internal Revenue Service (IRS) for the 2019 Federal tax year in the amount of $417 million. The primary adjustments proposed in the SNOD relate to the reallocation of income between Abbott’s U.S. entities and its foreign affiliates. Abbott believes that the income reallocation adjustments proposed in the SNOD are without merit, in part because certain adjustments contradict methods that were agreed to with the IRS in prior audit periods. The SNOD also contains other proposed adjustments that Abbott believes are erroneous and unsupported. Abbott filed a petition with the U.S. Tax Court contesting the SNOD in December 2023.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Abbott’s 2017 and 2018 Federal tax years are also currently under examination by the IRS with respect to income reallocation issues similar to those included in the 2019 Federal tax year. Abbott intends to vigorously defend its filing positions through ongoing discussions with the IRS, the IRS independent appeals process and/or through litigation as necessary.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Abbott reserves for uncertain tax positions related to unresolved matters with the IRS and other taxing authorities. Abbott continues to believe that its reserves for uncertain tax positions are appropriate.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Organization for Economic Cooperation &amp; Development (OECD) has proposed a two-pillared plan for a revised international tax system. Pillar 1 proposes to reallocate taxing rights among the jurisdictions in which in-scope multinational corporations operate. Abbott is continuing to analyze the Pillar 1 proposal. Pillar 2 proposes to assess a 15 percent minimum tax on the earnings of in-scope multinational corporations on a country-by-country basis. Numerous countries have enacted legislation to adopt the Pillar 2 model rules. A subset of the rules became effective January 1, 2024, and the remaining rules become effective January 1, 2025 or later.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Abbott continues to analyze the Pillar 2 model rules. The full implementation of the model rules may have a material impact on Abbott’s condensed consolidated financial statements in the future.</span></div> -25000000 -3000000 10000000 22000000 82000000 1340000000 417000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 15 — Segment Information</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott’s principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices and government agencies throughout the world.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott’s reportable segments are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Established Pharmaceutical Products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— International sales of a broad line of branded generic pharmaceutical products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nutritional Products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Worldwide sales of a broad line of adult and pediatric nutritional products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diagnostic Products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. For segment reporting purposes, the Core Laboratory Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care Diagnostics businesses are aggregated and reported as the Diagnostic Products segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical Devices</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. For segment reporting purposes, the Cardiac Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, Neuromodulation and Diabetes Care divisions are aggregated and reported as the Medical Devices segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. Intersegment transfers of inventory are recorded at standard cost and are not a measure of segment operating earnings. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the condensed consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.357%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Sales to External Customers</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Earnings</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months <br/>Ended March 31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months <br/>Ended March 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Established Pharmaceutical Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,226 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,189 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nutritional Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,068 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,967 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostic Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,688 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,453 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Reportable Segments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,961 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,744 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,478 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,409 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,964 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,747 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate functions and benefit plan costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net interest expense </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation (a) </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(304)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(472)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(491)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net (b)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,436 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,562 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.385%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards. </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other, net for the three months ended March 31, 2024 and March 31, 2023 includes charges related to restructuring actions. Other, net for the three months ended March 31, 2024 also includes integration costs associated with the acquisition of CSI and $38 million related to various investment impairments.</span></div></td></tr></table></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the condensed consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.357%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Sales to External Customers</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Earnings</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months <br/>Ended March 31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months <br/>Ended March 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Established Pharmaceutical Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,226 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,189 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nutritional Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,068 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,967 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostic Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,688 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,453 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Reportable Segments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,961 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,744 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,478 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,409 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,964 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,747 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate functions and benefit plan costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net interest expense </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation (a) </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(304)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(472)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(491)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net (b)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,436 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,562 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.385%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards. </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other, net for the three months ended March 31, 2024 and March 31, 2023 includes charges related to restructuring actions. Other, net for the three months ended March 31, 2024 also includes integration costs associated with the acquisition of CSI and $38 million related to various investment impairments.</span></div></td></tr></table></div> 1226000000 1189000000 267000000 300000000 2068000000 1967000000 377000000 380000000 2214000000 2688000000 474000000 651000000 4453000000 3900000000 1360000000 1078000000 9961000000 9744000000 2478000000 2409000000 3000000 3000000 9964000000 9747000000 66000000 77000000 -61000000 -52000000 304000000 281000000 472000000 491000000 139000000 -54000000 1436000000 1562000000 0.45 0.45 38000000